1,8-naphthyridine derivatives as antidiabetics

专利摘要:
The present invention relates generally to naphthyridine derivatives of formula (I). More specifically, the present invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. The method of the present invention comprises administering the naphthyridine derivative of the present invention for the treatment of diabetes and related disorders. <Formula I> Where U, X, Y and Z are nitrogen, the rest are C-R and R is hydrogen or a substituent.
公开号:KR20040041178A
申请号:KR10-2004-7004339
申请日:2002-09-23
公开日:2004-05-14
发明作者:야민 왕；데이비드 이. 건；큉지에 리우；시드니 엑스. 리앙；윌리엄 에이치. 불락；덩글레이 리우；스티븐 알. 매그너슨；틴디 리；에릭 에스. 물；질 이. 우드；닝 퀴
申请人:바이엘 파마슈티칼스 코포레이션；
IPC主号:

专利说明:

1,8-naphthyridine derivative as therapeutic agent for diabetes {1,8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS}
[2] Diabetes is characterized by impaired glucose metabolism, which is manifested by elevated blood glucose (blood glucose) levels in others with diabetes. Depending on the underlying defect, the type of diabetes is divided into two main groups: Type 1 diabetes or insulin dependent diabetes (IDDM) occurs when the patient's pancreatic gland lacks beta cells that produce insulin. Type 2 diabetes or insulin independent diabetes (NIDDM) occurs in patients with impaired beta cell function and altered insulin action.
[3] The current treatment for patients with type 1 diabetes is insulin injection, while the majority of patients with type 2 diabetes are treated with drugs that stimulate beta cell function or drugs that enhance the patient's tissue sensitivity to insulin. Agents currently used to treat type 2 diabetes include alpha-glucosidase inhibitors, insulin action enhancers, insulin secretagogues and metformin.
[4] Nearly half of people with type 2 diabetes stop responding to these drugs over time. Insulin treatment is performed after meals, exercise and oral drug treatments fail to control blood glucose sufficiently. The weaknesses of insulin treatment are the need for drug injection, the potential for hypoglycemia and weight gain.
[5] Because of the problems with current therapies, new therapies for treating type 2 diabetes are required. In particular, there is a need for new therapies that maintain normal (glucose-dependent) insulin secretion. These new drugs are glucose dependent for promoting insulin secretion (ie, must be compounds that stimulate insulin secretion only when blood glucose is elevated); Low first and second failure rates; And islet should have characteristics such as preservation of cell function. The method that developed the novel therapies described herein is based on the cyclic adenosine monophosphate (cAMP) signaling mechanism and its effect on insulin secretion.
[6] Metabolism of glucose promotes the closure of ATP-dependent K + channels, leading to cell depolarization and subsequent opening of Ca ++ channels. As a result, insulin granules are exocytosis. cAMP is a major regulator of glucose stimulated insulin secretion. However, there was little (if any) effect on insulin secretion in the absence of glucose or at low glucose concentrations (see Weinhaus, A., et al., Diabetes 47: 1426-1435 (1998)). The effect of cAMP on insulin secretion is thought to be mediated by the protein kinase A pathway.
[7] Endogenous Secretagogue-like pituitary adenylate cyclase active peptides (PACAP), VIP and GLP-1 regulate insulin secretion using the cAMP system in a glucose dependent manner (Komatsu, M., et al. , Diabetes 46: 1928-1938, (1997). Phosphodiesterases (PDEs) are also known to be involved in the regulation of cAMP systems.
[8] PACAP is a potent stimulant of glucose dependent insulin secretion from the beta cells of the pancreas. Three different PACAP receptor types (R1, R2 and R3) are described (see Harmar, A., et al., Pharmacol. Reviews 50: 265-270 (1998)). Insulin secretion of PACAP is mediated by the GTP binding protein Gs. Accumulation of intracellular cAMP also activates non-selective cation channels that increase [Ca ++] i in beta cells and enhance the exocytosis of insulin-containing secretory granules.
[9] Vascularly active long peptides (VIPs) are 28 amino acid bound peptides, first isolated from pig upper intestine (see Said and Mutt, Science 169: 1217-1218, 1970) and US Pat. No. 3,879,371. Such peptides belong to the group of structurally related small polypeptides, including hellodermin, secretin, somatostatin and glucagon. The biological effect of VIP is mediated by the activity of membrane-bound receptor proteins coupled with intracellular cAMP signaling systems. This receptor was originally known as VIP-R1 and VIP-R2, but was later found to be the same receptor as PACAP-R2 and PACAP-R3.
[10] GLP-1 is released from intestinal L-cells after meals and acts as an incretin hormone (ie, increases glucose-induced insulin release from beta cells of the pancreas). It is a 37-amino acid peptide that is expressed differently by the glucagon gene depending on the type of tissue. Clinical data were collected using GLP-1 supporting the benefit of raising cAMP concentration in β-cells. Infusion of GLP-1 in poorly controlled type 2 diabetes normalizes the subject's fasting blood glucose concentrations (Gutniak, M., et al., New Eng. J. Med. 326: 1316-1322, (1992). Longer infusions improve beta cell function on blood glucose levels in steady-state subjects (see Rachman, J. et al., Diabetes 45: 1524-1530, (1996)). Recent reports have shown that GLP-1 improves the ability of β-cells to respond to glucose in subjects with impaired glucose tolerance (Byrne M., et al., Diabetes 47: 1259-1265 (1998) ] Reference). However, all of these effects are temporary because the half-life of the peptide is short.
[11] <Overview of invention>
[12] The present invention provides compounds, pharmaceutical compositions, and methods of using the compounds for treating diabetes and related disorders. Compounds of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof.
[13]
[14] Where
[15] R ¹ is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, and AR ⁹ , or
[16] R ¹ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, wherein the heterocycloalkyl and the heterocycloalkenyl are further selected from phenyl, Or may be fused with 5 to 6 membered heteroaryls of 2 to 5 carbon atoms and 1 to 3 heteroatoms selected from N, S (= 0) _0-2 and O and / or the heterocycloalkyl or heterocyclo One or more carbon atoms in alkenyl may be oxidized to C (═O), these parent It may be substituted with one to three R ^10;
[17] R ¹⁰ is nitro, nitrile, hydroxy, halogen, acyl of 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, carbon of 1 to 6 carbon atoms 6 haloalkyl, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, aryl of 6 to 10 carbon atoms, 2 to 9 carbon atoms and N, S ( = O) 1 to 4 heteroaryls selected from _0-2 and O, NR ¹¹ R ¹² , C (= 0) OR ¹¹ , C (= 0) NHR ¹¹ , NHC (= 0) R ¹³ , NHS ( = O) ₂ R ¹³ , S (= O) _0-2 R ¹³ , S (= O) ₂ NHR ¹¹ , 3 to 6 cycloalkyl carbon atoms, 3 to 6 cycloalkenyl, 3 to carbon atoms 5 and 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from 6 and N, S (= 0) _0-2 and O, and 3 to 6 carbon atoms and N, S (= 0) _0-2 and Heteroatoms selected from O One to two five to seven membered heterocycloalkenyl; The heterocycloalkyl and the heterocycloalkenyl may further be selected from phenyl or 2 to 5 carbon atoms and 1 to 3 5 to 6 membered heteroaryl selected from N, S (= 0) _0-2 and O; May be fused and / or one or more carbon atoms in said heterocycloalkyl or heterocycloalkenyl may be oxidized to C (═O);
[18] R ¹³ is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, and carbon atoms 4 to 6 cycloalkenyl;
[19] R ¹¹ and R ¹² are hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms Independently selected from alkyl and cycloalkenyl of 4 to 6 carbon atoms;
[20] A is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, and haloalkyl of 1 to 8 carbon atoms;
[21] R ⁹ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, OAR ¹⁴ and NR ¹¹ R ¹² , or
[22] R ⁹ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S ( _═O ) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Selected from cycloalkenyl of 5 to 8 carbon atoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
[23] R ⁹ is 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl of 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N, S ( = O) from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and O, wherein said heterocycloalkyl and said heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon in the heterocycloalkyl or the heterocycloalkenyl An atom may be oxidized to C (═O), and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
[24] R ¹⁴ is cycloalkyl having 3 to 8 carbon atoms, cycloalkenyl having 5 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 5 heteroatoms selected from N, S (= 0) _0-2 and O; To 7 membered heterocycloalkyl and 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which are May be substituted with 1 to 3 R ¹⁰ ;
[25] R ² is selected from NR ¹⁵ R ¹⁶ , S (O) _0-2 R ^17, and OR ¹⁷ ;
[26] R ¹⁵ is hydrogen atom, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, cycloalkenyl of 4 to 8 carbon atoms , 5-6 membered heterocycloalkyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 3 to 6 carbon atoms and N, S (= 0) _From 5 to 7 membered heterocycloalkenyl having 1 to 2 heteroatoms selected from _0-2 and O, AR ⁹ , C (= 0) R ¹⁸ , C (= 0) NHR ¹⁸ and S (= 0) ₂ NHR ¹⁸ Selected;
[27] R ¹⁸ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ , or
[28] R ¹⁸ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, and alkynyl of 2 to 6 carbon atoms, all of which are 1 to 3 halogens, or alkoxy of 1 to 6 carbon atoms May be substituted with
[29] R ¹⁸ is AR ⁹ ;
[30] R ¹⁶ is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, and AR ⁹ , or
[31] R ¹⁶ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ , or
[32] R ¹⁵ and R ^16, in combination with the nitrogen atom to which they are attached, are 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S ( _═O ) _0-2 and O, or 3 to carbon atoms 6, and N, S (= O) _0-2, and 1 to 2 hetero atoms 5- to 7-membered heterocycloalkyl, 3-to 6 carbon atoms selected from N, O, and one N, S (= O) _0-2 and O 1 to 2 heteroatoms selected from 5 to 7 membered heterocycloalkenyl, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms and N, S (= 0) Or fused with 5 to 6 membered heteroaryls of 1 to 3 heteroatoms selected from _0-2 and O, wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) May all be substituted with 1 to 3 R ¹⁰ ;
[33] R ¹⁷ is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, haloalkyl of 1 to 8 carbon atoms, or AR ⁹ , or
[34] R ¹⁷ is 6-10 aryl carbon atoms, 2-9 carbon atoms and 1-4 heteroaryl heteroalkyls selected from N, S (= 0) _0-2 and O, 3-8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ ;
[35] R ³ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S ( _═O ) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, 3 to 6 carbon atoms and 1 to 2 heterocycloalkyl heteroatoms selected from N, S (= 0) _0-2 and O, 4 to 8 cycloalkenyl carbon atoms, and 3 to 6 carbon atoms and N , S (= 0) _0-2 and O is selected from 1 to 2 heterocycloalkenyl heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
[36] R ³ is alkyl having 1 to 6 carbon atoms, alkenyl having 2 to 6 carbon atoms, alkynyl having 2 to 6 carbon atoms, haloalkyl having 1 to 6 carbon atoms, hydrogen, nitro, halogen, NR ¹⁹ R ²⁰ , A -OR ¹⁹ , A-NR ¹⁹ R ²⁰ and AR ²⁰ ;
[37] R ¹⁹ and R ²⁰ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ⁹ ,
[38] R ¹⁹ and R ²⁰ are 6 to 10 aryl carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryl, 3 to 8 carbon atoms, selected from N, S (= 0) _0-2 and O Cycloalkyl, cycloalkenyl of 5 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and carbon Independently selected from 3 to 6 atoms and 1 to 2 5 to 7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, the heterocycloalkyl and the heterocycloalkenyl May further be fused with phenyl or 2 to 5 carbon atoms and 1 to 3 5 to 6 membered heteroaryl selected from N, S (= 0) _0-2 and O and / or the hetero In cycloalkyl or heterocycloalkenyl one or more carbon atoms may be oxidized to C (═O) And, all of which can be optionally substituted with one to three R ^10;
[39] R ⁴ is selected from ═O, = S and OR ²¹ ;
[40] R ²¹ is hydrogen,
[41] R ²¹ is alkyl having 1 to 8 carbon atoms, alkenyl having 2 to 8 carbon atoms, alkynyl having 2 to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms, cycloalkenyl having 4 to 8 carbon atoms 3 to 6 and N, S (= 0) _0-2 and 1 to 2 5-7 membered heterocycloalkyl heteroatoms selected from O, and 3 to 6 carbon atoms and N, S (= 0) _0- One or two 5-7 membered heterocycloalkenyl heteroatoms selected from ₂ and O, all of which may be substituted with 1 to 3 R ¹⁰ ;
[42] R ⁵ and R ⁶ are selected from cycloalkyls of 3 to 8 carbon atoms, cycloalkenyl of 4 to 8 carbon atoms, aryl of 6 to 10 carbon atoms, and heteroaryl of 1 to 4 carbon atoms and 2 to 9 carbon atoms. Independently selected, all of which may be substituted with one to three R ¹⁰ , or
[43] R ⁵ and R ⁶ are 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N , S (= 0) _0-2 and O independently selected from 2 to 5 membered heterocycloalkenyls of 2 to 5 members, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or carbon Can be fused with 5 to 6 membered heteroaryls of 2 to 5 atoms and 1 to 3 heteroatoms selected from N, S (= 0) _0-2 and O and / or the heterocycloalkyl or heterocycloalkenyl At least one carbon atom may be oxidized to C (═O), and the heterocycloalkyl or the heterocycloalkenyl is one to three R ¹⁰ , AR ²³ , ANR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , S (= O) ₂ R ²⁶ , AC (= O) R ²⁴ , AC (= O) OR ²⁴ or AC (= O) NR ^May be substituted with ²⁴ R ²⁵ Or
[44] R ⁵ and R ⁶ are hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, halo of 1 to 8 carbon atoms Alkyl, alkoxy of 1 to 8 carbon atoms, haloalkoxy of 1 to 8 carbon atoms, cycloalkoxy of 3 to 8 carbon atoms, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , AC (= O) R ²⁴ , AC Independently selected from (═O) OR ²⁴ and AC (═O) NR ²⁴ R ²⁵ ;
[45] Q is selected from O and S (= 0) _0-2 ;
[46] R ²² is selected from hydrogen, alkyl of 1 to 8 carbon atoms, haloalkyl of 1 to 8 carbon atoms, and cycloalkyl of 3 to 8 carbon atoms;
[47] R ²³ is selected from hydroxy, alkoxy of 1 to 8 carbon atoms, haloalkoxy of 1 to 8 carbon atoms, and cycloalkoxy of 3 to 8 carbon atoms, or
[48] R ²³ is cycloalkyl of 3 to 8 carbon atoms, cycloalkenyl of 4 to 8 carbon atoms, aryl of 6 to 10 carbon atoms, and 2 to 9 carbon atoms and N, S (= 0) _0-2 and O Selected from 1 to 4 heteroaryl heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
[49] R ²³ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and S (= O) _0-2 is selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O), and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ,
[50] With the proviso that when R ²³ for A (OR ²² ) -R ²³ is selected from hydroxy, alkoxy of 1 to 8 carbon atoms, haloalkoxy of 1 to 8 carbon atoms, and cycloalkoxy of 3 to 8 carbon atoms, Is not CH;
[51] R ²⁴ and R ²⁵ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ²³ ,
[52] R ²⁴ and R ²⁵ are 3 to 6 cycloalkyl carbon atoms, 3 to 6 cycloalkenyl carbon atoms, 6 to 10 aryl carbon atoms, and 2 to 9 carbon atoms and N, S (= 0) _0- Independently selected from 1 to 4 heteroaryl heteroatoms selected from ₂ and O, all of which may be substituted with 1 to 3 R ¹⁰ , or
[53] R ²⁴ and R ²⁵ are 3 to 6 carbon atoms and 5 to 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from N, O and S ( _═O ) _0-2 , and 3 to 6 carbon atoms and N , O and S (= 0) independently selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 , wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or carbon May be fused with 5 to 6 membered heteroaryls of 2 to 5 atoms and 1 to 3 heteroatoms selected from N, S ( _═O ) _0-2 and O and / or the heterocycloalkyl or heterocycloalkenyl At least one carbon atom may be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ , or
[54] R ²⁴ and R ²⁵ together with the nitrogen atom to which they are attached are 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 5 to 7 membered heterocycloalkenyl or 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and 0 hetero or 2 to 9 carbon atoms and 1 to 4 heteroatoms Aryl, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or from 5 to 5 carbon atoms and from 1 to 3 heteroatoms selected from N, S (= 0) _0-2 and O; May be fused with 6-membered heteroaryl and / or in said heterocycloalkyl or heterocycloalkenyl one or more carbon atoms may be oxidized to C (═O), all of which are substituted with 1 to 3 R ¹⁰ Can be;
[55] R ²⁶ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ Selected,
[56] R ²⁶ represents 3 to 6 cycloalkyl carbon atoms, 3 to 6 cycloalkenyl carbon atoms, 6 to 10 aryl carbon atoms, and 2 to 9 carbon atoms and N, S (= 0) _0-2 and O Selected from 1 to 4 heteroaryl heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
[57] R ²⁶ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and S (= O) _0-2 is selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
[58] R ²⁷ is selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ²³ , or
[59] R ²⁷ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, 6 to 10 carbon atoms, and 2 to 9 carbon atoms and N, S (= 0) _0-2 and O Selected from 1 to 4 heteroaryl heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
[60] R ²⁷ is 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, O and S (= 0) _0-2 , and 3 to 6 carbon atoms and N, O and S (= O) _0-2 is selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
[61] R ²⁸ is hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , C (= 0) R ²⁴ , C (= O) OR ²⁶ , C (= O) NR ²⁵ R ³⁰ , S (= O) ₂ R ²⁶ , AC (= O) R ²⁴ , AC (= O) OR ²⁴ and AC (= O) NR ^Or selected from ²⁴ R ²⁵ ;
[62] R ²⁸ is from 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, 6 to 10 aryl and 2 to 9 carbon atoms and N, S (= 0) _0-2 and O Selected from 1 to 4 heteroaryls, all of which may be substituted with 1 to 3 R ¹⁰ , or
[63] R ²⁸ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl heteroatoms selected from N, O and S ( _═O ) _0-2 , and 3 to 6 carbon atoms and N, O and S (= O) _0-2 is selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
[64] R ³⁰ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ Selected,
[65] R ³⁰ is 3 to 6 cycloalkyl carbon atoms, 3 to 6 cycloalkenyl carbon atoms, 6 to 10 aryl carbon atoms, and 2 to 9 carbon atoms and N, S (= 0) _0-2 and O Selected from 1 to 4 heteroaryl heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
[66] R ³⁰ is 5-6 membered heterocycloalkyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, O and S (= 0) _0-2 , and 3 to 6 carbon atoms and N, O and S (= O) _0-2 is selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
[67] R ²⁵ and R ³⁰ in combination with the nitrogen atom to which they are attached are 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 5 to 7 membered heterocycloalkenyl or 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and 0 hetero or 2 to 9 carbon atoms and 1 to 4 heteroatoms Aryl is formed, all of which may be substituted with one to three R ¹⁰ ;
[68] R ²⁹ is alkyl having 1 to 6 carbon atoms, alkenyl having 2 to 6 carbon atoms, alkynyl having 2 to 6 carbon atoms, haloalkyl having 1 to 6 carbon atoms, AR ²³ , AC (═O) R ²⁴ , AC (= O) OR ²⁴ , AC (= O) NR ²⁴ R ²⁵ , A-NR ²⁷ R ²⁸ , or
[69] R ²⁹ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, 6 to 10 aryl, and 2 to 9 carbon atoms and N, S (= 0) _0-2 and O Selected from 1 to 4 heteroaryl heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
[70] R ²⁹ is 5-6 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, O and S (= 0) _0-2 , and 3 to 6 carbon atoms and N, O and S (= O) _0-2 is selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
[71] R ⁷ is selected from cycloalkyl of 3 to 8 carbon atoms, cycloalkenyl of 4 to 8 carbon atoms, aryl of 6 to 10 carbon atoms, and heteroaryl of 1 to 4 carbon atoms and 2 to 9 carbon atoms, All of which may be substituted with 1 to 3 R ¹⁰ , or
[72] R ⁷ is 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl of 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N, S ( = O) from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and O, wherein said heterocycloalkyl and said heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O), wherein the heterocycloalkyl or the heterocycloalkenyl is one to three R ¹⁰ , A (OR ²² ) -R ²³ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , S (= O) ₂ R ²⁶ , AC (= O) R ²⁴ , AC (= O) OR ²⁴ or AC (= O) itgeo may be substituted with NR ²⁴ R ²⁵ ,
[73] R ⁷ is hydrogen, nitrile, nitro, hydroxy, alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, haloalkyl of 1 to 8 carbon atoms, carbon atom 1 To 8 alkoxy, haloalkoxy of 1 to 8 carbon atoms, cycloalkoxy of 3 to 8 carbon atoms, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , AC (= O) R ²⁴ , AC (= O) OR ²⁴ and AC (= 0) NR ²⁴ R ²⁵ ,
[74] Of the compounds of formula (I)
[75] 1,5-dimethyl-2- (methylamino) -7- (4-morpholinyl) -1,8-naphthyridin-4 (1H) -one,
[76] 1,5-dimethyl-2- (methylamino) -7- (4-methyl-1-piperazinyl) -1,8-naphthyridin-4 (1H) -one,
[77] 1,5-dimethyl-2- (methylamino) -7- (1-pyrrolidinyl) -1,8-naphthyridin-4 (1H) -one,
[78] 1,5-dimethyl-2- (methylamino) -7- (1-piperidinyl) -1,8-naphthyridin-4 (1H) -one,
[79] 1,5-dimethyl-2- (methylamino) -7- (4-methyl-1-piperazinyl) -3-nitro-1,8-naphthyridin-4 (1H) -one,
[80] 1,5-dimethyl-2- (methylamino) -3-nitro-7- (1-pyrrolidinyl) -1,8-naphthyridin-4 (1H) -one or
[81] 1- (3-chlorophenyl) -2- (4-morpholinyl) -1,8-naphthyridin-4 (1H) -one is excluded.
[82] Another aspect of the invention is that R ¹ is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms and AR ⁹ , or
[83] R ¹ is 6 to 10 aryl carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryl heteroatoms selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, wherein the heterocycloalkyl and the heterocycloalkenyl are further selected from phenyl, Or may be fused with 5 to 6 membered heteroaryls of 2 to 5 carbon atoms and 1 to 3 heteroatoms selected from N, S (= 0) _0-2 and O and / or the heterocycloalkyl or heterocyclo One or more carbon atoms in alkenyl may be oxidized to C (═O), these parent It may be substituted with one to three R ^10;
[84] R ¹⁰ is nitro, nitrile, hydroxy, halogen, acyl of 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, carbon of 1 to 6 carbon atoms 6 haloalkyl, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, aryl of 6 to 10 carbon atoms, 2 to 9 carbon atoms and N, S ( = O) 1 to 4 heteroaryls selected from _0-2 and O, NR ¹¹ R ¹² , C (= 0) OR ¹¹ , C (= 0) NHR ¹¹ , NHC (= 0) R ¹³ , NHS ( = O) ₂ R ¹³ , S (= O) _0-2 R ¹³ , S (= O) ₂ NHR ¹¹ , 3 to 6 cycloalkyl carbon atoms, 3 to 6 cycloalkenyl, 3 to carbon atoms 6, and N, S (= O) _0-2, and 1 to 2 hetero atoms 5- to 7-membered heterocycloalkyl, 3-to 6 carbon atoms selected from N, O, and one N, S (= O) _0-2 and O Heteroatoms selected from 1 Not selected from 2 or 5 to 7 membered heteroaryl and cycloalkenyl; The heterocycloalkyl and the heterocycloalkenyl may further be selected from phenyl or 2 to 5 carbon atoms and 1 to 3 5 to 6 membered heteroaryl selected from N, S (= 0) _0-2 and O; May be fused and / or one or more carbon atoms in said heterocycloalkyl or heterocycloalkenyl may be oxidized to C (═O);
[85] R ¹³ is 1-6 alkyl carbon atoms, alkenyl 2-6 carbon atoms, 2-6 alkynyl carbon atoms, 1-6 haloalkyl carbon atoms, 3-6 cycloalkyl carbon atoms, and carbon atoms 4 to 6 cycloalkenyl;
[86] R ¹¹ and R ¹² are hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms Independently selected from alkyl and cycloalkenyl of 4 to 6 carbon atoms;
[87] A is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, and haloalkyl of 1 to 8 carbon atoms;
[88] R ⁹ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, OAR ¹⁴ , NR ¹¹ R ¹² , or
[89] R ⁹ is 6-10 aryl carbon atoms, 2-9 carbon atoms and 1-4 heteroaryl selected from N, S (= 0) _0-2 and O, cycloalkyl having 3-8 carbon atoms, Selected from cycloalkenyl of 5 to 8 carbon atoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
[90] R ⁹ is 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N, S ( = O) from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and O, wherein said heterocycloalkyl and said heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon in the heterocycloalkyl or the heterocycloalkenyl The atom may be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
[91] R ¹⁴ is 5 to 8 carbon atoms of cycloalkyl, 5 to 8 cycloalkenyl of carbon atoms, 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O To 7 membered heterocycloalkyl and 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which are May be substituted with 1 to 3 R ¹⁰ ;
[92] R ² is NR ¹⁵ R ¹⁶ ;
[93] R ¹⁵ is hydrogen atom, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, cycloalkenyl of 4 to 8 carbon atoms , 5-6 membered heterocycloalkyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 3 to 6 carbon atoms and N, S (= 0) _From 5 to 7 membered heterocycloalkenyl having 1 to 2 heteroatoms selected from _0-2 and O, AR ⁹ , C (= 0) R ¹⁸ , C (= 0) NHR ¹⁸ and S (= 0) ₂ NHR ¹⁸ Selected;
[94] R ¹⁸ is 6 to 10 aryl carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryl heteroalkyls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ , or
[95] R ¹⁸ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, and alkynyl of 2 to 6 carbon atoms, all of which are 1 to 3 halogens, or alkoxy of 1 to 6 carbon atoms May be substituted with
[96] R ¹⁸ is AR ⁹ ;
[97] R ¹⁶ is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms and AR ⁹ , or
[98] R ¹⁶ is 6 to 10 aryl carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryl heteroalkyls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ , or
[99] R ¹⁵ and R ^{16 taken} together with the nitrogen atom to which they are attached have 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S ( _═O ) _0-2 and O, or 3 to carbon atoms 6, and N, S (= O) _0-2, and 1 to 2 hetero atoms 5- to 7-membered heterocycloalkyl, 3-to 6 carbon atoms selected from N, O, and one N, S (= O) _0-2 and O 1 to 2 heteroatoms selected from 5 to 7 membered heterocycloalkenyl, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms and N, S (= 0) Or fused with 5 to 6 membered heteroaryls of 1 to 3 heteroatoms selected from _0-2 and O, wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) May all be substituted with 1 to 3 R ¹⁰ ;
[100] R ³ is selected from cycloalkyls of 3 to 6 carbon atoms, heterocarbons of 1 to 2 heterocycloalkyls selected from 3 to 6 carbon atoms and N, S (= 0) _0-2 and O, all of which are 1 Or may be substituted with 3 R ¹⁰ ;
[101] R ³ is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, hydrogen, nitro, halogen, NR ¹⁹ R ²⁰ , A-OR ¹⁹ , A-NR ¹⁹ R ²⁰ and AR ²⁰ ;
[102] R ¹⁹ and R ²⁰ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ⁹ ,
[103] R ¹⁹ and R ²⁰ are 6 to 10 aryl carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 8 carbon atoms Cycloalkyl, cycloalkenyl of 5 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and carbon Independently selected from 3 to 6 atoms and 1 to 2 5 to 7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, the heterocycloalkyl and the heterocycloalkenyl May further be fused with phenyl or 2 to 5 carbon atoms and 1 to 3 5 to 6 membered heteroaryl selected from N, S (= 0) _0-2 and O and / or the hetero In cycloalkyl or heterocycloalkenyl one or more carbon atoms may be oxidized to C (═O) And, all of which can be optionally substituted with one to three R ^10;
[104] R ⁴ is selected from ═O, = S and OR ²¹ ;
[105] R ²¹ is hydrogen,
[106] R ²¹ is alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, cycloalkenyl of 4 to 8 carbon atoms, carbon atom 3 to 6 and N, S (= 0) _0-2 and 1 to 2 5-7 membered heterocycloalkyl heteroatoms selected from O, and 3 to 6 carbon atoms and N, S (= 0) _0- One or two 5-7 membered heterocycloalkenyl heteroatoms selected from ₂ and O, all of which may be substituted with 1 to 3 R ¹⁰ ;
[107] R ⁵ and R ⁶ are independently selected from cycloalkyls of 3 to 6 carbon atoms, cycloalkenyl of 4 to 6 carbon atoms, phenyl, and monocyclic heteroaryls of 2 to 5 carbon atoms and 1 to 3 carbon atoms All of which may be substituted with 1 to 3 R ¹⁰ , or
[108] R ⁵ and R ⁶ are 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N , S (= 0) _0-2 and O independently selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms, wherein at least one carbon atom in the heterocycloalkyl or heterocycloalkenyl is selected from C ( ═O), wherein the heterocycloalkyl or the heterocycloalkenyl is one to three R ¹⁰ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= 0) OR ²⁴ , C (= 0) NR ²⁴ R ²⁵ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ or AC (= 0) NR ²⁴ R ²⁵ Can be, or
[109] R ⁵ and R ⁶ are hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, halo of 1 to 6 carbon atoms Alkyl, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , AC (= O) R ²⁴ , AC Independently selected from (═O) OR ²⁴ and AC (═O) NR ²⁴ R ²⁵ ;
[110] Q is selected from O and S (= 0) _0-2 ;
[111] R ²² is selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms;
[112] R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, or
[113] R ²³ is a cycloalkyl having 3 to 6 carbon atoms, cycloalkenyl having 4 to 6 carbon atoms, phenyl, and 2 to 5 carbon atoms and heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
[114] R ²³ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O and S (= 0) _0-2 , and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) Wherein the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ,
[115] With the proviso that when R ²³ for A (OR ²² ) -R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, Is not CH;
[116] R ²⁴ and R ²⁵ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ²³ ,
[117] R ²⁴ and R ²⁵ are heteroalkyls selected from 3 to 6 cycloalkyl carbon atoms, 3 to 6 cycloalkenyl carbon atoms, phenyl, and 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; Independently selected from monocyclic heteroaryl of 1 to 3 atoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
[118] R ²⁴ and R ²⁵ are carbon atoms and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N , O and S (= 0) are independently selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 , wherein at least one carbon atom in the heterocycloalkyl or heterocycloalkenyl is selected from C ( = 0), and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ , or
[119] R ²⁴ and R ²⁵ together with the nitrogen atom to which they are attached 5 to 7 membered heterocycloalkyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 5 to 7 membered heterocycloalkenyl or 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O or 2 to 5 carbon atoms and 1 to 3 monoatoms Forms a cyclic heteroaryl, wherein at least one carbon atom in the heterocycloalkyl or heterocycloalkenyl may be oxidized to C (═O), all of which may be substituted with 1 to 3 R ¹⁰ ;
[120] R ²⁶ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ Selected,
[121] R ²⁶ represents 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and heteroatoms selected from N, S (= 0) _0-2 and O; 3 monocyclic heteroaryl, all of which may be substituted with 1 to 3 R ¹⁰ , or
[122] R ²⁶ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
[123] R ²⁷ is selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ²³ , or
[124] R ²⁷ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
[125] R ²⁷ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl of N, O and S ( _═O ) _0-2 , and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
[126] R ²⁸ is hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , C (= 0) R ²⁴ , C (= 0) OR ²⁶ , C (= 0) NR ²⁵ R ³⁰ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ and AC (= 0) NR ^Or selected from ²⁴ R ²⁵ ;
[127] R ²⁸ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, 2 to 5 carbon atoms and 1 to 3 heteroatoms selected from N, S (= 0) _0-2 and O Monocyclic heteroaryl, all of which may be substituted with 1 to 3 R ¹⁰ , or
[128] R ²⁸ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
[129] R ³⁰ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ Selected,
[130] R ³⁰ has 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
[131] R ³⁰ is 1 to 2 5 to 7 membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O, and _0-2 hetero atoms selected from carbon atoms and 3 to 6 N, O or S (= O) One or two 5- to 7-membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
[132] R ²⁵ and R ^{30 taken} together with the nitrogen atom to which they are attached are 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 5 to 7 membered heterocycloalkenyl or 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O or 2 to 5 carbon atoms and 1 to 3 monoatoms Cyclic heteroaryl, all of which may be substituted with one to three R ¹⁰ ;
[133] R ²⁹ is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , AC (= 0) R ²⁴ , AC (= O) OR ²⁴ , AC (= O) NR ²⁴ R ²⁵ , A-NR ²⁷ R ²⁸ , or
[134] R ²⁹ is a heteroatom selected from 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
[135] R ²⁹ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
[136] R ⁷ is selected from 3 to 6 cycloalkyl, 4 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls, all of which are May be substituted with 1 to 3 R ¹⁰ , or
[137] R ⁷ is 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N, S ( = O) from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and 0, wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) Wherein the heterocycloalkyl or the heterocycloalkenyl is one to three R ¹⁰ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= 0) OR ²⁴ , C ( = 0) NR ²⁴ R ²⁵ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ or AC (= 0) NR ²⁴ R ²⁵ , or
[138] R ⁷ is hydrogen, nitrile, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, carbon atom 1 To alkoxy of 6 to 6, haloalkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , AC (= O) R ²⁴ , AC (= O) OR ²⁴ and AC (═O) NR ²⁴ R ²⁵ , and a pharmaceutically acceptable salt thereof, provided that the compound is
[139] 1,5-dimethyl-2- (methylamino) -7- (4-morpholinyl) -1,8-naphthyridin-4 (1H) -one,
[140] 1,5-dimethyl-2- (methylamino) -7- (4-methyl-1-piperazinyl) -1,8-naphthyridin-4 (1H) -one,
[141] 1,5-dimethyl-2- (methylamino) -7- (1-pyrrolidinyl) -1,8-naphthyridin-4 (1H) -one, 1,5-dimethyl-2- (methylamino)- 7- (1-piperidinyl) -1,8-naphthyridin-4 (1H) -one,
[142] 1,5-dimethyl-2- (methylamino) -7- (4-methyl-1-piperazinyl) -3-nitro-1,8-naphthyridin-4 (1H) -one,
[143] 1,5-dimethyl-2- (methylamino) -3-nitro-7- (1-pyrrolidinyl) -1,8-naphthyridin-4 (1H) -one or
[144] It is not 1- (3-chlorophenyl) -2- (4-morpholinyl) -1,8-naphthyridin-4 (1H) -one.
[145] The present invention provides methods for treating or preventing diabetes and related disorders, including type 1 and type 2 diabetes by administering a compound of the present invention. Related disorders include adolescent adult developmental diabetes (MODY), adult latent autoimmune diabetes (LADA), impaired glucose tolerance (IGT), fasting glucose disorders (IFG), gestational diabetes and metabolic syndrome X.
[146] In another embodiment, the invention provides a method of administering a compound of the invention in combination with a PPAR agonist, insulin enhancer, sulfonylurea, insulin secretagog, a compound that lowers hepatic glucose production, an α-glucosidase inhibitor, or insulin. Provide a method. PPAR agonists include rosiglitazone and pioglitazone. Sulfonylureas include glybenclamide, glymepyride, chlorpropamide and glypideide. Insulin secretagogues include GLP-1, GIP, PAC / VPAC receptor agonists, secretin, nateglinide, meglitinide, lepaglinide, glybenclamide, glymepyride, chlorpropamide and glipizide. α-glycosidase inhibitors include acarbose, miglytol and boligose. A compound that lowers hepatic glucose production is metformin.
[147] In another embodiment, the present invention provides a method of administering a compound of the present invention in combination with an HMG-CoA reductase inhibitor, nicotinic acid, bile acid sequestrant, fibric acid derivative, antihypertensive or anti-obesity. Anti-obesity drugs include β-3 agonists, CB-1 antagonists and lipase inhibitors.
[148] In another embodiment of the present invention there is provided a method of treating or preventing a second cause of diabetes such as glucocorticoid hyperplasia, growth hormone hyperplasia, pheochromocytoma and drug induced diabetes.
[149] Finally, the present invention provides a method for increasing the sensitivity of the beta cells of the pancreas to insulin secretagog by administering a compound of the present invention. Insulin secretagogues include GLP-1, GIP, PAC / VPAC receptor agonists, secretin, nateglinide, meglitinide, lepaglinide, glybenclamide, glymepyride, chlorpropamide and glipizide.
[150] The present invention therefore provides compounds and methods for the treatment of diabetes and related disorders. These and other aspects of the invention will become more apparent from the following description and claims.
[1] The present invention relates to 1,8-naphthyridine derivatives, pharmaceutical compositions containing the same, and their use for treating diabetes and related disorders in a subject.
[151] The present invention generally relates to naphthyridine derivatives of the formula
[152]
[153] Wherein one of U, X, Y and Z is nitrogen and the other is CR, wherein R is hydrogen or a substituent such as R ⁵ , R ⁶ or R ⁷ as described above for Formula I and R ¹ , R ² , R ³ and R ⁴ are as defined above for Formula (I).)
[154] The present invention also relates to the compounds of formula (I) described above and to compounds of formula (II).
[155]
[156] Wherein R ^{1 ′} , R ^{2 ′} , R ^{3 ′} , R ^{4 ′} , R ^{5 ′} , R ^{7 ′} and R ^{8 ′} are each of R ¹ , R ² , R ³ , R ⁴ , R ⁵ , Corresponds to R ⁶ and R ⁷ .
[157] Such compounds can be used for the treatment of diabetes and related disorders.
[158] In one embodiment, the present invention relates to a compound of formula (I) as described above. In another embodiment, the invention provides that R ¹ is phenyl which may be substituted with 1 to 3 R ¹⁰ , R ² is NR ¹⁵ R ¹⁶ , R ³ is 3 to 6 cycloalkyl, carbon atom 3 _Or from 1 to 2 heterocycloalkyls selected from N 6 and N, S ( _═O ) _0-2 and O (both may be substituted with 1 to 3 R ¹⁰ ), or R ³ is Is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, hydrogen, nitro, halogen, NR ¹⁹ R ²⁰ , A-OR ¹⁹ , A-NR ¹⁹ R ²⁰ and AR ²⁰ , R ⁴ = O is a compound of formula (I).
[159] In another embodiment, the present invention relates to a method for treating diabetes and related disorders by administering a compound of formula (I). Preferred methods relate to the treatment of type 2 diabetes. In the methods of the invention, the compounds of formula (I) can be administered in combination with PPAR agonists, insulin agonists, sulfonylureas, insulin secretagogues, metformin, α-glucosidase inhibitors and insulin. In another embodiment, the compound of formula (I) is administered in combination with an HMG-CoA reductase inhibitor, nicotinic acid, bile acid sequestrant, fibric acid derivative, antihypertensive or anti-obesity.
[160] In another method of the invention, the compound of formula (I) is administered to treat or prevent a second cause of diabetes or to increase the sensitivity of the beta cells of the pancreas to insulin secretagogues.
[161] General manufacturing method
[162] The compounds of the present invention can be prepared using known chemical reactions and methods. Nevertheless, the following general synthetic schemes are provided to aid the reader in understanding the synthesis of the compounds of the present invention. Particular examples will be presented in the experimental section describing the examples.
[163] In general, compounds of formula (I) wherein R ⁴ is ═O can be prepared from suitably substituted nicotinic acid through several routes summarized in Schemes I through IV below. Compounds of formula (II) wherein R ^{4 ′} is ═O can be prepared from suitably substituted nicotinic acid via the route summarized in Scheme V below. The very similar schemes I and V demonstrate that the route used to synthesize the compounds of formula I can be applied to synthesize the compounds of formula II. The compounds of formula II may also be synthesized from suitably substituted nicotinic acid using the routes shown in Schemes II-IV.
[164]
[165]
[166]
[167]
[168]
[169] Nicotinic acid used in the above schemes can be purchased from commercial raw materials, prepared according to Scheme VI, or described in the literature (Biorg. Med. Chem. Lett. 2001, 475-477; J. Prakt. Chem. 2002, 33). [Eur. J. Org. Chem. 2001, 1371]; J. Org. Chem. 2000, 65, 4618; J Med. Chem. 1997, 40, 2674; Bioorg Med. Chem. Lett. 2000, 10, 1151; US Pat. No. 3838156, etc.).
[170]
[171] Further treatment of compounds of formula I (when R ⁴ == O) and compounds of formula II (when R ^{4 '} == O) resulted in a more diversely substituted compound. Such treatments include aromatic nucleophilic substitution, metal-mediated coupling, reduction, oxidation, amide formation, and the like.
[172] Scheme VII illustrates alkylation and the formation of amide, urea and sulfonamides in compounds of formula I wherein R ² is NHR ¹⁶ . Similar transformations could be carried out in compounds of formula II wherein R ^{2 ′} is NHR ¹⁶ .
[173]
[174] Schemes VIII and IX illustrate the transformation at R ³ of a compound of Formula (I). This transformation could also be applied to R ^{3 ′} of the compound of formula II.
[175]
[176]
[177] Scheme X illustrates the treatment of R ⁴ in a compound of Formula I, which could also be used for R ^{4 ′} in a compound of Formula II.
[178]
[179] Scheme XI illustrates the treatment of R ⁶ in a compound of Formula (I). This treatment could also be applied to R ⁵ and R ⁷ in the compounds of Formula I, and R ^{5 '} , R ^7' and R ^{8 '} in the compounds of Formula II.
[180]
[181] Scheme XII illustrates the treatment on R ⁷ of a compound of Formula (I). This process could also be applied to the R ^{5 'and} R ^7' in the compound of formula (II) and R ⁵ in the compound of formula I.
[182]
[183] Scheme XIII illustrates the treatment on R ⁵ of a compound of Formula (I). This process could also be applied to the R ^{5 'and} R ^7' in the compound of formula II and R ⁷ in the compound of formula I.
[184]
[185] Scheme XIV illustrates the transformation of some functional groups present in compounds of Formula I or II.
[186]
[187] Alternative forms of novel compounds
[188] Compounds of the invention also include (a) stereoisomers thereof, (b) pharmaceutically acceptable salts thereof, (c) tautomers thereof, (d) protected acids and conjugate acids thereof, and (e) pros Drugs are included.
[189] (a) stereoisomers
[190] Examples of stereoisomers of the compounds include, but are not limited to, enantiomers, diastereomers, racemic mixtures, and combinations thereof. Such stereoisomers can be prepared and separated using conventional techniques by reacting enantiomeric starting materials, or by separating isomers of the compounds of the present invention. Isomers may include geometric isomers. Examples of geometric isomers include, but are not limited to, cis isomers or trans isomers following double bonds. It is anticipated that other isomers will be present among the compounds of the present invention. Isomers may be used in pure form or in admixture with other isomers of the inhibitors described above.
[191] (b) pharmaceutically acceptable salts
[192] Pharmaceutically acceptable salts of the compounds of the present invention include salts conventionally used to form alkali metal salts or to form addition salts of free acids or free bases. The nature of the salt is not important if it is pharmaceutically acceptable. Suitable pharmaceutically acceptable acid addition salts can be prepared from inorganic acids or from organic acids. Examples of such inorganic acids are hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, sulfuric acid and phosphoric acid. Suitable organic acids can be selected from aliphatic, cycloaliphatic, aromatic, heterocyclic, carboxyl and sulfone-based organic acids. Examples of such organic and sulfonic organic acids include formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, gluconic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, glucuronic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid, glutamic acid, Benzoic acid, anthranilic acid, mesylic acid, salicylic acid, 4-hydroxybenzoic acid, phenylacetic acid, mandelic acid, embonic acid (palmic acid), methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, pantothenic acid, 2-hydroxyethanesulfonic acid, toluenesulfonic acid , Sulfanilic acid, cyclohexylaminosulfonic acid, stearic acid, algenic acid, N-hydroxybutyric acid, salicylic acid, galactaric acid and galacturonic acid and combinations thereof, but are not limited thereto.
[193] (c) tautomers
[194] Tautomers of the compounds of the present invention are included in the present invention. That is, for example, carbonyl includes hydroxy tautomers thereof.
[195] (d) protected acids and conjugate acids
[196] Examples of protected acids include, but are not limited to, esters, hydroxyamino derivatives, amides and sulfonamides.
[197] (e) Prodrugs
[198] The present invention includes prodrugs and salts of prodrugs. The formation of prodrugs is well known in the art for improving the properties of the parent compound, and examples of such properties include solubility, absorbency, biostability and release time (see, for example, the references cited herein by reference [ " Pharmaceutical Dosage Form and Drug Delivery Systems " (Sixth Edition), edited by Ansel et al., Publ. By Williams & Wilkins, pgs. 27-29, (1995). Commonly used prodrugs are designed to take advantage of the main drug biotransformation response and are also considered to be within the scope of the present invention. Examples of major drug bioconversion reactions include N-dealkylation, O-dealkylation, aliphatic hydroxylation, aromatic hydroxylation, N-oxidation, S-oxidation, deamination, hydrolysis reaction, glucuronation, sulfated and Acetylation ( Goodman and Gilman's The Pharmacological Basis of Therapeutics (Ninth Edition), editor Molinoff et al., Publ.by McGraw-Hill, pages 11-13, (1996). )] Reference).
[199] Dosage and Treatment Prescription
[200] Dosage levels of the compounds of the invention are typically from about 0.001 mg to about 10,000 mg per day, preferably from about 0.005 mg to about 1,000 mg per day. In single or divided doses, based on the daily dose of mg / kg, the dosage is typically from about 0.001 / 75 mg / kg to about 10,000 / 75 mg / kg, preferably from about 0.005 / 75 mg / kg to about In the range of 1,000 / 75 mg / kg.
[201] The total daily administration of each drug may be administered to the patient either alone or in multiple subdoses. Typically, subdoses can be administered 2 to 6 times per day, preferably 2 to 4 times per day, even more preferably 2 to 3 times per day. Administration may be immediate or sustained release sufficiently effective to achieve the desired control effect depending on the symptoms of diabetes.
[202] Dosage regimens for the prevention, treatment, alleviation, or amelioration of diabetic symptoms or disorders, or otherwise for protection from diabetic symptoms or for treating diabetic symptoms with the combinations and compositions of the present invention, are selected according to various factors. Examples of such factors include type of subject, age, weight, sex, diet, and medical condition, severity of disease, route of administration; Pharmacological considerations such as the activity, efficacy, pharmacokinetics and toxicity of the specific inhibitor used, whether the drug delivery system is used, and whether the inhibitor is administered with other active ingredients. In other words, the dosage regimen used in practice may vary widely and therefore may deviate from the preferred dosage regimens described above.
[203] Pharmaceutical composition
[204] For the prevention or treatment of the above mentioned symptoms and disorders, the compounds of the present invention can be administered as the compounds themselves. Alternatively, pharmaceutically acceptable salts are particularly suitable for medical applications because of their greater water solubility compared to the parent compound.
[205] The compounds of the present invention can also be administered in the form of pharmaceutical compositions with a suitable carrier. The carrier should be suitable in terms of miscibility with other components of the composition and should not be unacceptably harmful to the recipient. The carrier may be a solid or a liquid, or both, preferably a unit such as a tablet which may contain, for example, from about 0.05% to about 95% by weight of the active compound (s), based on the total weight of the dosage form. It is formulated with a compound of the present invention as a dosage composition. In addition, other pharmacologically active substances may be present, including other compounds useful for the treatment of diabetes symptoms.
[206] The active compounds of the present invention can be administered by any suitable route, preferably in the form of pharmaceutical compositions adapted to such routes, and in therapeutically effective dosages for the intended treatment. The active compounds and compositions can be administered, for example, orally, sublingually, intranasally, lungs, mucosa, parenterally, intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically. Unit dosage formulations, particularly orally administrable unit dosage formulations such as tablets or capsules, are generally for example from about 0.001 to about 500 mg, preferably from about 0.005 mg to about 100 mg, more preferably from about 0.01 to It contains about 50 mg of active ingredient. In the case of pharmaceutically acceptable salts, the abovementioned weights for the active ingredient refer to the weight of the pharmaceutically active ions derived from the salt.
[207] For oral administration, the pharmaceutical composition may be in the form of a tablet, capsule, suspension, emulsion, paste, solution, syrup or other liquid form, for example. Pharmaceutical compositions are preferably prepared in the form of dosage units containing a specific amount of active ingredient. For oral administration, the compounds are for example lactose, sucrose, starch powder, cellulose esters of cellulose, cellulose alkyl esters, talc, stearic acid, magnesium stearate, sodium oxides of calcium oxide, phosphoric acid and sulfuric acid, calcium salts, gelatin , Acacia gum, sodium alginate, polyvinylpyrrolidone, and / or polyvinyl alcohol, and then can be tableted or encapsulated for convenient administration.
[208] Oral delivery of a compound of the present invention may include agents that promptly deliver or prolong or delay delivery of the drug to the gastrointestinal tract by any number of mechanisms, as is well known in the art. Examples of immediate delivery formulations include, but are not limited to, oral solutions, oral suspensions, fast dissolving tablets or capsules, sublingual tablets, disintegrating tablets, and the like. Examples of extended or delayed delivery formulations include pH sensitive release of the active ingredient from the dosage form based on changes in pH of the small intestine, slow erosion of tablets or capsules, retention of the stomach based on the physical properties of the preparation, dosage form on the mucosal wall of the intestine Biological attachment, or enzymatic release of the active drug from the dosage form. The intended effect is to prolong the time that the active drug molecule is delivered to the active site by manipulation of the dosage form. That is, enteric coated release formulations, and enteric coated controlled release formulations are within the scope of the present invention. Examples of suitable enteric coatings include cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethyl-cellulose phthalate, and anionic polymers of methacrylic acid and methacrylic acid methyl ester.
[209] Pharmaceutical compositions suitable for oral administration may be presented in discrete units such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of one or more compounds of the present invention; As a powder or granules; As a solution or suspension in an aqueous or non-aqueous liquid; Or as oil-in-water or water-in-oil emulsions. As mentioned above, such compositions may be prepared by any suitable method of preparation including the step of bringing into association with the inhibitor (s) and the carrier (which may constitute one or more additional ingredients). Generally, the composition is prepared by uniformly and intimately mixing the inhibitor (s) with a liquid or finely divided solid carrier, or both, and then molding the product, if necessary. For example, tablets may be made by compacting or molding the powder or granules of the inhibitor, optionally with one or more additional ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, a compound in free flowing form, such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent and / or surface active / dispersant (s). Molded tablets can be prepared, for example, by molding powdered compounds in a suitable machine.
[210] Examples of liquid dosage forms for oral administration include pharmaceutically suitable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also include adjuvants such as wetting agents, emulsifiers, suspending agents, sweetening agents, flavoring agents and fragrances.
[211] Examples of pharmaceutical compositions suitable for buccal (sublingual) administration include flavoring bases, typically sucrose, and lozenges comprising the compounds of the invention in acacia or tragacanth, and inert bases such as gelatin and glycerin or sucrose and acacia. Pastilles containing inhibitors.
[212] Formulations for parenteral administration may, for example, be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. Such solutions and suspensions may be prepared from aseptic powders or granules having one or more of the mentioned carriers or diluents for use in the formulation for oral administration. The compound may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride and / or various buffers. Other adjuvants and dosage forms are widely and widely known in the pharmaceutical art.
[213] Pharmaceutically acceptable carriers include all of the foregoing, and the like. The pharmaceutical composition of the present invention may be prepared by any well known preparation technique such as mixing of ingredients. The above considerations regarding effective formulation and methods of administration are well known in the art and are described in the standard literature.
[214] How to use
[215] The present invention also includes methods of treating diabetes and related diseases and symptoms. One such method includes administering a therapeutically effective amount of one or more compounds of Formula (I) to a subject in need thereof.
[216] Compounds of formula (I) can be used in the methods of the invention for the treatment of diseases such as diabetes, including both type 1 and type 2 diabetes. In addition, these methods can delay the onset of diabetes and diabetic complications. Examples of other diseases and conditions that can be treated or prevented using the compounds of formula I in the methods of the present invention include adult developmental diabetes mellitus (MODY) in adolescents (Herman, et al., Diabetes 43:40 (1994) ]), Potential autoimmune diabetes (LADA) in adults (Zimmet, et al., Diabetes Med. 11: 299 (1994)), impaired glucose tolerance (IGT) (Expert Committee on Classification of Diabetes Mellitus) , Diabetes Care 22 (Supp. 1) S5 (1999)]), fasting glucose disorders (IFG) (Charles, et al., Diabetes 40: 796 (1991)), gestational diabetes (Metzger, Diabetes , 40: 197 (1991)), and metabolic syndrome X.
[217] Compounds of formula (I) may also be used in the methods of the present invention to treat secondary causes of diabetes (Expert Committee on Classification of Diabetes Mellitus, Diabetes Care 22 (Supp. 1), S5 (1999)). Examples of such secondary causes include glucocorticoid hyperplasia, growth hormone hyperplasia, pheochromocytoma, and drug-induced diabetes. Examples of drugs that can cause diabetes include, but are not limited to, pyriminyl, nicotinic acid, glucocorticoids, phenytoin, thyroid hormones, β-adrenergic agents, α-interferon and drugs used to treat HIV infection.
[218] The methods and compounds of the present invention can be used alone or in combination with additional therapies and / or compounds known to those skilled in the art in the treatment of diabetes and related disorders. Alternatively, the methods and compounds described herein can be used in combination therapy, partially or completely.
[219] Compounds of formula (I) also include PPAR agonists, sulfonylurea drugs, non-sulfonylurea secretagogues, α-glucosidase inhibitors, insulin enhancers, insulin secretagogues, compounds that lower liver glucose production, insulin and anti-obesity drugs It can be administered in combination with other known therapies for the treatment of diabetes, including. Such therapies may be administered before, simultaneously or after administration of the compound of formula (I). Insulin includes both short-acting forms and preparations of insulin. PPAR agents may include agents of any PPAR subunit or combination thereof. For example, the PPAR agent may comprise PPAR-α, PPAR-γ, PPAR-δ or any combination of two or three PPAR subunits. PPAR agonists include, for example, rosiglitazone and pioglitazone. Sulfonylurea drugs include, for example, glyburide, glymepiride, chlorpropamide, and glipizide. Examples of α-glucosidase inhibitors that may be useful in the treatment of diabetes when administered in combination with a compound of formula (I) include acarbose, miglitol and boligose. Examples of insulin action enhancers that may be useful in the treatment of diabetes when administered with a compound of formula (I) include thiazolidinedione and non-thiazolidinedione. Examples of compounds that lower liver glucose production that may be useful in the treatment of diabetes when administered with a compound of formula (I) include metformin, such as glucophage and glucose XR. Examples of insulin secretagogues that may be useful in the treatment of diabetes when administered in combination with a compound of formula (I) include sulfonylureas and non-sulfonylurea drugs: GLP-1, GIP, PAC / VPAC receptor agonists, secretin, nate Gliide, meglitinide, repaglinide, glibenclamide, glimepiride, chlorpropamide, and glipizide. Examples of GLP-1 include derivatives of GLP-1 with longer half-lives than the original GLP-1, such as fatty acid-derived GLP-1 and exendin. In one embodiment of the invention, the compound of formula (I) is used in combination with insulin secretagog to increase the sensitivity of pancreatic beta cells to insulin secretagog.
[220] The compounds of formula (I) can also be used in combination with anti-obesity agents in the process of the invention. Examples of anti-obesity drugs include β-3 agonists, CB-1 antagonists such as appetite suppressants such as sibutramine (Meridia), and lipase inhibitors such as, for example, Orstat (Xenical). have.
[221] The compounds of formula (I) can also be used in combination with drugs commonly used to treat lipid disorders in diabetic patients in the methods of the invention. Examples of such drugs include, but are not limited to, HMG-CoA reductase inhibitors, nicotinic acid, bile acid sequestrants, and fibric acid derivatives. The compounds of formula (I) can also be used in combination with antihypertensive drugs such as, for example, β-blockers and ACE inhibitors.
[222] Such co-therapy may be administered in any combination of two or more drugs (eg, in combination with a compound of formula (I) and insulin enhancers and anti-obesity drugs). Such co-therapy may be administered in the form of the pharmaceutical composition described above.
[223] Terms
[224] Various terms used herein are defined as follows.
[225] When introducing elements of the present invention or preferred embodiments thereof, the articles "a", "an", "the" and "above" are intended to mean that there is one or more elements. The terms "comprising", "including", "having" are intended to mean including, meaning that there may be additional elements other than the listed elements.
[226] The term "subject" as used herein includes mammals (eg, humans and animals).
[227] The term “treatment” includes any method, action, application, therapy, etc. that provides a subject, including a human, with direct or indirect medical assistance for the purpose of ameliorating the subject's symptoms or slowing the progress of the subject's symptoms or disorders. .
[228] The term "therapeutically effective" means the amount of each agent administered that achieves the goal of improving the severity of the diabetic symptoms or disorders while avoiding or minimizing the side effects associated with a given treatment.
[229] The term "pharmaceutically acceptable" means that the item of interest is suitable for use in pharmaceutical products.
[230] The term “prodrug” includes a compound that is a drug precursor that is administered to a subject and is absorbed and then converted to the active species in vivo. Conversion to the active species in vivo typically occurs through several methods, such as metabolic conversion. An example of a prodrug is an acylated form of the active compound.
[231] The following definitions relate to the structure of the compound: In the groups, radicals, or moieties defined below, the number of carbon atoms is usually specified, for example, with 1-8 carbon atoms or C1-C8 alkyl. The use of the term representing monovalent radicals where divalent radicals are suitable will be understood to denote divalent radicals and vice versa. Unless otherwise specified, conventional definitions of these term controls and conventional stable valences are assumed and achieved in all formulas and groups.
[232] When a symbol such as "AQR" is used, it refers to a group formed by combining groups A, Q and R in this order, and the attachment of the group "AQR" takes place at any position of group A forming a stable structure. . The group Q may be bonded at any position of the group A to form a stable structure, and the group R may be bonded at any position of the group Q to form a stable structure.
[233] When a symbol such as "A (OR ')-R" is used, it refers to a group formed by substituting group A with both groups OR' and R, wherein the attachment of the group "A (OR ')-R" is a stable structure At any position of group A to form The groups OR 'and R may be bonded at any position of the group A to form a stable structure.
[234] The term "halogen" refers to a halogen radical selected from fluoro, chloro, bromo or iodo.
[235] The term "alkyl" refers to a saturated aliphatic hydrocarbon radical. "Alkyl" refers to both branched and unbranched alkyl groups. Examples of "alkyl" include straight chain alkyl groups containing 1 to 10 carbon atoms and branched chain alkyl groups containing 3 to 10 carbon atoms. Other examples include straight chain alkyl groups containing 1 to 6 carbon atoms and branched chain alkyl groups containing 3 to 6 carbon atoms. The term is exemplified by groups such as methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), 1,1-dimethylethyl (tert-butyl) and the like. It may also be abbreviated as "Alk". Any combinational term using the "alk" or "alkyl" prefix should be understood to refer to analogy according to the above definition of "alkyl". For example, terms such as "alkoxy", "alkylthio", "alkylamino" refer to alkyl groups bonded to a second group via oxygen, sulfur, or nitrogen atoms, respectively.
[236] The term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms have been replaced with halogen atoms. The term is exemplified by groups such as trifluoromethyl. More preferred haloalkyl groups are alkyl groups substituted with one or more fluoro or chloro. The term "haloalkoxy" refers to a haloalkyl group bonded to a second group via an oxygen atom.
[237] The term "alkenyl" refers to a mono or polyunsaturated aliphatic hydrocarbon radical. Mono or polyunsaturated aliphatic hydrocarbon radicals contain one or more carbon-carbon double bonds. "Alkenyl" refers to both branched or unbranched alkenyl groups, each optionally optionally partially or fully halogenated. Examples of "alkenyl" include straight chain alkenyl groups containing 2 to 10 carbon atoms and branched chain alkenyl groups containing 3 to 10 carbon atoms. Other examples include straight chain alkenyl groups containing 2 to 6 carbon atoms and branched alkenyl groups containing 3 to 6 carbon atoms. The term is exemplified by groups such as ethenyl, propenyl, n-butenyl, isobutenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, decenyl and the like.
[238] The term "alkynyl" refers to a mono or polyunsaturated aliphatic hydrocarbon radical. Mono or polyunsaturated aliphatic hydrocarbon radicals contain one or more carbon-carbon triple bonds. "Alkynyl" refers to both branched or unbranched alkynyl groups, each optionally optionally partially or fully halogenated. Examples of "alkynyl" include straight chain alkynyl groups containing 2 to 10 carbon atoms and branched chain alkynyl groups containing 4 to 10 carbon atoms. Other examples include straight chain alkynyl groups containing 2 to 6 carbon atoms and branched chain alkynyl groups containing 4 to 6 carbon atoms. The term is exemplified by groups such as ethynyl, propynyl, octinyl and the like.
[239] The term "cycloalkyl" refers to mono- or polycyclic analogs of alkyl groups as defined above. Unless otherwise specified, the cycloalkyl ring may be attached to any carbon atom that results in a stable structure and, if substituted, may be substituted for any suitable carbon atom that results in a stable structure. Examples of cycloalkyl groups are saturated cycloalkyl groups containing 3 to 10 carbon atoms. Another example is a cycloalkyl group containing 3 to 6 carbon atoms. Examples of the cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, cyclononyl, cyclodecyl, norbornane, adamantyl, and the like.
[240] The term "cycloalkenyl" refers to mono- or polycyclic analogs of alkenyl groups as defined above. Unless otherwise specified, the cycloalkenyl ring may be attached to any carbon atom that results in a stable structure and, if substituted, may be substituted for any suitable carbon atom that results in a stable structure. Examples of cycloalkenyl groups are saturated cycloalkenyl groups containing 4 to 10 carbon atoms. Another example is a cycloalkenyl group containing 4 to 6 carbon atoms. Examples of the cycloalkenyl group include cyclobutenyl, cyclopentenyl, cyclohexenyl, norbornene and the like.
[241] The term “heterocycloalkyl” refers to a mono- or polycyclic structure of “cycloalkyl” in which one or more carbon atoms are replaced with one or more atoms independently selected from nitrogen, oxygen, or sulfur atoms. Any nitrogen atom can be optionally oxidized or quaternized and any sulfur atom can be optionally oxidized. Unless otherwise specified, the heterocycloalkyl ring may be attached to any carbon atom or heteroatom that results in a stable structure and, if substituted, may be substituted for any suitable carbon atom or heteroatom that results in a stable structure. . Examples of heterocycloalkyl groups are saturated heterocycloalkyl groups containing 2 to 9 carbon atoms and 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur atoms. Examples of the heterocycloalkyl group include morpholino, pyrazino, tetrahydrofurano and the like.
[242] The term "heterocycloalkenyl" refers to a mono- or polycyclic structure of "cycloalkenyl" in which one or more carbon atoms are replaced with one or more atoms independently selected from nitrogen, oxygen, or sulfur atoms. Any nitrogen atom can be optionally oxidized or quaternized and any sulfur atom can be optionally oxidized. Unless otherwise specified, the heterocycloalkenyl ring may be attached to any carbon atom or heteroatom that results in a stable structure and, if substituted, may be substituted for any suitable carbon atom or heteroatom that results in a stable structure. have. Examples of heterocycloalkenyl groups are saturated heterocycloalkenyl groups containing 2 to 9 carbon atoms and 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur atoms. Examples of the heterocycloalke group include dihydropyran, dihydrofuran and the like.
[243] The term “cycloalkoxy” refers to a monovalent radical of the formula —O-cycloalkyl, ie a cycloalkyl group bonded to a second group via an oxygen atom.
[244] The term “acyl” refers to a monovalent radical of the formula —C (═O) -alkyl and —C (═O) -cycloalkyl, ie an alkyl or cycloalkyl group bonded to a second group via a carbonyl group C (═O), The alkyl may be further substituted with cycloalkyl, aryl, or heteroaryl. Examples of the acyl group include -C (= 0) Me (acetyl), -C (= 0) CH ₂ -cyclopropyl (cyclopropylacetyl), -C (= 0) CH ₂ Ph (phenylacetyl), and the like. have.
[245] The term "aryl" refers to 6-10 membered mono- or polycyclic aromatic carbocycles such as phenyl and naphthyl. Unless otherwise specified, the aryl ring may be attached to any carbon atom that results in a stable structure and, if substituted, may be substituted for any suitable carbon atom that results in a stable structure. The term "aryl" refers to unsubstituted aryl and halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C4-C6 cycloalkenyl, C2-C6 alkynyl, nitro, cyano, hydroxyl , C 1 -C 6 alkoxy, C 3 -C 6 cycloalkoxy, amino, C 1 -C 6 alkylamino (eg -NHMe and -N (Me) ₂ ), C 1 -C 6 acyl, thiol, alkylthio, carboxylic acid groups Aryl optionally substituted with one or more of; All such substituents may be further substituted with optionally selected groups to form stable structures. This may be abbreviated as "Ar". Any combinational term using the "ar" or "aryl" prefix should be understood to refer to analogy according to the above definition of "aryl". For example, terms such as "aryloxy", "arylthio", "arylamino" refer to an aryl group bonded to a second group via an oxygen, sulfur, or nitrogen atom, respectively.
[246] The term “heteroaryl” refers to a stable 5-8 membered (but preferably 5 or 6 membered) monocyclic or 8-11 membered bicyclic aromatic heterocyclic radical. Each heteroaryl contains 1 to 10 carbon atoms and 1 to 5 heteroatoms independently selected from nitrogen, oxygen and sulfur, any sulfur heteroatom may be optionally oxidized, and any nitrogen heteroatom is Optionally oxidized or quaternized. Unless otherwise specified, the heteroaryl ring may be attached to any suitable heteroatom or carbon atom that results in a stable structure and, if substituted, may be substituted for any suitable heteroatom or carbon atom that results in a stable structure. . The term "heteroaryl" refers to an unsubstituted heteroaryl group, or C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C4-C6 cycloalkenyl, C2-C6 alkynyl, nitro, cyano, Hydroxyl, C1-C6 alkoxy, C3-C6 cycloalkoxy, amino, C1-C6 alkylamino (eg -NHMe and -N (Me) ₂ ), C1-C6 acyl, thiol, alkylthio, carboxylic acid And optionally substituted with one or more of the groups of. Examples of “heteroaryl” include furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl , Pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolinyl, indolyl, isoindoleyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, Benzisoxazolyl, benzisothiazolyl, furinyl, quinolininyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pterridinyl, Radicals such as carbazolyl, acridinyl, phenazinyl, phenothiazinyl and phenoxazinyl. Terms such as "heteroaryloxy", "heteroarylthio", "heteroarylamino" refer to a heteroaryl group bonded to a second group via an oxygen, sulfur, or nitrogen atom, respectively.
[247] The term "optionally" or "optionally" means that an event or situation described subsequently may or may not occur, and that the description includes examples where and when the event or situation occurs. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted, and that the description includes both substituted and unsubstituted aryl radicals.
[248] A comprehensive list of abbreviations used by one of skill in the art of organic chemistry is shown in the first edition of each volume of the Journal of Organic Chemistry , which is typically presented in a table titled Standard List of Abbreviations . Abbreviations included in the above list, and all abbreviations used by those skilled in the art of organic chemistry, are incorporated herein by reference.
[249] For the purposes of the present invention, chemical elements are identified according to the inlay of the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87.
[250] Acronyms and Acronyms
[251] When the following abbreviations are used throughout this specification, they have the following meanings:
[252] CH ₂ Cl ₂ methylene chloride
[253] THF tetrahydrofuran
[254] CH ₃ CNacetonitrile
[255] Na ₂ SO ₄ anhydrous sodium sulfate
[256] MgSO ₄ Anhydrous Magnesium Sulfate
[257] DMSO dimethyl sulfoxide
[258] EtOAc ethyl acetate
[259] Et ₂ O diethyl ether
[260] Et ₃ N triethylamine
[261] H ₂ hydrogen
[262] CO carbon monoxide
[263] HCl hydrochloric acid
[264] Hex Hexane
[265] ¹ H NMR proton nuclear magnetic resonance
[266] HPLC high performance liquid chromatography
[267] K ₂ CO ₃ Potassium Carbonate
[268] Cs ₂ CO ₃ Cesium Carbonate
[269] NH ₄ Cl Ammonium Chloride
[270] LC / MS Liquid Chromatography / Mass Spectroscopy
[271] MeOH Methanol
[272] Mass Spectroscopy Using MS ES Electrospray
[273] NaHCO ₃ Sodium Bicarbonate
[274] NaOH sodium hydroxide
[275] RT residence time
[276] h hours
[277] min min
[278] Pd (OAc) ₂ palladium acetate
[279] Ni (dppp) Cl ₂ [1,3-bis (diphenylphosphino) propane] dichloronickel (II)
[280] DMF N, N-dimethylformamide
[281] EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
[282] LTMP Lithium Tetramethylpiperidine
[283] BuLi Butyl Lithium
[284] TLC thin layer chromatography
[285] TFA trifluoroacetic acid
[286] TMEDA tetramethylethylenediamine
[287] BINAP 2,2'-bis (diphenylphosphino) -1,1 'vinaphthyl
[288] HOBt 1-hydroxybenzotriazole hydrate
[289] NaH sodium hydride
[290] MeMgBr Magnesium Bromide
[291] DPPP (diphenylphosphino) propane
[292] DME Dimethoxyethane
[293] AlCl ₃ Aluminum Chloride
[294] TEA triethyl amine
[295] CS ₂ carbon disulfide
[296] MeI methyl iodide
[297] t-BuOK potassium tert-butoxide
[298] KHMDS Potassium Hexamethyldisilazide
[299] LiHMDS Lithium hexamethyldisilazide
[300] NaOBr sodium hypobromite
[301] Br ₂ bromine
[302] Conc. thick
[303] Pd / C Palladium on Carbon
[304] EtOH Ethanol
[305] NH3 ammonia
[306] NaOMe Sodium Methoxide
[307] PPh ₃ triphenylphosphine
[308] NaH sodium hydride
[309] LDA Lithium Diisopropylamide
[310] SOCl ₂ thionyl chloride
[311] MsCl methanesulfonyl chloride
[312] DMAP 4-dimethylaminopyridine
[313] NMM 4-methylmorpholine
[314] AcOH acetic acid
[315] Na ₂ S ₂ O ₃ Sodium Thiosulfate
[316] H ₂ SO ₄ sulfuric acid
[317] CHCl ₃ chloroform
[318] Mn0 ₂ manganese oxide (IV)
[319] LAH Lithium Aluminum Hydride
[320] ADDP 1,1 '-(azodicarbonyl) -dipiperidine
[321] EDTA ethylenediaminetetraacetic acid
[322] CCl ₂ FCClF ₂ 1,1,2-trichlorotrifluoroethane
[323] NaNO ₂ Sodium Nitrite
[324] Manufacturing Example
[325] Examples of the preparation of the compounds of the present invention are provided in the following detailed synthetic methods. In Tables 1A and 2A, the synthesis of each compound is re-quoted in the preparation steps of the above examples. In Tables 1B and 2B, the synthesis of each compound is re-quoted in the preparation steps of the above examples.
[326] All reactions were performed under a positive pressure of dry argon or dry nitrogen and magnetically stirred unless otherwise indicated. Sensitive liquids and solutions were transferred via syringe or cannula and introduced into the reaction tube through the rubber septum. Commercial grade reagents and solvents were used without further purification.
[327] Unless stated otherwise, the term 'concentration under reduced pressure' refers to using a Buchi rotary evaporator at about 15 mm Hg. All temperatures were recorded calibrated in degrees Celsius (° C.). Unless stated otherwise, all parts and percentages are by volume.
[328] Proton ( ¹ H) nuclear magnetic resonance (NMR) spectra were either Me ₄ Si (δ0.00) or residual protonated solvent (CHCl ₃ δ7.26; MeOH δ3.30; DMSO δ2.49) as standard. With Varian Mercury (300 MHz) or Bruker Avance (500 MHz) spectrometer. The NMR data of the synthesized examples not disclosed in the detailed characterizations below correspond to those correspondingly structurally designated.
[329] HPLC-MS spectra are equipped with a quaternary pump, a variable wavelength tracker tuned to 254 nm, a YMC Pro C-18 column (2 x 23 mm, 120A), and a Finnigan LCQ ion trap mass spectrometer with electrospray ionization Measured by Hewlett-Packard 1100 HPLC. Spectra were scanned from 120-1200 amu using varying ion times depending on the number of ions in the source. Eluent was 2% CH ₃ CN in water with A: 0.02% TFA and B: 2% water in CH ₃ CN with 0.018% TFA. Elution gradients from 10% B to 95% B over 3.5 minutes at a flow rate of 1.0 mL / min were used for the first 0.5 minutes and 95% B for the last 0.5 minutes. Total run time was 6.5 minutes.
[330] Elemental analysis was performed by Robertson Microlit Labs, Madison, NJ. The results of elemental analysis when performed but not disclosed in the detailed characterizations below correspond to those correspondingly structurally designated.
[331] The following specific examples are presented to illustrate the invention with respect to formula I as described herein, but should not be construed to limit the scope of the invention in any way.
[332] Intermediate A:
[333] 2,6-dichloro-4-methyl-nicotinic acid
[334]
[335] Method 1
[336] A solution of sodium nitrite (2.73 g, 39.6 mmol) in water (15 mL) was commercially available in concentrated sulfuric acid (Maybridge) 2,6-dichloro-4-methylnicotinamide (4.5 g, 22 mmol) Was slowly added to the solution, resulting in heat and brown gas. The mixture was stirred at room temperature for 15 minutes and then heated to 60 ° C. for 7 hours. The solution was cooled to 0 ° C. and then water (15 mL) was added. The white precipitate obtained was collected by filtration and washed with hexane. The aqueous filtrate was extracted with EtOAc (3X) and the combined organic extracts were dried over MgSO ₄ and concentrated in vacuo. The residue was combined with a white precipitate to give 2,6-dichloro-4-methyl-nicotinic acid (4.39 g, 97%) as a white solid:
[337] Method 2
[338] Concentrated nitric acid (14 mL) was added to chilled (0 ° C.) concentrated sulfuric acid (43 mL) while maintaining the internal temperature below 10 ° C. After addition, the acid mixture was heated to 70 ° C. and a commercially available (Avocado) 2,6-dichloro-4-methylnicotinonitrile (20.0 g, 107 mmol) was added. The temperature was raised until the internal temperature of the reaction reached 105 ° C. Heating was stopped at this point and TLC analysis confirmed that the reaction was complete after 2 hours. The reaction mixture was cooled to rt and slowly added to ice (100 g) with vigorous stirring. The solid was filtered off and washed with cold water (10 mL). The solid was dissolved in EtOAc (100 mL) and the solution was dried over Na ₂ SO ₄ and concentrated to give 2,6-dichloro-4-methyl-nicotinic acid (21.0 g, 96%) as a white solid:
[339]
[340] Intermediate B:
[341] 2,6-dichloro-4-methyl-nicotinoyl chloride
[342]
[343] A solution of 2,6-dichloro-4-methyl-nicotinic acid (3.94 g, 19.1 mmol) in thionyl chloride (18 mL) was heated to 80 ° C. for 2 h. After cooling, the solution was concentrated in vacuo to give 2,6-dichloro-4-methyl-nicotinoyl chloride as a yellow oil. It was used for the next step without further purification. The conversion can also be carried out using oxalyl chloride in conjunction with catalyst DMF instead of thionyl chloride.
[344] Intermediate C:
[345] 3,3-Dichloro-1- (2,6-dichloro-4-methyl-pyridin-3-yl) -propenone
[346]
[347] A solution of 2,6-dichloro-4-methyl-nicotinoyl chloride from the previous reaction in CH ₂ Cl ₂ (10 mL) was diluted with AlCl ₃ (2.54 g, 19.1 mmol) in CH ₂ Cl ₂ (54 mL). Cooling (0 ° C.) and slow addition to the stirred slurry solution. After 15 minutes, vinylidene chloride (1.5 mL, 1.85 g, 19.1 mmol) was added dropwise to the mixture. The reaction was warmed to rt and stirred overnight. The mixture was poured onto ice and the ice slurry acidified with 1 N HCl (50 mL). Stirring was continued for 20 minutes, then the product was extracted with CH ₂ Cl ₂ (3X). The combined organic extracts were dried over Na ₂ SO ₄ and concentrated in vacuo to give 3,3-dichloro-1- (2,6-dichloro-4-methyl-pyridin-3-yl) -propenone (4.22 g, 77% ) Was obtained as a yellow oil:
[348] Intermediate D:
[349] 1- (2,6-Dichloro-4-methyl-pyridin-3-yl) -3,3-bis-phenylamino-propenone
[350]
[351] A solution of aniline (4.04 mL, 44.4 mmol) in TEA (6.2 mL, 44.4 mmol) was added to 3,3-dichloro-1- (2,6-dichloro-4-methyl-pyridine-3- in dioxane (50 mL). Cooling of (i) -propenone (4.22 g, 14.8 mmol) (0 ° C.) and slow addition to the stirred solution. The reaction was warmed to rt and stirred overnight. The mixture was concentrated in vacuo until most solvent was removed, then the residue was diluted with water and extracted with EtOAc (3X). The combined organic extracts were washed with water, dried over Na ₂ S0 ₄ and concentrated in vacuo. Silicagel flash chromatography of the residue with 7: 1 EtOAc: Hex gave 1- (2,6-dichloro-4-methyl-pyridin-3-yl) -3,3-bis-phenylamino-propenone as a yellow solid ( 2.22 g, 40%).
[352] Intermediate E:
[353] 7-chloro-5-methyl-1-phenyl-2-phenylamino-1H- [1,8] -naphthyridin-4-one
[354]
[355] 1- (2,6-dichloro-4-methyl-pyridin-3-yl) -3,3-bis-phenylaminopropenone (2.17 g, 5.45 mmol) and t-BuOK (1.10) in dioxane (55 mL) g, 9.81 mmol) was heated to 80 ° C. overnight. The reaction was cooled, concentrated in vacuo, diluted with water and extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na ₂ S0 ₄ and concentrated in vacuo. Silicagel flash chromatography of the residue with 1: 1 EtOAc: Hex gave 7-chloro-5-methyl-1-phenyl-2-phenylamino-1H- [1,8] naphthyridin-4-one (1.297 g, 66 %) Was obtained as an orange solid: LCMS RT: 2.52 min, MH ⁺ : 362.3, R _f = 0.18 (1: 1 EtOAc: Hex). The conversion may also be performed using other aprotic solvents such as DMF and THF in combination with other bases such as NaH.
[356] Intermediate F:
[357] 2,6-dichloro-4- (trifluoromethyl) nicotinic acid
[358]
[359] Method 1
[360] A solution of NaNO ₂ (9.59 g, 139 mmol) in water (95 mL) was commercially available (Oakwood) 2,6-dichloro-4- (trifluoromethyl) nicotine in concentrated H ₂ SO ₄ . To the solution of amide (20.0 g, 77 mmol) was added slowly, resulting in heat and brown gas. The mixture was stirred at room temperature for 15 minutes and then heated to 60 ° C. for 18 hours. The solution was cooled to 0 ° C. and then water (15 mL) was added. The resulting mixture was extracted with Et ₂ O (3 ×) and the combined organic extracts were dried over MgSO ₄ and concentrated in vacuo. The residue was triturated with hexanes and vacuum filtered to give 2,6-dichloro-4- (trifluoromethyl) nicotinic acid (19 g, 95%) as off-white solid:
[361]
[362] Method 2
[363] Concentrated HNO ₃ (13.3 mL) was added to cooled (0 ° C.) conc. H ₂ SO ₄ (60 mL) while maintaining the internal temperature below 10 ° C. After addition, the acid mixture was heated to 70 ° C. and a commercially available (mage) 2,6-dichloro-4- (trifluoromethyl) nicotinonitrile (20.0 g, 83 mmol) was added. The temperature was raised until the internal temperature of the reaction reached 100 ° C. After heating for 1 hour TLC analysis confirmed that the reaction was complete. The reaction mixture was cooled to room temperature, added slowly to ice (100 g) with vigorous stirring, and extracted with Et ₂ O (3X). The organic layers were combined and washed with brine. The solution was dried over Na ₂ SO ₄ and concentrated in vacuo to give 2,6-dichloro-4- (trifluoromethyl) nicotinic acid (19.1 g, 89%) as off-white solid:
[364]
[365] Intermediate G:
[366] 2,6-dichloro-4- (trifluoromethyl) nicotinoyl chloride
[367]
[368] A solution of 2,6-dichloro-4- (trifluoromethyl) nicotinic acid (3.22 g, 13.2 mmol) in thionyl chloride (9 mL) was heated at reflux for 3 h. After cooling, the solution was concentrated in vacuo to give 2,6-dichloro-4- (trifluoromethyl) nicotinoyl chloride as a yellow oil which was used in the next step without further purification. The conversion can also be carried out using oxalyl chloride in conjunction with catalyst DMF instead of thionyl chloride.
[369] Intermediate H:
[370] 3,3-dichloro-1- [2,6-dichloro-4- (trifluoromethyl) -3-pyridinyl] -2-propen-1-one
[371]
[372] _{CH 2 Cl 2 AlCl 3 (4.4} g of (14 mL) of (trifluoromethyl) 2,6-Dichloro-4 from the previous reaction, a solution of Nikko Martino chloride _{CH 2 Cl 2 (14 mL)} , 33.0 mmol) was added slowly to the cooled (0 ° C.) and stirred slurry solution. After 15 minutes, vinylidene chloride (2.6 mL, 33.0 mmol) was added dropwise to the mixture. The reaction was warmed to rt and stirred overnight. The mixture was poured over ice and partitioned with CH ₂ Cl ₂ . The organic layer was collected, cooled to 0 ° C. and then TEA (4.6 mL, 33 mmol) was added. After 15 minutes, the ice bath was removed and the reaction was allowed to warm to room temperature and stirred for an additional 30 minutes. The solution was washed with 1N HCl, NaHCO ₃ , and water. The organic layer was passed through a pad of silica gel and concentrated in vacuo to give 3,3-dichloro-1- [2,6-dichloro-4- (trifluoromethyl) -3-pyridinyl] -2-propene-1- One (4.3 g, 95%) was obtained as a brown oil:
[373]
[374] Intermediate I:
[375] 3,3-Dianilino-1- [2,6-dichloro-4- (trifluoromethyl) -3-pyridinyl] -2-propen-1-one
[376]
[377] A solution of aniline (18.4 mL, 202 mmol) in TEA (28.2 mL, 202 mmol) was added to 3,3-dichloro-1- [2,6-dichloro-4- (trifluoromethyl) in dioxane (220 mL). -3-pyridinyl] -2-propen-1-one (22.9 g, 67.4 mmol) was added slowly to the cooled (0 ° C.) and stirred solution. The reaction was warmed to rt and stirred overnight. The mixture was treated with 10% HCl and extracted with Et ₂ O (3 ×). The combined organic extracts were washed with brine, dried over Na ₂ S0 ₄ and concentrated in vacuo. Silicagel flash chromatography of the residue with 6: 1 Hex: EtOAc gave 3,3-dianilin-1- [2,6-dichloro-4- (trifluoromethyl) -3-pyridinyl] -2-pro Phen-1-one was obtained as an off-white solid (13.10 g, 43%):
[378]
[379] Intermediate J:
[380] 2-anilino-7-chloro-1-phenyl-5- (trifluoromethyl) -1,8-naphthyridin-4 (1H) -one
[381]
[382] 3,3-Danilino-1- [2,6-dichloro-4- (trifluoromethyl) -3-pyridinyl] -2-propen-1-one (12.9 g) in dioxane (200 mL) , 28.5 mmol) and t-BuOK (28.5 mL, 28.5 mmol, 1M in THF) were heated at reflux overnight. The reaction was cooled, concentrated in vacuo, treated with saturated NH ₄ Cl and extracted with EtOAc (3 ×). The combined organic extracts were washed with brine, dried over MgSO ₄ and concentrated in vacuo. Silicagel flash chromatography of the residue with 6: 1 Hex: EtOAc to 2-anilino-7-chloro-1-phenyl-5- (trifluoromethyl) -1,8-naphthyridin-4 (1H) -one (11.2 g, 95%) was obtained as an off-white solid: LCMS RT: 3.00 min, MH ⁺ : 416.7, R _f = 0.25 (3: 1 Hex: EtOAc). The conversion may also be performed using other aprotic solvents such as DMF and THF in combination with other bases such as NaH.
[383] Intermediate K:
[384] 2,6-dichloro-5-fluoronicotinoyl chloride
[385]
[386] A solution of commercially available (Aldrich) 2,6-dichloro-5-fluoronicotinic acid (5.00 g, 23.8 mmol) in thionyl chloride (15 mL) was heated at reflux for 3 h. After cooling, the solution was concentrated in vacuo to give 2,6-dichloro-5-fluoronicotinoyl chloride as a brown oil which was used for the next step without further purification. The conversion can also be carried out using oxalyl chloride in conjunction with catalyst DMF instead of thionyl chloride.
[387] Intermediate L:
[388] 3,3-dichloro-1- (2,6-dichloro-5-fluoro-3-pyridinyl) -2-propen-1-one
[389]
[390] CH ₂ of _{AlCl 3 (7.9 g, 59.5 mmol} ) of Cl ₂ (25 mL) and a solution of 2,6-dichloro-5-fluoro Nikko one from the previous reaction Martino of chloride CH ₂ Cl ₂ (25 mL) Cooling (0 ° C.) and slow addition to the stirred slurry solution. After 15 minutes, vinylidene chloride (4.75 mL, 59.5 mmol) was added dropwise to the mixture. The reaction was warmed to rt and stirred overnight. The mixture was poured over ice and partitioned with CH ₂ Cl ₂ . The organic layer was collected, cooled to 0 ° C. and then TEA (8.3 mL, 59.5 mmol) was added. After 15 minutes, the ice bath was removed and the reaction was allowed to warm to room temperature and stirred for an additional 30 minutes. The solution was washed with 1N HCl, NaHCO ₃ , and water. The organic layer was passed through a pad of silica gel and concentrated in vacuo to give 3,3-dichloro-1- (2,6-dichloro-5-fluoro-3-pyridinyl) -2-propen-1-one (6.1 g , 90%) was obtained as a brown oil:
[391]
[392] Intermediate M:
[393] 3,3-Dianilino-1- (2,6-dichloro-5-fluoro-3-pyridinyl) -2-propen-1-one
[394]
[395] 0 of 3,3-dichloro-1- (2,6-dichloro-5-fluoro-3-pyridinyl) -2-propen-1-one (6.70 g, 23.2 mmol) in dioxane (50 mL) To the C solution was added TEA (9.7 mL, 69.6) followed by aniline (6.3 mL, 69.6 mmol). After 1 hour, the reaction was allowed to warm to room temperature and stirred overnight. The mixture was concentrated in vacuo until most solvent was removed, then the residue was diluted with water and extracted with CH ₂ Cl ₂ (2X). The combined organic extracts were washed with water, dried over Na ₂ S0 ₄ and concentrated in vacuo. Purify the residue by silica gel Biotage chromatography to give 3,3-Dianilino-1- (2,6-dichloro-5-fluoro-3-pyridinyl) -2-propene-1- One was obtained as a yellow solid (4.2 g, 49%):
[396] Intermediate N:
[397] 2-anilino-7-chloro-6-fluoro-1-phenyl-1,8-naphthyridin-4 (1H) -one
[398]
[399] 3,3-Dianilino-1- (2,6-dichloro-5-fluoro-3-pyridinyl) -2-propen-1-one (2.3 g, 5.7 mmol) in dioxane (80 mL) And a mixture of t-BuOK (1.28 g, 11.4 mmol) was stirred at 80 ° C. overnight. The reaction was cooled, concentrated in vacuo, diluted with water and extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na ₂ S0 ₄ and concentrated in vacuo. Silicagel flash chromatography of the residue gave 2-anilino-7-chloro-6-fluoro-1-phenyl-1,8-naphthyridin-4 (1H) -one (1.0 g, 50%) as a light yellow solid. Obtained: LCMS RT: 2.60 min, MH ⁺ : 366.8. The conversion may also be performed using other aprotic solvents such as DMF and THF in combination with other bases such as NaH.
[400] Using the appropriate amine, as for the intermediate N 3,3- dichloro-1- (2,6-dichloro-5-fluoro-3-pyridinyl) -2-propene-1-one from the intermediate N ₁ To N ₁₂ were synthesized.
[401] Intermediate N ₁ :
[402]
[403]
[404] Intermediate N ₂ :
[405]
[406]
[407] Intermediate N ₃ :
[408]
[409]
[410] Intermediate N ₄ :
[411]
[412]
[413] Intermediate N ₅ :
[414]
[415]
[416] Intermediate N ₆ :
[417]
[418]
[419] Intermediate N ₇ :
[420]
[421]
[422] Intermediate N ₈ :
[423]
[424]
[425] Intermediate N ₉ :
[426]
[427]
[428] Intermediate N ₁₀ :
[429]
[430]
[431] Intermediate N ₁₁ :
[432]
[433]
[434] Intermediate N ₁₂ :
[435]
[436]
[437] Intermediate N ₁₃ :
[438]
[439]
[440] Intermediate O:
[441] 2,6-dichloronicotinoyl chloride
[442]
[443] A commercially available solution of (Aldrich) 2,6-dichloro-nicotinic acid (2.0 g, 10.4 mmol) in thionyl chloride (10 mL) was heated to 80 ° C. for 2 hours. After cooling, the solution was concentrated in vacuo to give 2,6-dichloro-nicotinoyl chloride as a yellow oil which was used in the next step without further purification. The conversion may also be carried out using oxalyl chloride in conjunction with catalyst DMF instead of thionyl chloride.
[444] Intermediate P:
[445] 3,3-dichloro-1- (2,6-dichloro-3-pyridinyl) -2-propen-1-one
[446]
[447] A solution of 2,6-dichloro-nicotinoyl chloride (1.0 g, 4.76 mmol) from the previous reaction in CH ₂ Cl ₂ (5 mL) was added with AlCl ₃ (0.64 g, 4.76 in CH ₂ Cl ₂ (20 mL). cooling) (0 mmol) and slowly added to the stirred slurry solution. After 15 minutes, vinylidene chloride (0.38 mL, 0.46 g, 4.76 mmol) was added dropwise to the mixture. The reaction was warmed to rt and stirred overnight. The mixture was poured onto ice and acidified with 1 N HCl (15 mL). Stirring was continued for 20 minutes, then the product was extracted with CH ₂ Cl ₂ (3X). The combined organic extracts were dried over Na ₂ SO ₄ and concentrated in vacuo to give 3,3-dichloro-1- (2, 6-dichloro-3-pyridinyl) -2-propen-1-one (0.88 g, 68 %) Was obtained as a light yellow oil:
[448]
[449] Intermediate Q:
[450] 3,3-Dianilino-1- (2,6-dichloro-3-pyridinyl) -2-propen-1-one
[451]
[452] A solution of aniline (1.01 mL, 11.1 mmol) in TEA (1.55 mL, 11.1 mmol) was added to 3,3-dichloro-1- (2,6-dichloro-3-pyridinyl) -2- in dioxane (20 mL). Cooling of propen-1-one (1.0 g, 3.69 mmol) (0 ° C.) and slow addition to the stirred solution. The reaction was warmed to rt and stirred overnight. The mixture was concentrated in vacuo until most solvent was removed. The residue was diluted with water and extracted with EtOAc (3X). The combined organic extracts were washed with water, dried over Na ₂ S0 ₄ and concentrated in vacuo. Silicagel flash chromatography of the residue with 6: 1 EtOAc: Hex gave 3,3-dianilin-1- (2,6-dichloro-3-pyridinyl) -2propen-1-one as pale yellow solid ( 0.69 g, 49%).
[453] Intermediate R:
[454] 2-anilino-7-chloro-1-phenyl-2,3-dihydro-1,8-naphthyridin-4 (1H) -one
[455]
[456] 3,3-Dianilino-1- (2,6-dichloro-3-pyridinyl) -2-propen-1-one (0.08 g, 0.21 mmol) and NaH (0.009 g, in THF (6 mL) 0.23 mmol) was heated to 80 ° C. overnight. The reaction was cooled, concentrated in vacuo, diluted with water and extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na ₂ S0 ₄ and concentrated in vacuo. Silicagel flash chromatography of the residue with 3: 1 Hex: EtOAc gave 2-anilino-7-chloro-1-phenyl-2,3-dihydro-1,8-naphthyridin-4 (1H) -one (49 mg, 68%) was obtained as an off-white solid: LC-MS RT: 2.56 min, MH ⁺ : 348.2. The conversion can be performed using aprotic solvents such as dioxane and DMF in combination with other bases such as t-BuOK.
[457] Intermediate S:
[458] Ethyl 3- (2-chloro-6-methyl (3-pyridyl))-3-oxopropanoate
[459]
[460] Ethyl 3- (2-chloro-6-methyl (3-pyridyl))-3-oxopropanoate was prepared by the general method described in the Journal of Medicinal Claemistry , 1986, 29, 2363. The product has MH ⁺ : 242.1, LCMS RT: 2.33 and 3.06 min (keto-enol).
[461] Intermediate T:
[462] Ethyl (2Z) -2-[(2-chloro-6-methyl (3-pyridyl)) carbonyl] -3,3-dimethylthio-prop-2-enoate
[463]
[464] CS ₂ CO ₃ (24.0 g, 72.5 mmol) was diluted with ethyl 3- (2-chloro-6-methyl (3-pyridyl))-3-oxopropanoate (7.0 g, 29 mmol) in THF (290 mL). Was added to the solution. The reaction mixture was cooled to -10 ° C and after 15 minutes CS ₂ (8.7 mL, 145 mmol) was added. Stirring was continued for 2 hours, and MeI (4.5 mL, 72.5 mmol) was added. The reaction was slowly warmed to room temperature over 18 hours and filtered. The filtrate was concentrated in vacuo to afford ethyl (2Z) -2-[(2-chloro-6-methyl (3-pyridyl)) carbonyl] -3,3-dimethylthioprop-2-enoate as a yellow oil. Obtained and used without purification. LCMS RT: 2.79 min, MH ⁺ : 345.8. Various alkyl halides can be used to quench the sulfur anions generated.
[465] Intermediate U:
[466] Ethyl (2E) -3,3-bis (phenylamino) -2-[(2-chloro-6-methyl (3-pyridyl))-carbonyl] prop-2-enoate
[467]
[468] Ethyl (2Z) -2-[(2-chloro-6-methyl (3-pyridyl)) carbonyl] -3,3-dimethylthioprop-2-enoate in THF (1.4 mL) (100 mg, 0.28 mmol) and aniline (0.076 mL, 0.83 mmol) were heated at reflux for 18 h. The reaction was cooled to rt and concentrated in vacuo. Silicagel flash chromatography of the residue with 1: 1 EtOAc: Hex to ethyl (2E) -3,3-bis (phenylamino) -2-[(2-chloro-6-methyl (3-pyridyl)) carbonyl ] Prop-2-enoate (55.6 mg, 44%) was obtained:
[469] Intermediate V:
[470] Ethyl 7-methyl-2-methylthio-4-oxo-1-phenylhydropyridino [2,3-b] -pyridine-3-carboxylate
[471]
[472] Aniline (3.96 mL, 43.5 mmol) was diluted with ethyl (2Z) -2-[(2-chloro-6-methyl (3-pyridyl)) carbonyl] -3,3-dimethylthioprop in DMSO (72.5 mL). To a solution of -2-enoate (5.13 g, 14.5 mmol). The reaction solution was heated to 70 ° C. for 18 hours and then cooled to room temperature. The solution was diluted with EtOAc, washed with water and brine, dried over Na ₂ S0 ₄ and concentrated in vacuo. The orange oil obtained was triturated with Et ₂ 0 to afford some desired product as a yellow solid. Further product was obtained by silica gel flash chromatography of the mother liquor with 1: 1 EtOAc: Hex. Purification twice gave ethyl 7-methyl-2-methylthio-4-oxo-1-phenylhydropyridino [2,3b] pyridine-3-carboxylate (2.87 g, 56%) as a yellow solid:
[473] Intermediate W:
[474] Ethyl 7-methyl-4-oxo-1-phenyl-2- (phenylamino) hydro-pyridino [2,3-b] -pyridine-3-carboxylate
[475]
[476] Ethyl (2E) -3,3-bis (phenylamino) -2-((2-chloro-6-methyl (3-pyridyl)) carbonyl) prop-2-enoate in dioxane (2 mL) (85.0 mg, 0.195 mmol) and t-BuOK (67 mg, 0.60 mmol) were heated at reflux for 48 h. The reaction was cooled to rt and concentrated in vacuo. Silicagel flash chromatography of the residue with 3: 1 Hex: EtOAc to 100% EtOAc in ethyl 7-methyl-4-oxo-1-phenyl-2- (phenylamino) hydropyridino [2,3-b] pyridine- 3-carboxylate (39 mg, 49%) was obtained as a white solid: LCMS RT: 2.80 min, MH ⁺ 400.0. The conversion can be performed using other aprotic solvents such as DMF and THF in combination with other bases such as NaH.
[477] Intermediate X:
[478] Ethyl 2-[(4-chlorophenyl) amino] -7-methyl-4-oxo-1-phenyl-hydropyridino- [2, 3b] pyridine-3-carboxylate
[479]
[480] KHMDS (0.5 M in toluene, 0.84 mL, 0.42 mmol) was added to a cooled (-78 ° C.) solution of 4-chloroaniline (71.4 mg, 0.560 mmol) in THF (0.70 mL). After 2 h, ethyl 7-methyl-2-methylthio-4-oxo-1-phenylhydropyridino [2,3-b] pyridine-3-carboxylate (100 mg, 0.28 mmol) in THF (0.70 mL) ) Solution was added and an orange solution formed immediately. The reaction was slowly warmed to rt, stirred for 21 h and quenched with saturated aqueous NH ₄ Cl. The aqueous solution was extracted with Et ₂ O (3X) and the combined organic extracts were washed with water and brine, dried over Na ₂ SO ₄ and concentrated in vacuo. Silicagel flash chromatography of the residue using 1: 1 EtOAc: Hex to ethyl 2-[(4-chlorophenyl) amino] -7-methyl-4-oxo-1-phenylhydropyridino [2,3-b] pyridine 3-carboxylate (30.0 mg, 25%) was obtained as a white solid:
[481] Intermediate Y:
[482] 5-Bromo-2-hydroxy-6-methylnicotinic acid
[483]
[484] A solution of NaOBr was prepared by adding Br ₂ (11.4 g, 3.66 mL, 71.3 mmol) to cooling (0 ° C.) and stirred solution of NaOH (7.8 g, 196 mmol) in water (90 mL). The solution is allowed to warm to room temperature and then commercially available (Aldrich) 2-hydroxy-6-methylpyridine-3-carboxylic acid (10.0 g, 65.1 mmol) and NaOH (7.8) in water (30 mL). g, 196 mmol). After stirring for 5 minutes, the mixture was cooled to 0 ° C. and carefully acidified with concentrated HCl. The precipitate was filtered off and dried over MgSO ₄ to afford 5-bromo-2-hydroxy-6-methylnicotinic acid (15.0 g, 99%):
[485]
[486] Intermediate Z (same as Intermediate BA):
[487] 2,4-dichloro-6-methylnicotinic acid
[488]
[489] Commercially available (mage) ethyl 2,4-dichloro-6-methylpyridine-3-carboxylate (1.0 g, 4.3 mmol) and NaOH (342 mg, in water (1.7 mL) and MeOH (1.5 mL) 8.6 mmol) was heated to 80 ° C. for 4 hours. The mixture was acidified with 50% H ₂ SO ₄ and filtered. The solid was washed with cold water and dried to give 2,4-dichloro-6-methylpyridine-3-carboxylic acid (582 mg, 66%):
[490]
[491] Intermediate AA (same as Intermediate BB):
[492] 3,3-dichloro-1- (2,4-dichloro-6-methyl-3-pyridinyl) -2-propen-1-one
[493]
[494] The compound was prepared according to the method described for the following intermediate BB:
[495]
[496] Intermediate AB (same as Intermediate BC):
[497] 3,3-Dianilino-1- (2,4-dichloro-6-methyl-3-pyridinyl) -2-propen-1-one
[498]
[499] The compound was prepared according to the method described for the following intermediate BC:
[500]
[501] Intermediate AC:
[502] (2Z) -3-anilino-1- (2,6-dichloro-5-fluoro-3-pyridinyl) -3- (isopropylamino) -2-propen-1-one
[503]
[504] 3,3-dichloro-1- (2,6-dichloro-5-fluoro-3-pyridinyl) -2-propen-1-one (374.0 mg, 1.29 mmol) was diluted with CH ₂ Cl ₂ (5 mL). It melt | dissolved in and cooled to 10 degreeC. Aniline (120.0 mg, 1.29 mmol) and isopropylamine (76.5 mg, 1.29 mmol) were added dropwise to 3 mL of 1,4-dioxane as a mixture. TEA (0.897 mL, 6.45 mmol) was added and the reaction mixture was allowed to warm to rt, left to stir for 2 h. Dioxane was removed in vacuo and the brown residue was partitioned between EtOAc and saturated aqueous NaHCO ₃ . The aqueous layer was extracted with EtOAc. The combined organic extracts were washed with brine, dried over MgSO ₄ and concentrated in vacuo. Purification of the residue using Biotage silica gel chromatography eluting with 6: 1 to 7: 3 Hex: EtOAc (2Z) -3-anilino-1- (2,6-dichloro-5-fluoro-3-pyridine Dinil) -3- (isopropylamino) -2-propen-1-one (45 mg, 10%) was obtained as off-white solid:
[505] Intermediate AD:
[506] 4-nitrophenyl 2-{[3- (trifluoromethyl) phenyl] amino} nicotinate
[507]
[508] EDCI in CH ₂ Cl ₂ (20 mL) in a warmed (40 ° C.) suspension of niflumic acid (10.0 g, 35.4 mmol) and 4-nitrophenol (4.9 g, 35.4 mmol) in CH ₂ Cl ₂ (80 mL). 6.8 g, 35.4 mmol) was added. The reaction was stirred for 16 hours and then cooled to room temperature. The solution was quenched with water (50 mL) and the aqueous layer was extracted with CH ₂ Cl ₂ . The combined organic extracts were washed with water and dried over Na ₂ SO ₄ . The solvent is removed in vacuo and the residue is purified by trituration with Hex: CH ₂ Cl ₂ to give 4-nitrophenyl 2-{[3- (trifluoromethyl) phenyl] amino} nicotinate (4.5 g, 31 %) Was obtained:
[509]
[510] Intermediate AE:
[511] Ethyl 2-cyano-3-oxo-3- (2-{[3- (trifluoromethyl) phenyl] amino} -3-pyridinyl) propanoate
[512]
[513] To a stirred mixture of NaH (524 mg, 21.8 mmol) in toluene (20 mL) was added dropwise ethyl cyanoacetate (3.7 g, 32.7 mmol, 3.5 mL). The slurry was stirred for 1 hour and then 4-nitrophenyl 2-{[3- (trifluoromethyl) phenyl] amino} nicotinate (4.4 g, 10.9 mmol) was added. The reaction mixture was stirred for 1 h and then quenched with water (20 mL). CH ₂ Cl ₂ (30 mL) was added and the layers were partitioned. The organic layer was washed with brine (2X) and dried over Na ₂ S0 ₄ . The solvent is removed in vacuo and the residue is purified by silica gel flash chromatography (5: 1 to 2: 1 Hex: EtOAc) to give 3 ethyl 2-cyano-3-oxo-3- (2-{[3- (Trifluoromethyl) phenyl] amino} -3-pyridinyl) propanoate was obtained (6 g, 87%):
[514] Intermediate AF:
[515] 2-amino-1- [3- (trifluoromethyl) phenyl] -1,8-naphthyridin-4 (1H) -one
[516]
[517] Ethyl 2-cyano-3-oxo-3- (2-{[3- (trifluoromethyl) phenyl] amino} -3-pyridinyl) propanoate (2.0 g, 5.3 mmol) was concentrated in HCl (4 mL) and glacial acetic acid (2 mL) were heated to 120 ° C. for 3 h. The reaction mixture was cooled to room temperature and neutralized by the slow addition of NaOH pellets. The mixture was extracted with CH ₂ Cl ₂ (3X). The combined organic extracts were washed with saturated aqueous NaHCO ₃ (10 mL) and brine (10 mL), dried over MgSO ₄ and concentrated in vacuo. The residue was purified by prep-HPLC (YMC-Pack Pro C18 column, 150 × 20 mm ID; 30-70% CH ₃ CN in water, 20 min) to 2-amino-1- [3- (Trifluoromethyl) phenyl] -1,8-naphthyridin-4 (1H) -one (880 mg, 55%) was obtained:
[518] Intermediate AG:
[519] 7-chloro-6-fluoro-2- (isopropylamino) -1-phenyl-1,8-naphthyridin-4 (1H) -one
[520]
[521] (2Z) -3-anilino-1- (2,6-dichloro-5-fluoro-3-pyridinyl) -3- (isopropylamino) -2-propen-1-one (40.0 mg, 0.109 mmol) was dissolved in 4 mL of DMF. NaH (8.70 mg, 0.217 mmol, 60% dispersion in oil) was added and the reaction heated to 85 ° C. for 2 h under argon. The reaction mixture was cooled to rt, diluted with water and the aqueous layer was extracted with EtOAc. The combined organic extracts were washed with brine, dried over MgSO ₄ and concentrated in vacuo. Purification of the residue using Biotage silica gel chromatography eluting with 100% EtOAc to 95: 5 EtOAc: MeOH to 7-chloro-6-fluoro-2- (isopropylamino) -1-phenyl-1,8-naphthy Ridin-4 (1H) -one (21 mg, 64%) was obtained as a white solid:
[522] Intermediate AH:
[523] 2-anilino-7-chloro-6-fluoro-5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one
[524]
[525] Solution of LTMP [freshly prepared at 0 ° C. from tetramethylpiperidine (227.2 mg, 1.62 mmol), TMEDA (188.3 mg, 1.62 mmol) and n-BuLi (1 mL, 1.62 mmol) in THF (5 mL) Cooling of 2-anilino-7-chloro-6-fluoro-1-phenyl-1,8-naphthyridin-4 (1H) -one (200 mg, 0.54 mmol) in THF (10 mL) (-40 C) and stirred solution. The reaction mixture was warmed to 0 ° C. for 1 hour and then recooled to −40 ° C. MeI (766 mg, 5.35 mmol) was added and the reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction was carefully quenched with water (50 mL) and then extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na ₂ S0 ₄ and concentrated in vacuo. Silicagel flash chromatography of the residue using 1: 1 EtOAc: Hex to 2-anilino-7-chloro-6-fluoro-5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one (184 mg, 88%) was obtained as a white solid: LCMS RT: 2.74 min, MH ⁺ : 380.3. The conversion can also be carried out using other amide bases such as LDA.
[526] Intermediate AI:
[527] 2-anilino-7-chloro-6-fluoro-1-phenyl-5- (trifluoroacetyl) -1,8-naphthyridin-4 (1H) -one
[528]
[529] Solution of LTMP [freshly prepared at 0 ° C. from tetramethylpiperidine (154 mg, 1.10 mmol), TMEDA (127.8 mg, 1.10 mmol) and n-BuLi (0.688 mL, 1.10 mmol) in THF (5 mL) Cooling of 2-anilino-7-chloro-6-fluoro-1-phenyl-1,8-naphthyridin-4 (1H) -one (100 mg, 0.273 mmol) in THF (10 mL) (-40 C) and stirred solution. The reaction was stirred for 1 hour and then cooled to -78 ° C. Methyl trifluoroacetate (350 mg, 2.74 mmol) was added and stirring continued for 2 hours. The reaction was carefully quenched with water (50 mL), cooled to rt and extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na ₂ S0 ₄ and concentrated in vacuo. Silicagel flash chromatography of the residue with 3: 1 Hex: EtOAc gave 2-anilino-7-chloro-6-fluoro-1-phenyl-5- (trifluoroacetyl) -1,8-naphthyridine-4 (1H) -one (71 mg, 56%) was obtained as a light yellow solid: LCMS RT: 3.43 min, MH ⁺ : 462.3. Anions generated from LTMP deprotonation can be quenched with other electrophiles, including carbon dioxide and 4-nitrophenyl acetate.
[530] Intermediate AJ:
[531] 7-chloro-5-methyl-2- [methyl (phenyl) amino] -1-phenyl-1,8-naphthyridin-4 (1H) -one
[532]
[533] MeI (0.10 mL, 228 mg, 1.6 mmol) was diluted with K ₂ CO ₃ (23.5 mg, 0.17 mmol) and 2-anilino-7-chloro-5-methyl-1-phenyl-1,8 in THF (3 mL). Naphthyridin-4 (1H) -one (50 mg, 0.14 mmol) was added to the stirred solution. The suspension was heated to 40 ° C. and stirred overnight. The reaction was quenched with water (5.0 mL) and extracted with EtOAc. The combined organic extracts were dried over Na ₂ SO ₄ and concentrated in vacuo. Recrystallization of the residue with EtOAc gave 7-chloro-5-methyl-2- [methyl (phenyl) amino] -1-phenyl-1,8-naphthyridin-4 (1H) -one (18 mg, 35%). Obtained:
[534]
[535] Intermediate AK:
[536] N- (7-chloro-5-methyl-4-oxo-1-phenyl-1,4-dihydro-1,8-naphthyridin-2-yl) -N '-(4-fluorophenyl) -N -Phenyl urea
[537]
[538] 4-fluorophenyl isocyanate (45.0 mg, 0.33 mmol) was added 2-anilino-7-chloro-5-methyl-1-phenyl-1,8-naphthyridine-4 (1H) in CH ₂ Cl ₂ (3 mL). ) -One (100 mg, 0.276 mmol) was added to the stirred solution. After 16 hours, an additional equivalent of 4-fluorophenyl isocyanate (45.0 mg) was added and the reaction stirred for an additional 16 hours. The reaction was concentrated in vacuo and the residue dissolved in EtOAc. The solution was washed with 1 N HCl, dried over MgSO ₄ and concentrated in vacuo. Purification of the residue using reverse phase prep-HPLC showed N- (7-chloro-5-methyl-4-oxo-1-phenyl-1,4-dihydro-1,8-naphthyridin-2-yl) -N '. -(4-fluorophenyl) -N-phenylurea (2.2 mg, 1.6%) was obtained:
[539]
[540] Intermediate AL:
[541] 2-anilino-7-chloro-3-iodo-5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one
[542]
[543] K ₂ CO ₃ (210 mg, 1.52 mmol) and I ₂ (390 mg, 1.52 mmol) were added to 2-anilino-7-chloro-5-methyl-1-phenyl-1,8-naphti in DMF (10 mL). To a solution of lidin-4 (1H) -one (500 mg, 1.38 mmol). The mixture was stirred for 30 minutes and then poured into saturated aqueous solution of Na ₂ S ₂ O ₃ (10 mL). The aqueous solution was extracted with EtOAc. The combined organic extracts were dried over MgSO ₄ and concentrated in vacuo. Silicagel flash chromatography of the residue using 4: 1 to 1: 1 Hex: EtOAc to 2-anilino-7chloro-3-iodo-5-methyl-1-phenyl-1,8-naphthyridine-4 (1H ) -One (380 mg, 56%) was obtained:
[544]
[545] Intermediate AM:
[546] 2-anilino-7-chloro-6-fluoro-5- (1-hydroxypropyl) -1-phenyl-1,8-naphthyridin-4 (1H) -one
[547]
[548] A -40 ° C solution of 2-anilino-7-chloro-6-fluoro-1-phenyl-1,8-naphthyridin-4 (1H) -one (100 mg, 0.274 mmol) in THF (10 mL) LTMP (freshly prepared by mixing 1.10 mmol, 2,2,6,6-tetramethyl piperidine and n-BuLi at 0 ° C. for 30 minutes). The mixture was then warmed to 0 ° C. for 2 hours. The reaction mixture was cooled to -30 ° C and propionaldehyde (159 mg, 2.74 mmol) was added. The reaction was stirred at -30 [deg.] C. for 2 hours and then slowly quenched with saturated aqueous NH ₄ Cl. The mixture was extracted with EtOAc, and the organic layer was dried over MgSO ₄ and concentrated in vacuo. The residue was purified by silica gel flash chromatography to give 2-anilino-7-chloro-6-fluoro-5- (1-hydroxypropyl) -1-phenyl-1,8-naphthyridine-4 (1H) -One (120 mg, 97%) was obtained as a white solid: LCMS RT: 3.14 min, MH ⁺ : 424.2. Other electrophiles such as disulfides can be used to quench the anions.
[549] Example 1:
[550] 2-anilino-5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one
[551]
[552] 2-anilino-7-chloro-5-methyl-1-phenyl-1, 8-naphthyridin-4 (1H) -one (95.0 mg, 0.263 mmol) in EtOAc (2.5 mL) and EtOH (2.5 mL), A solution of TEA (0.65 mmol), and 10% Pd / C was stirred under H ₂ (1 atm) for 3.5 hours. The reaction mixture was filtered and washed through a pad of Celite with EtOH and EtOAc. The combined filtrates were concentrated in vacuo and purified by Biotage silica gel chromatography using 1: 1 EtOAc: Hex to 2-anilino-5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one (84 mg, 98%) was obtained as a pale yellow solid.
[553] Example 2:
[554] 5-Methyl-7-morpholin-4-yl-1-phenyl-2-phenylamino-1H- [1,8] -naphthyridin-4-one
[555]
[556] 7-chloro-5-methyl-1-phenyl-2-phenylamino-1H- [1,8] naphthyridin-4-one (68.3 mg, 0.189 mmol) and morpholine (0.05 mL) in dioxane (3 mL) , 0.48 mmol) was heated to 80 ° C. for 2 hours. The reaction was cooled, concentrated in vacuo, diluted with water and extracted with EtOAc (3X). The combined organic extracts were washed with brine, dried over Na ₂ SO ₄ and concentrated in vacuo to afford 5-methyl-7-morpholin-4-yl-1-phenyl-2-phenylamino-1H- [1,8] Naphthyridin-4-one (67 mg, 92%) was obtained as a yellow solid:
[557] Example 3:
[558] 5-methyl-1-phenyl-2,7-bis-phenylamino-1H- [1,8] naphthyridin-4-one
[559]
[560] 7-chloro-5-methyl-1-phenyl-2-phenylamino-1H- [1,8] naphthyridin-4-one (15.1 mg, 0.042 mmol) in THF (0.5 mL), aniline (2 drops), A mixture of Pd (OAc) ₂ (0.27 mg, 0.001 mmol), CS ₂ CO ₃ (19.5 mg, 0.06 mmol), and BINAP (1.68 mg, 0.003 mmol) was heated at reflux for 16 h. The reaction was quenched with water and extracted with EtOAc (3X). The combined organic extracts were washed with brine, dried over Na ₂ SO ₄ and concentrated in vacuo to afford 5-methyl-1-phenyl-2,7-bis-phenylamino-1H- [1,8] naphthyridine-4- Warm (6.0 mg, 38%) was obtained:
[561] Example 4:
[562] 2-anilino-1,7-diphenyl-5- (trifluoromethyl) -1,8-naphthyridin-4 (1H) -one
[563]
[564] 2-anilino-7-chloro-1-phenyl-5- (trifluoromethyl) -1,8-naphthyridin-4 (1H) -one (10.0 mg, 0.241 mmol), Ph ₃ P (6.00 in DME mg, 0.024 mmol) and a solution of phenylboronic acid (36.0 mg, 0.290 mmol) were treated with 2M K ₂ CO ₃ (0.482 mL, 0.964 mmol) and Pd (OAc) ₂ (1.35 mg, 0.006 mmol). The mixture was heated at reflux for 24 h. After cooling to rt, the mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO ₄ and concentrated in vacuo. Purification HPLC (10% CH ₃ CN in water with 0.1% TFA to 95% CH ₃ CN in water, 10 mL / min, 10 min) to purify 2-anilino-1,7-diphenyl-5- ( Trifluoromethyl) -1,8-naphthyridin-4 (1H) -one (45.0 mg, 41%) was obtained:
[565] Example 5:
[566] 2-anilino-7-benzyl-5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one
[567]
[568] Ni (dppp) Cl ₂ (37.0) in a solution of 2-anilino-7-chloro-5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one (100 mg, 0.277 mmol) in THF mg, 0.069 mmol) was added. After stirring for 5 minutes, benzyl magnesium chloride (2M, 1.45 mL, 2.90 mmol) was added dropwise through a syringe and the mixture was stirred for 24 hours. The mixture was quenched with 1 N HCl and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO ₄ and concentrated in vacuo. Purification by purification HPLC (10% MeNC in water with 0.1% TFA to 95% CH ₃ CN in water, 10 mL / min, 10 min) to 2-anilino-7-benzyl-5-methyl-1-phenyl -1,8-naphthyridin-4 (1H) -one (47.3 mg, 41%) was obtained:
[569] Example 6:
[570] Ethyl {[7-anilino-5-oxo-8-phenyl-4- (trifluoromethyl) -5,8-dihydro-1,8-naphthyridin-2-yl] sulfanyl} acetate
[571]
[572] NaH (60% dispersion in oil, 18.0 mg, 0.434 mmol) was added to cooling (0 ° C.) and stirred solution of ethyl mercaptoacetate in DMF (0.05 mL, 0.434 mmol). After 0.5 h, some 2-anilino-7-chloro-1-phenyl-5- (trifluoromethyl) -1,8-naphthyridin-4 (1H) -one (150.0 mg, 0.361 mmol) as a solid Minutely added. The mixture was warmed to rt and stirred for 24 h. The reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO ₄ and concentrated in vacuo. Purification Purified by HPLC (10% CH ₃ CN in water with 0.1% TFA to 95% CH ₃ CN in water, 10 mL / min, 10 min) to obtain ethyl {[7-anilino-5-oxo-8- Phenyl-4- (trifluoromethyl) -5,8-dihydro-1,8-naphthyridin-2-yl] sulfanyl} acetate (50 mg, 53%) was obtained:
[573] Example 7
[574] {[7-anilino-5-oxo-8-phenyl-4- (trifluoromethyl) -5,8-dihydro-1,8-naphthyridin-2-yl] sulfanyl} acetic acid
[575]
[576] NaOH (160 mg, 4.0 mmol) was dissolved in ethyl {[7-anilino-5-oxo-8-phenyl-4- (trifluoromethyl) -5, in aqueous EtOH (100 mL EtOH in 4 mL H ₂ 0). To a stirred solution of 8-dihydro-1,8-naphthyridin-2-yl] sulfanyl} acetate (30.0 mg, 0.060 mmol). The mixture was stirred for 4 hours and then concentrated in vacuo. The reaction was acidified with 1N HCl and extracted with CH ₂ Cl ₂ . The organic layer was dried over MgSO ₄ and concentrated in vacuo. Purification Purified by HPLC (10% CH ₃ CN in water with 0.1% TFA to 95% CH ₃ CN in water, 10 mL / min, 10 min) to obtain {[7-anilino-5-oxo-8-phenyl- 4- (trifluoromethyl) -5,8-dihydro-1,8-naphthyridin-2-yl] sulfanyl} acetic acid (19.0 mg, 66%) was obtained:
[577]
[578] Example 8
[579] 2-anilino-1-phenyl-7- (1-piperidinyl) -5- (trifluoromethyl) -1,8-naphthyridin-4 (1H) -one
[580]
[581] Of 2-anilino-7-chloro-1-phenyl-5- (trifluoromethyl) -1,8-naphthyridin-4 (1H) -one (100.0 mg, 0.241 mmol) in dioxane (2.5 mL) To the solution was added piperidine (40.9 mg, 0.481 mmol). The mixture was stirred at 80 ° C. overnight. The mixture was cooled to rt, poured into 1N HCl (1 mL) and extracted with CH ₂ Cl ₂ . The organic extracts were combined, washed with saturated aqueous NaHCO ₃ , dried over Na ₂ SO ₄ and concentrated in vacuo. The residue was purified by biotage silica gel chromatography (1: 1 EtOAc: Hex) to give 2-anilino-1-phenyl-7- (1-piperidinyl) -5- (trifluoromethyl) -1 , 8-naphthyridin-4 (1H) -one (89.5 mg, 80%) was obtained as a pale yellow solid:
[582]
[583] Example 9
[584] 2-anilino-7- [2- (2-oxo-1-pyrrolidinyl) ethoxy] -1-phenyl-5- (trifluoromethyl) -1,8-naphthyridine-4 (1H)- On
[585]
[586] NaH (60% dispersion, 20.0 mg, 0.514 mmol) was added to a cooled (0 ° C.) stirred solution of 1- (2-hydroxyethyl) -2-pyrrolidinone (0.06 mL, 0.514 mmol) in DMF. After 0.5 hour, 2-anilino-7-chloro-1-phenyl-5- (trifluoromethyl) -1,8-naphthyridin-4 (1H) -one (178 mg, 0.428 mmol) as a solid was partially Minutes were added and the mixture was heated to 130 ° C. for 48 hours. The mixture was cooled to rt, then quenched with saturated aqueous NH ₄ Cl and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO ₄ and concentrated in vacuo. Purification by HPLC (10% CH ₃ CN in water with 0.1% TFA to 95% CH ₃ CN in water, 10 mL / min, 10 min) to 2-anilino-7- [2- (2-oxo- 1-pyrrolidinyl) ethoxy] -1-phenyl-5- (trifluoromethyl) -1,8-naphthyridin-4 (1H) -one (0.047 g, 64%) was obtained: This conversion can be carried out at suitable temperatures for these solvents using other aprotic solvents such as DMSO, THF and dioxane. Commercial alkoxides can also be used in the absence of a base.
[587] Example 10
[588] 2-anilino-5- (hydroxymethyl) -1-phenyl-1,8-naphthyridin-4 (1H) -one
[589]
[590] A solution of LDA (freshly prepared from 38.2 mmol, n-BuLi and diisopropylamine) in THF (53 mL) was added 2-anilino-5-methyl-1-phenyl-1,8- in THF (100 mL). Naphthyridin-4 (1H) -one (2.50 g, 7.64 mmol) was added to a cooled (-78 ° C) stirred suspension. After the resulting mixture was stirred for 1 hour, oxygen gas was bubbled through the sintered glass tube to the bottom of the reaction vessel. The mixture was continued with bubbling of oxygen and stirred overnight while slowly warming to room temperature. The reaction was quenched with water and 1M HCl (5 mL) and then extracted with CH ₂ Cl ₂ . The organic phase was dried over Na ₂ S0 ₄ and concentrated in vacuo to give an orange solid which was recrystallized from EtOAc to 2-anilino-5- (hydroxymethyl) -1-phenyl-1,8-naphthyridine-4 (1H) -one (1.38 g, 53%) was obtained:
[591]
[592] Example 11
[593] 2-anilino-1-phenyl-5- (1-piperazinylmethyl) -1,8-naphthyridin-4 (1H) -one
[594]
[595] ₂ -anilino-5- (hydroxymethyl) -1-phenyl-1,8-naphthyridin-4 (1H) -one (180 mg, 0.52 mmol), N, N in CH ₂ Cl ₂ (7 mL) A solution of diisopropylethylamine (0.10 mL, 0.52 mmol) and SOCl ₂ (0.12 mL, 1.57 mmol) was stirred at rt for 2 h. Excess SOCl ₂ and solvent were removed under vacuum to give a brown solid. Crude 2-anilino-5- (chloromethyl) -1-phenyl-1,8-naphthyridin-4 (1H) -one was used without further purification:
[596]
[597] DMF (1 mL) was added crude 2-anilino-5- (chloromethyl) -1-phenyl-1,8-naphthyridin-4 (1H) -one (15.0 mg) in 1,4-dioxane (2 mL). , 0.041 mmol), N, N-diisopropylethylamine (0.036 mL, 0.21 mmol) and piperazine (36 mg, 0.21 mmol) were added to a stirred suspension. The solution was heated to 50 ° C. overnight, then cooled to rt and concentrated in vacuo. Reversed phase purification of residue HPLC (CH ₃ CN and 0.1% TFA in water) 2-anilino-1-phenyl-5- (1-piperazinylmethyl) -1,8-naphthyridin-4 (1H) -one (8.0 mg, 37%) was obtained as TFA salt:
[598] Example 12
[599] 5-methyl-1-phenyl-2-phenylamino-7-piperazin-1-yl-1H- [1,8] naphthyridin-4-one
[600]
[601] 5-methyl-1-phenyl-2-phenylamino-7-piperazin-1-yl-1H- [1,8] naphthyridin-4-one (22.6 mg, 0.055 mmol in CH ₂ Cl ₂ (0.8 mL) ) And MsCl (0.083 mmol, 0.006 mL) were stirred overnight at room temperature and the solvent was removed in vacuo. The resulting residue was purified by purification-TLC to give 7- (4-methanesulfonyl-piperazin-1-yl) -5-methyl-1-phenyl-2-phenylamino-1H- [1,8] naphthyridine 4-one (3.4 mg, 6%) was obtained:
[602] Example 13
[603] 5-methyl-1-phenyl-2-phenylamino-7- (4-propionyl-piperazin-1-yl) -1H- [1,8] naphthyridin-4-one
[604]
[605] 5-methyl-1-phenyl-2-phenylamino-7-piperazin-1-yl-1H- [1,8] naphthyridin-4-one (21.0 mg, 0.052 mmol in CH ₂ Cl ₂ (0.8 mL) ), Propionic acid (0.004 mL, 0.055 mmol), EDCI (11.9 mg, 0.062 mmol), DMAP (7.6 mg, 0.062 mmol) and NMM (0.006 mL, 0.062) were stirred overnight at room temperature. The reaction was diluted with water and extracted with CH ₂ Cl ₂ . The combined organic extracts were washed with 0.5N HCl and brine and concentrated in vacuo. The residue was purified by purification-TLC eluting with 100% EtOAc to give 5-methyl-1-phenyl-2-phenylamino-7- (4-propionyl-piperazin-1-yl) -1H- [1,8 ] Naphthyridin-4-one (9.0 mg, 37%) was obtained:
[606]
[607] Example 14
[608] 2-anilino-5-bromo-6-fluoro-7-methoxy-1-phenyl-1,8-naphthyridin-4 (1H) -one
[609]
[610] Solution of LTMP [freshly prepared from tetramethylpiperidine (785.4 mg, 5.6 mmol), TMEDA (651 mg, 5.6 mmol) and n-BuLi (3.5 mL, 5.6 mmol) in THF (10 mL) Was cooled down of 2-anilino-6-fluoro-7-methoxy-1-phenyl-1,8-naphthyridin-4 (1H) -one (507 mg, 104 mmol) in THF (20 mL) ( -40 ° C.) was added to the stirred solution. The reaction mixture was allowed to warm to room temperature. After 1 hour, the mixture was cooled to -30 ° C and 1,2-dibromotetrachloroethane (457 mg, 1.4 mmol) was added. After 30 minutes, water (50 mL) was added slowly, then the reaction was allowed to warm to room temperature and extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na ₂ SO ₄ and concentrated in vacuo. Silica gel flash chromatography of the residue with EtOAc gives 2-anilino-5-bromo-6-fluoro-7-methoxy-1-phenyl-1,8-naphthyridin-4 (1H) -one (101). mg, 16%) was obtained as a light yellow solid:
[611] Example 15
[612] 7-methyl-1-phenyl-2- (phenylamino) hydropyridino [2,3-b] pyridin-4-one
[613]
[614] Ethyl 7-methyl-4-oxo-1-phenyl-2- (phenylamino) hydropyridino [2,3-b] pyridine-3-carboxylate (67 mg, 0.17 mmol) in 2: 1 HCl: AcOH Dissolved in solution (8.5 mL). The reaction was heated to 120 ° C. for 5 hours and then cooled to room temperature. The aqueous solution was washed with Et ₂ O, then neutralized with 2N NaOH and extracted with EtOAc. The combined organic extracts were washed with saturated aqueous NaHC0 ₃ and brine, dried over anhydrous Na ₂ S0 ₄ and concentrated in vacuo to 7-methyl-1-phenyl-2- (phenylamino) hydropyridino [2,3-b ] Pyridin-4-one (40 mg, 72%) was obtained:
[615]
[616] Example 16
[617] 2-anilino-5-chloro-7-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one
[618]
[619] 3,3-Danilino-1- (2,4-dichloro-6-methyl-3-pyridinyl) -2-propen-1-one (100 mg, 0.25 mmol) in dioxane anhydride (4 mL) And a mixture of t-BuOK (42 mg, 0.38 mmol) was heated to 80 ° C. for 4 hours. The solvent was removed in vacuo and the residue dissolved in EtOAc. The solution was washed with water and brine, dried over MgSO ₄ and concentrated in vacuo. Silica gel flash chromatography of the residue using 1: 1 EtOAc: Hex to 2-anilino-5-chloro-7-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one (13 mg, 14%) was obtained: Also isolated was 2-anilino-5-chloro-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one (68 mg, 75%): This conversion can be accomplished using a combination of other aprotic solvents such as DMF and THF with other bases such as NaH.
[620] Example 17
[621] Ethyl 7-anilino-3-fluoro-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine carboxylate
[622]
[623] 2-anilino-7-chloro-6-fluoro-1-phenyl-1,8-naphthyridin-4 (1H) -one (200 mg, 0.55 mmol), DPPP (12 mg, 0.030 mmol), Pd ( OAc) ₂ (6.0 mg, 0.028 mmol) and Cs ₂ CO ₃ (114 mg, 0.42 mmol) were dissolved in a 1: 1 mixture of EtOH (3 mL) / DMF (3 mL). A balloon filled with CO was attached to the flask and the solution was vigorously stirred. After degassing the flask, the solution was saturated with CO again by filling the flask with CO. This was repeated three times and the solution was heated to 70 ° C. After stirring for 4 hours, all starting material was consumed and the reaction cooled to room temperature. The solution was diluted with EtOAc and washed with water. The organic layer was collected, dried over Na ₂ SO ₄ and concentrated in vacuo. The crude solid was triturated with Et ₂ 0, filtered and dried to ethyl 7-anilino-3-fluoro-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2- Carboxylate (900 mg, 81%) was obtained as a light brown solid:
[624] Example 18
[625] 7-anilino-3-fluoro-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2-carboxamide
[626]
[627] Ethyl 7-anilino-3-fluoro-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2- in concentrated NH ₃ (3 mL) and MeOH (8 drops) A suspension of carboxylate (50 mg, 0.12 mmol) and NH ₄ Cl (10 mg, 0.19 mmol) was stirred at rt for 16 h. The solid was collected by filtration and washed with water. Trituration with Et ₂ O 7-anilino-3-fluoro-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2-carboxamide (32 mg, 71%) Was obtained as a yellow solid: This conversion can be done using EDCI / HOBT coupled with NH ₃ .
[628] Example 19
[629] 7-anilino-N-methoxy-N, 4-dimethyl-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2-carboxamide
[630]
[631] 7-anilino-4-methyl-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2-carboxylic acid (50 mg, 0.14 mmol), N, O-dimethylhydrate Oxylamine hydrochloride (39 mg, 0.40 mmol), HOBT (28 mg, 0.21 mmol) and EDCI (40 mg, 0.21 mmol) were dissolved in CH ₂ Cl ₂ (3 mL). To this solution was added TEA (78 uL, 0.56 mmol). The reaction was stirred for 1 h, diluted with CH ₂ Cl ₂ and washed with 0.5N HCl, saturated NaHCO ₃ and brine. The organic layer was collected, dried over Na ₂ SO ₄ and concentrated in vacuo. The obtained solid was triturated with Et ₂ O and dried to 7-anilino-N-methoxy-N, 4-dimethyl-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine- 2-Carboxamide (34 mg, 59%) was obtained as a light yellow solid: This transformation can also be carried out by coupling the corresponding acid chloride with a suitable amine.
[632] Example 20
[633] 7-acetyl-2-anilino-5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one
[634]
[635] 7-anilino-N-methoxy-N, 4-dimethyl-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2-car in THF (5 mL) at 0 ° C. To a suspension of voxamide (100 mg, 0.24 mmol) was added MeMgBr (3M in Et ₂ 0, 322 uL, 0.97 mmol). The suspension became a red solution. As the reaction proceeded, the solution lost its red color. After 1 hour the reaction was quenched with saturated NH ₄ Cl, diluted with EtOAc and washed with brine. The organic layer was dried over Na ₂ SO ₄ and concentrated in vacuo. The crude residue was purified by Biotage silica gel chromatography using EtOAc to afford 7-acetyl-2-anilino-5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one (65 mg). , 74%) was obtained as a light yellow solid:
[636] Example 21
[637] 2-anilino-7- (butylsulfonyl) -1-phenyl-5- (trifluoromethyl) -1,8-naphthyridin-4 (1H) -one
[638]
[639] To a solution of montmorillonite K10 (107.5 mg) in CHCl ₃ was added 13 uL of water. Then 2-anilino-7- (butylsulfanyl) -1-phenyl-5- (trifluoromethyl) -1,8-naphthyridin-4 (1H) -one (25 mg, 0.06 mmol) is added Oxone (85.2 mg, 0.14 mmol) was then added. The reaction was stirred at rt for 24 h. After 24 hours the solution became light bluish green which was filtered and washed with a large amount of CHCl ₃ . The filtrate was then concentrated in vacuo. Silica gel flash chromatography using 3: 1 Hex: EtOAc for 2-anilino-7- (butylsulfonyl) -1-phenyl-5- (trifluoromethyl) -1,8-naphthyridine-4 (1H ) -One (13.8 mg, 46%) was obtained as a yellow oil:
[640] Example 22
[641] N- [7-anilino-5-oxo-8-phenyl-4- (trifluoromethyl) -5,8-dihydro-1,8-naphthyridin-2-yl] methanesulfonamide
[642]
[643] Solution of 2-anilino-7-chloro-1-phenyl-5- (trifluoromethyl) -1,8-naphthyridin-4 (1H) -one (100 mg, 0.241 mmol) in DMSO (5 mL) To this was added methyl sulfonamide and K ₂ CO ₃ (76.5 mg, 0.554 mmol). The reaction was stirred at 120 ° C. for 24 hours. The reaction was then cooled to rt, quenched with water and extracted with Et ₂ O. The organic layer was dried over MgSO ₄ and concentrated in vacuo. The crude residue is then passed through a plug of silica gel eluting with 1: 1 Hex: EtOAc to 9: 1 CH ₂ Cl ₂ : MeOH to N- [7-anilino-5-oxo-8-phenyl-4- (Trifluoromethyl) -5,8-dihydro-1,8-naphthyridin-2-yl] methanesulfonamide (4.4 mg, 4%) was obtained as a white solid:
[644] Example 23
[645] 7-anilino-3-fluoro-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2-carbaldehyde
[646]
[647] 2-anilino-6-fluoro-7- (hydroxymethyl) -1-phenyl-1,8-naphthyridin-4 (1H) -one (100 mg, 0.277 mmol) was dissolved in 4.5 mL CHCl ₃ . . MnO ₂ (311 mg, 3.05 mmol) was added and the reaction was heated to 70 ° C. for 3 days under argon. The reaction mixture was filtered through celite and concentrated in vacuo. Purified by silica gel flash chromatography eluting with 3: 1 to 100: 0 EtOAc: Hex to 7-anilino-3-fluoro-5-oxo-8-phenyl-5,8-dihydro-1,8- Naphthyridine-2-carbaldehyde (15 mg, 15%) was obtained as a white solid:
[648] Example 24
[649] 7-amino-2-anilino-5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one
[650]
[651] Pd / C (30 mg, 1.75 mmol, 10%) was added to a 25 mL round bottom flask and blanketed with argon. 7- (allylamino) -2-anilino-5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one (150 mg, 0.392 mmol) was dissolved in EtOH (2 mL) and Pd To / C and then to methane sulfonic acid (0.041 mL, 0.63 mmol). The reaction was heated to 80 ° C. for 3 days, then cooled to room temperature, diluted with EtOAc and filtered through celite. The filtrate was concentrated in vacuo and the residue was purified by biotage silica gel chromatography eluting with 100% EtOAc to give 7-amino-2 anilino-5-methyl-1-phenyl-1,8-naphthyridine-4 ( 1H) -one (182 mg, 41%) was obtained as a yellow solid:
[652] Example 25
[653] 2-anilino-7- (hydroxymethyl) -5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one
[654]
[655] Ethyl 7-anilino-3-fluoro-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2-carboxylate (100.0 mg, 0.25 mmol in THF (2.5 mL) To the 0 ° C. suspension of LAH (0.750 mmol, 1M in THF) was added dropwise over 10 minutes. After 5 minutes the reaction was slowly quenched with EtOAc (10 mL), stirred for 15 minutes, and concentrated in vacuo. The residue was dissolved in CH ₂ Cl ₂ (10 mL) and 1N HCl (5 mL) and stirred for 30 minutes. The layers were separated and the aqueous layer was extracted with CH ₂ Cl ₂ . The combined organic extracts were washed with brine, dried over MgSO ₄ and concentrated in vacuo. Trituration with Et ₂ O to give 2-anilino-6-fluoro-7- (hydroxymethyl) -1-phenyl-1,8-naphthyridin-4 (1H) -one (55.2 mg, 61%) Obtained as a solid:
[656] Example 26
[657] 2-anilino-7-[(4-methoxyphenoxy) methyl] -5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one
[658]
[659] 2-anilino-6-fluoro-7- (hydroxymethyl) -1-phenyl-1,8-naphthyridin-4 (1H) -one (62 mg, 0.175 mmol) was dissolved in CH ₂ Cl ₂ (1.2 mL )). 4-methoxyphenol (22 mg, 0.175 mmol) was added followed by Ph ₃ P (91.8 mg, 0.35 mmol) and ADDP (88.31 mg, 0.35 mmol). The reaction was stirred overnight at room temperature under argon. Hexane (5 mL) was added and the reaction was filtered. The filtrate was concentrated in vacuo. Purification of the residue using Biotage silica gel chromatography eluting with 7: 3 to 9: 1 EtOAc: Hex. 2-anilino-6-fluoro-7-[(4-methoxyphenoxy) methyl]- 1-phenyl-1,8-naphthyridin-4 (1H) -one (30.0 mg, 37%) was obtained as a white solid:
[660]
[661] Example 27
[662] 7-ethoxy-5-ethyl-2- [methyl (phenyl) amino] -1-phenyl-1,8-naphthyridin-4 (1H) -one
[663]
[664] And Example 28
[665] 2-anilino-7-ethoxy-5-ethyl-3-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one
[666]
[667] And Example 29
[668] 7-ethoxy-5-ethyl-3-methyl-2- [methyl (phenyl) amino] -1-phenyl-1,8-naphthyridin-4 (1H) -one
[669]
[670] N-BuLi (1.6 M, 0.68 mL, 1.08 mmol) and TMEDA in a suspension of 2,2,6,6-tetramethylpiperidine (153 mg, 0.18 mL, 1.08 mmol) in THF (10 mL) at 0 ° C. Was added via syringe. The reaction mixture was stirred for 1 h under argon. The reaction mixture was cooled to −60 ° C. using acetone / dry ice bath and 2-anilino-7-ethoxy-5-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one (100 mg, 0.269 mmol) was added as a solution in THF (5 mL) via syringe. The mixture was stirred for 1 hour. MeI was added via syringe and the reaction was allowed to warm to room temperature and stirred for 18 hours. A saturated aqueous solution of NH ₄ Cl (20 mL) and EtOAc (20 mL) was added, the organic layer was separated, dried over MgSO ₄ and concentrated in vacuo. The residue was purified by silica gel flash chromatography using 7: 3 to 100: 0 EtOAc: Hex to afford the three products as follows:
[671] Example 27: (35 mg, 32%), Example 28: (11 mg, 10%), Example 29: (16 mg, 14%).
[672] Example 30
[673] 2-anilino-6-fluoro-7-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one
[674]
[675] Pd (PPh ₃ ) to 2-anilino-7-chloro-6-fluoro-1-phenyl-1,8-naphthyridin-4 (1H) -one (100 mg, 0.273 mmol) in THF (5 mL) ₄ (13 mg, 0.001 mmol) and methyl zinc chloride (2M, 0.819 mL, 1.64 mmol) were added and the reaction was heated to 75 ° C. for 18 h. The reaction was then cooled to rt, poured into a solution of EDTA in water (2.5 g / 20 mL) and extracted with Et ₂ O. The organic layer was washed with brine and concentrated in vacuo. The residue was then dissolved in MeOH and filtered. The filtrate was concentrated in vacuo to afford 2-anilino-6-fluoro-7-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one (83.0 mg, 89%):
[676] Example 31
[677] Methyl (2E) -3- (7-anilino-2-methyl-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridin-3-yl) -2-propenoate
[678]
[679] Pd (OAc) in a suspension of 2-anilino-6-bromo-7-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one (41 mg, 0.1 mmol) in DMF (2.0 mL) ) ₂ (0.70 mg, 0.003 mmol), Ph ₃ P (5.2 mg, 0.02 mmol), TEA (0.03 mL) and methyl acrylate (17.2 mg, 0.2 mmol) were added sequentially. The suspension was heated in a sealed tube at 120 ° C. for 64 hours. After concentration in vacuo the residue obtained was washed with water and extracted with EtOAc. The organic layer was dried over MgSO ₄ and concentrated in vacuo. Purification- Purification by HPLC, methyl (2E) -3- (7-anilino-2-methyl-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridin-3-yl)- 2-propenoate (10.0 mg, 24%) was obtained:
[680]
[681] Example 32
[682] (2E) -3- (7-anilino-2-methyl-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridin-3-yl) -2-propenoic acid
[683]
[684] 2-anilino-6-[(E) -3-methoxy-3-oxo-1-propenyl] -7-methyl-1-phenyl-1, 8-naphthyridine- in CH ₃ CN (2.0 mL) To a suspension of 4 (1H) -one (10 mg, 0.025 mmol) was added 1N NaOH (2.0 mL). The suspension was stirred at rt for 18 h. The mixture was diluted with water (10 mL) and extracted with EtOAc. The organic layer was dried over MgSO ₄ and concentrated in vacuo to afford (2E) -3- (7-anilino-2-methyl-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-3 -Yl) -2-propene acid (6.2 mg, 63%) was obtained:
[685]
[686] Example 33
[687] 3- (7-anilino-2-methyl-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridin-3-yl) propanoic acid
[688]
[689] 2-anilino-6-[(E) -3-hydroxy-3-oxo-1-propenyl] -7-methyl-1-phenyl-1,8-naphthyridine-4 in MeOH (2.0 mL) To a stirred suspension of 1H) -one (40.0 mg, 0.100 mmol) was added Pd / C (5.3 mg, 10 wt.% On carbon) under argon atmosphere, followed by the addition of ammonia formic acid (19.0 mg, 0.30 mmol) in portions. It was. The reaction mixture was heated at reflux for 2 hours, cooled and filtered. The filtrate was diluted with water (10 mL) and extracted with EtOAc. The organic layer was dried over MgSO ₄ and concentrated in vacuo. The residue was washed with water and dried under vacuum to afford 3- (7-anilino-2-methyl-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridin-3-yl) propanoic acid (34.5 mg, 86%) was obtained:
[690] Example 34
[691] 2-anilino-6,7-dimethyl-1-phenyl-1,8-naphthyridin-4 (1H) -one
[692]
[693] Example 35
[694] 2-anilino-7-ethyl-1- (3-methylphenyl) -1,8-naphthyridin-4 (1H) -one
[695]
[696] A suspension of 2-anilino-6-bromo-7-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one (203 mg, 0.5 mmol) in THF (10 mL) was placed under argon atmosphere. Cooled to -78 ° C. A solution of n-BuLi in hexanes (1.0 mL, 1.6 mmol, 1.6 M) was added and the suspension was stirred for 10 minutes at 0 ° C. until a clear solution. Excess MeI (0.2 mL, 3.2 mmol) was added and the reaction stirred for an additional 10 minutes. The reaction was quenched with saturated aqueous NH ₄ Cl (2.0 mL) and water (10 mL) and the mixture was extracted with EtOAc. The organic layer was dried over MgSO ₄ and concentrated in vacuo. The residue was purified by purification-HPLC to give 2-anilino-6,7-dimethyl-1-phenyl-1,8-naphthyridin-4 (1H) -one (55 mg, 32%): LCMS RT : 2.33 min, MH ⁺ : 342.4, R _f = 0.39 (EtOAc). 2-anilino-7-ethyl-1- (3-methylphenyl) -1,8-naphthyridin-4 (1H) -one (13.3 mg, 7.5%) was also obtained as a byproduct: LCMS RT: 2.54 min, MH ⁺ : 356.3, R _f = 0.40 (EtOAc). Electrolytes such as aldehydes, carbon dioxide, disulfides, trifluoroacetate acid chlorides and other alkyl halides can also be used to quench the aryl lithium produced.
[697] Example 36
[698] Ethyl 7-anilino-4-chloro-3-fluoro-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2-carboxylate
[699]
[700] Ethyl 7-anilino-3-fluoro-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2-carboxylate (40.0 mg, 0.099 in anhydrous THF (10 mL) mmol) was cooled to -78 ° C under argon atmosphere. LiHMDS (5 mL, 5 mmol) was then added to the suspension and the suspension was stirred at 0 ° C. for 2 h, then cooled to −78 ° C. and treated with CCl ₂ FCClF ₂ (94 mg, 0.5 mmol). The reaction was stirred at 0 ° C. for additional time and then quenched with saturated aqueous NH ₄ Cl (2.0 mL) and water (10 mL) and extracted with EtOAc. The organic layer was dried over MgSO ₄ and concentrated in vacuo. Purification- The residue was purified by HPLC to give ethyl 7-anilino-4-chloro-3-fluoro-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2-carboxyl Yield (13.2 mg, 31%) was obtained:
[701] Example 37
[702] 7-anilino-4-chloro-3-fluoro-N, N-diisopropyl-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2-carboxamide
[703]
[704] LDA was prepared by adding n-BuLi (0.31 mL, 0.5 mmol, 1.6 M) to diisopropylamine (50 mg, 0.5 mmol) in THF (15 mL) at −15 ° C. Ethyl 7-anilino-3-fluoro-5-oxo-8-phenyl-5,8-dihydro-1,8-naphthyridine-2-carboxylate (40.0 mg, 0.915 in anhydrous THF (10 mL) mmol) was cooled to -78 ° C under argon atmosphere. LDA was added and the suspension was stirred for 2 h at 0 ° C., then cooled to −78 ° C. and treated with CCl ₂ FCClF ₂ (94 mg, 0.5 mmol). The reaction was stirred at 0 ° C. for additional time and then quenched with saturated aqueous NH ₄ Cl (2.0 mL) and water (10 mL). The aqueous solution was extracted with EtOAc and the organic layer was dried over MgSO ₄ and concentrated in vacuo. Purification- The residue was purified by HPLC to give 7-anilino-3-bromo-4-chloro-N, N-diisopropyl-5-oxo-8-phenyl-5,8-dihydro-1,8- Naphthyridine-2-carboxamide (20 mg, 41%) was obtained:
[705]
[706] Example 38
[707] 2-[(4-methylbenzyl) amino] -1- [3- (trifluoromethyl) phenyl] -1,8-naphthyridin-4 (1H) -one
[708]
[709] 2-amino-1- [3- (trifluoromethyl) phenyl] -1,8-naphthyridin-4 (1H) -one (50 mg, 0.16 mmol) in THF ( ₃ mL), CsCO ₃ (160 mg , 0.49 mmol) and 4-methylbenzyl bromide (35 mg, 0.25 mmol) were heated to 80 ° C. in a sealed tube for 16 hours. The reaction was cooled to rt and quenched with water (3 mL). The mixture was extracted with CH ₂ Cl ₂ (3X) and the combined organic extracts were dried over Na ₂ SO ₄ and concentrated in vacuo. Purify the residue-HPLC (YMC-Pack Pro C18 column, 150 x 20 mm inner diameter; first run: 20-80% CH ₃ CN in water, 11 min; second run: 50-90% MeOH in water , 20 minutes) to give 2-[(4-methylbenzyl) amino] -1- [3- (trifluoromethyl) phenyl-1,8-naphthyridin-4 (1H) -one (2.2 mg, 3 %) Was obtained:
[710]
[711] The following specific examples are provided to illustrate the present invention with respect to the compounds of formula (II) described herein, but are not to be construed as limiting the scope of the invention in any way.
[712] Intermediate BA
[713] 2,4-dichloro-6-methylnicotinic acid
[714]
[715] Commercially available (Maybridge) ethyl 2,4-dichloro-6-methylpyridine-3-carboxylate (1.0 g, 4.3 mmol) and NaOH (342 mg, in water (1.7 mL) and MeOH (1.5 mL) 8.6 mmol) was heated to 80 ° C. for 4 hours. The mixture was acidified with 50% H ₂ S0 ₄ and filtered. The collected solid was washed with cold water and dried to give 2,4-dichloro-6-methylpyridine-3-carboxylic acid (582 mg, 66%):
[716]
[717] Intermediate BB
[718] 3,3-dichloro-1- (2,4-dichloro-6-methyl-3-pyridinyl) -2-propen-1-one
[719]
[720] 2,4-Dichloro-6-methylnicotinic acid (8.7 g, 43.0 mmol) was mixed with SOCl ₂ (31 mL). The resulting mixture was heated to 80 ° C. for 2 h and concentrated in vacuo to give the acid chloride as a yellow oil. The oil was then dissolved in CH ₂ Cl ₂ (10 mL) and the solution was added to a cooled suspension of AlCl ₃ (21.3 g, 160.0 mmol) in CH ₂ Cl ₂ (50 mL) at 0 ° C. After 2 hours at 0 ° C., vinylidene chloride (2.16 mL, 80.0 mmol) was added to the suspension. The resulting mixture was then warmed to room temperature and stirred overnight. The reaction mixture was poured into crushed ice and the resulting mixture was extracted with CH ₂ Cl ₂ . The combined organic layers were cooled to 0 ° C. and TEA (14.9 mL) was added. After stirring for 1 hour, the organic layer was washed with 10% aqueous HCl (100 mL), water (200 mL), brine (100 mL) and dried over Na ₂ SO ₄ . The solvent was removed in vacuo and the residue was purified by passage through a pad of silica gel using 15% EtOAc in Hex as eluent to give 3,3-dichloro-1- (2,4-dichloro-6-methyl-3-pyri Diyl) -2-propen-1-one (5.2 g, 46%) was obtained:
[721] Alternatively, acid chlorides could be prepared using oxalyl chloride with a catalytic amount of DMF.
[722] Intermediate BC
[723] 3,3-Dianilino-1- (2,4-dichloro-6-methyl-3-pyridinyl) -2-propen-1-one
[724]
[725] 3,3-dichloro-1- (2,4-dichloro-6-methyl-3-pyridinyl) -2-propen-1-one (5.2 g, 18.0 mmol) in 1,4-dioxane (25 mL) ) Was cooled to 0 ° C. and aniline (5.1 mL, 55.0 mmol) and TEA (7.7 mL, 55.0 mmol) were added dropwise. The reaction mixture was stirred at 0 ° C. for 1 hour and at room temperature for 2 hours. The solvent was removed in vacuo. The residue was purified by passing through a pad of silica gel using EtOAc: Hex (1: 5) as eluent to give 3,3-dianilin-1- (2,4-dichloro-6-methyl-3-pyridinyl) 2-propen-1-one (7.1 g, 99%) was obtained:
[726] Intermediates BA1, BB1, BC1, BA2, BB2 and BC2 can be prepared in the same manner as described above for BA, BB and BC starting with suitable known starting nicotinic acid (Eur. J. Org. Chem. 2001, 1371).
[727] Intermediate BA1
[728] 4,6-dichloronicotinic acid
[729]
[730] Intermediate BB1
[731] 3,3-dichloro-1- (4,6-dichloro-3-pyridinyl) -2-propen-1-one
[732]
[733] Intermediate BC1
[734] 3,3-Dianilino-1- (4,6-dichloro-3-pyridinyl) -2-propen-1-one
[735]
[736] Intermediate BA2
[737] 4,5-dichloronicotinic acid
[738]
[739] Intermediate BB2
[740] 3,3-dichloro-1- (4,5-dichloro-3-pyridinyl) -2-propen-1-one
[741]
[742] Intermediate BC2
[743] 3,3-Dianilino-1- (4,5-dichloro-3-pyridinyl) -2-propen-1-one
[744]
[745] Example 39
[746] 2-anilino-5-chloro-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one
[747]
[748] 3,3-Danilino-1- (2,4-dichloro-6-methyl-3-pyridinyl) -2-propen-1-one (100 mg, 0.25 mmol) in dioxane anhydride (4 mL) And a mixture of t-BuOK (42 mg, 0.38 mmol) was heated to 80 ° C. for 4 hours. The solvent was removed in vacuo and the residue dissolved in EtOAc. The solution was washed with water and brine, dried over MgSO ₄ and concentrated in vacuo. Silica gel flash chromatography on residue with 1: 1 EtOAc: Hex to give 2-anilino-5-chloro-7-methyl-1-phenyl-1,8-naphthyridin-4 (1H) -one (13 mg, 14%) (LCMS RT: 2.47 min, MH ⁺ : 362) and 2-anilino-5-chloro-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one (68 mg, 75%) (LCMS RT: 2.24 min, MH ⁺ : 362.3). Alternatively, cyclization could be performed using other bases, such as NaH, and other aprotic solvents, such as THF and DMF.
[749] Examples 40 and 41 can be prepared in the same manner as in Example 39.
[750] Example 40
[751] 2-anilino-7-chloro-1-phenyl-1,6-naphthyridin-4 (1H) -one
[752]
[753] Example 41
[754] 2-anilino-8-chloro-1-phenyl-1,6-naphthyridin-4 (1H) -one
[755]
[756] Example 42
[757] 2-anilino-5-chloro-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one
[758]
[759] Ni (dppp) Cl in a solution of 2-anilino-5-chloro-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one (80 mg, 0.22 mmol) in THF (3 mL) ₂ (24 mg, 0.044 mmol) was added at room temperature. After stirring for several minutes MeMgBr (3M, 0.59 mL, 1.76 mmol) was added and the mixture was stirred for 24 h. The mixture was quenched with 1N HCl and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO ₄ and concentrated in vacuo. 2-anilino-5,7-dimethyl-1-phenyl by purification with reverse phase purification HPLC (10% CH ₃ CN in water with 0.1% TFA to 95% CH ₃ CN in water, 10 mL / min, 10 minutes) -1,6-naphthyridin-4 (1H) -one (31 mg, 40%) was obtained:
[760]
[761] Example 43
[762] 2-anilino-5- (dimethylamino) -7-methyl-1-phenyl-1,6-naphthyridin-4- (1H) -one
[763]
[764] 2-anilino-5-chloro-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one (80 mg, 0.22 mmol) in dioxane (3 mL) and dimethylamine (in THF 3M, 0.73 mL, 2.20 mmol) was heated to 80 ° C. for 24 h. The reaction mixture was cooled down, concentrated in vacuo, diluted with water and the resulting mixture extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na ₂ SO ₄ and concentrated in vacuo to afford 2-anilino-5- (dimethylamino) -7-methyl-1-phenyl-1,6-naphthyridine-4 ( 1H) -one (74 mg, 91%) was obtained:
[765] Example 44
[766] Ethyl [(2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridin-5-yl) sulfanyl] acetate
[767]
[768] A solution of 2-anilino-5-chloro-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one (200 mg, 0.55 mmol) in EtOH (10 mL) was diluted with ethyl 2-mer. Captoacetate (0.12 mL, 1.10 mmol) and TEA (0.23 mL, 1.65 mmol) were added. The reaction was heated at reflux for 24 h. The reaction mixture was cooled down, concentrated in vacuo, diluted with water and extracted with EtOAc. The combined organic extracts were washed with water and brine and dried over Na ₂ S0 _{4. The} solvent was removed in vacuo and the residue was purified by reverse phase HPLC (10% CH ₃ CN in water with 0.1% TFA to 95% CH in water). ₃ CN, 10 mL / min, 10 min), purified by ethyl [(2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridine-5- I) sulfanyl] acetate (120 mg, 49%) was obtained:
[769] Example 45
[770] [(2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridin-5-yl) sulfanyl] acetic acid
[771]
[772] Aqueous NaOH (2N, 1 mL) was added to ethyl [(2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridine in EtOH (8 mL) at room temperature. -5-yl) sulfanyl] acetate (100 mg, 0.23 mmol) was added to a stirred solution. The mixture was stirred for 4 hours and concentrated in vacuo. The reaction mixture was acidified with 1N HCl and extracted with CH ₂ Cl ₂ . The organic layer was dried over MgSO ₄ and concentrated in vacuo. Reversed phase purification purified by HPLC (10% CH ₃ CN in water with 0.1% TFA to 95% CH ₃ CN in water, 10 mL / min, 10 min) to [(2-anilino-7-methyl-4-oxo -1-phenyl-1,4-dihydro-1,6-naphthyridin-5-yl) sulfanyl] acetic acid (56 mg, 60%) was obtained:
[773]
[774] Example 46
[775] Ethyl N- (2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridin-5-yl) glycinate
[776]
[777] Glycine ethyl ester hydro in a solution of 2-anilino-5-chloro-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one (80 mg, 0.22 mmol) in EtOH (8 mL) Chloride (46 mg, 0.44 mmol) and TEA (0.23 mL, 1.65 mmol) were added. The reaction was heated at reflux for 3 days. The reaction mixture was cooled down, concentrated in vacuo, diluted with water and extracted with EtOAc. The combined organic extracts were washed with water and brine, dried over Na ₂ SO ₄ and concentrated in vacuo. The residue was purified by reverse phase purification HPLC (10% CH ₃ CN in water with 0.1% TFA to 95% CH ₃ CN in water, 10 mL / min, 10 min) to ethyl N- (2-anilino-7- Methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridin-5-yl) glycinate (43 mg, 46%) was obtained:
[778] Example 47
[779] 2-[(2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridin-5-yl) sulfanyl] -N-cyclopropylacetamide
[780]
[781] [(2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridin-5-yl) sulfanyl] acetic acid in CH ₂ Cl ₂ (5 mL) To a mixture of (20 mg, 0.05 mmol), EDCI (18 mg, 0.10 mmol), HOBT (13 mg, 0.10 mmol) and cyclopropylamine (0.004 mL, 0.06 mmol) was added TEA (0.02 mL, 0.14 mmol). . The reaction solution was stirred at rt for 24 h before the mixture was diluted with CH ₂ Cl ₂ , washed with 0.5N HCl, saturated aqueous NaHCO ₃ and brine, and dried over Na ₂ SO ₄ . The solvent was removed in vacuo and the residue was purified by reverse phase purification HPLC (10% CH ₃ CN in water with 0.1% TFA to 95% CH ₃ CN in water, 10 mL / min, 10 min) to give 2-[(2 -Anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridin-5-yl) sulfanyl] -N-cyclopropylacetamide (13 mg, 59% ) Was obtained:
[782] Example 48
[783] 2-anilino-7-methyl-1-phenyl-5- (2,2,2-trifluoroethoxy) -1,6-naphthyridin-4 (1H) -one
[784]
[785] Trifluoroethanol (0.08 mL, 1.1 mmol) was added to a suspension of NaH (60% oil dispersion, 44 mg, 1.1 mmol) in DMSO (4 mL) at 0 ° C., and the mixture was heated at 60 ° C. for 1 h. . The mixture was cooled to room temperature and purified of 2-anilino-5-chloro-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one (200 mg, 0.55 mmol) in DMSO (2 mL). The solution was added. The resulting mixture was stirred at 50 ° C. for 16 h. The reaction mixture was cooled down, poured into cold water and extracted with CH ₂ Cl ₂ . The organic layer was washed with brine, dried over MgSO ₄ and concentrated in vacuo. The residue was purified by biotage silica gel chromatography (2: 1 EtOAc: Hex) to give 2-anilino-7-methyl-1-phenyl-5- (2,2,2-trifluoroethoxy)- 1,6-naphthyridin-4 (1H) -one (159 mg, 68%) was obtained: LCMS RT: 2.65 min, MH ⁺ : 426.4. This conversion can be carried out at suitable temperatures for these solvents using other aprotic solvents such as DMF, THF and dioxane. Commercial alkoxides can also be used in the absence of a base.
[786] Example 49
[787] 2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridine-5-carboxylic acid
[788]
[789] 2-anilino-5-chloro-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one (1.0 g, 2.8 mmol), DPPP (64 mg, 0.15 mmol), Pd (OAc ) ₂ (31 mg, 0.14 mmol), Cs ₂ CO ₃ (580 mg, 4.20 mmol) was dissolved in EtOH (10 mL) and DMF (10 mL). A balloon filled with CO was attached to the flask and the solution was vigorously stirred. The flask was purged with CO for 5 minutes and then heated to 70 ° C. After 4 h the mixture was cooled to rt and diluted with EtOAc. The mixture was washed with water and brine and dried over Na ₂ SO ₄ . The solvent was removed in vacuo and the residue triturated with Et ₂ 0 to ethyl 2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridine-5-carr Cylates (800 mg, 71%) were obtained. The ethyl ester was then dissolved in MeOH (5 mL) and THF (20 mL). KOH (3N, 10 mL) was added to this stirred solution, and the mixture was stirred at room temperature for 6 hours, and then extracted with Et ₂ O. The aqueous layer was acidified to pH = 1 with 2N HCl and the product precipitated out of solution. The solid was filtered and dried to afford 2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridine-5-carboxylic acid (683 mg, 92%). Obtained as a white solid:
[790] Example 50
[791] 2-anilino-N-methoxy-N, 7-dimethyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridine-5-carboxamide
[792]
[793] 2-anilino-7-methyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridine-5-carboxylic acid (80 mg, 0.22 mmol), N, O-dimethylhydrate Oxylamine hydrochloride (64 mg, 0.66 mmol), HOBT (89 mg, 0.66 mmol) and EDCI (126 mg, 0.66 mmol) were dissolved in CH ₂ Cl ₂ (9 mL). To this solution was added TEA (120 uL, 0.88 mmol). The reaction was stirred for 1 h and diluted with CH ₂ Cl ₂ and washed with 0.5N HCl, saturated NaHCO ₃ and brine. The organic layer was collected, dried over Na ₂ SO ₄ and concentrated in vacuo. The obtained solid was triturated with Et ₂ O and dried to afford 2-anilino-N-methoxy-N, 7-dimethyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridine- 5-Carboxamide (50 mg, 55%) was obtained as a light yellow solid: . This conversion can also be carried out by coupling a suitable amine with the corresponding acid chloride.
[794] Example 51
[795] 5-acetyl-2-anilino-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one
[796]
[797] 2-anilino-N-methoxy-N, 7-dimethyl-4-oxo-1-phenyl-1,4-dihydro-1,6-naphthyridine-5-carboxamide (60 mg, 0.14 mmol) Was suspended in THF (5 mL). To this stirred suspension at 0 ° C. MeMgBr (0.19 mL, 0.56 mmol, 3M in Et ₂ O) was added. The reaction was stirred at rt for 6 h and quenched with saturated aqueous NH ₄ Cl, diluted with EtOAc and washed with brine. The organic layer was collected, dried over Na ₂ SO ₄ and concentrated in vacuo. The residue was purified by biotage silica gel chromatography using EtOAc as eluent to afford 5-acetyl-2-anilino-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one (34 mg, 66%) was obtained as a light yellow solid:
[798]
[799] Example 52
[800] 2-anilino-7-methyl-1-phenyl-5- (trifluoromethyl) -1,6-naphthyridin-4 (1H) -one
[801]
[802] And Example 53
[803] 7-methyl-2- [methyl (phenyl) amino] -1-phenyl-5- (trifluoromethyl) -1,6-naphthyridin-4 (1H) -one
[804]
[805] Methyl fluorosulfonyldifluoroacetate (0.78 mL, 6.10 mmol) and 2-anilino-5-chloro-7-methyl-1-phenyl-1,6-naphthyridine-4 (1H) in DMF (15 mL) A mixture of -one (2.0 g, 5.50 mmol) was mixed with copper iodide (I) (1.05 g, 5.50 mmol) at 80 ° C. for 6 h, then the mixture was filtered and concentrated in vacuo. The residue was diluted with CH ₂ Cl ₂ , washed with water and brine and dried over MgSO ₄ . The solvent is removed in vacuo and the residue is purified by biotage silica gel chromatography using 1: 1 EtOAc: Hex to 2-anilino-7-methyl-1-phenyl-5- (trifluoromethyl) -1 , 6-naphthyridin-4 (1H) -one (477 mg, 22%) was obtained as a light yellow solid: Also isolated 7-methyl-2- [methyl (phenyl) amino] -1-phenyl-5- (trifluoromethyl) -1,6-naphthyridin-4 (1H) -one (270 mg, 12%) Was:
[806] Example 54
[807] 2-anilino-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one
[808]
[809] 2-anilino-5-chloro-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one (10 mg, 0.03 mmol) in EtOAc (2 mL) and EtOH (2 mL) at room temperature To the flask containing) one drop of TEA and Pd / C (10% by weight on activated carbon Degussa type E101, 2 mg) was added. The system was purged with H ₂ and stirred overnight at room temperature. The reaction mixture was filtered and concentrated in vacuo to afford 2-anilino-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one (8 mg, 91%):
[810]
[811] Example 55
[812] 2-anilino-5- (4-methoxyphenyl) -7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one
[813]
[814] 2-anilino-5-chloro-7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one (72 mg, 0.20 mmol) in 4-mL amber vial, 4-methoxyphenylboronic acid (36 mg, 0.24 mmol), Pd (OAc) ₂ (1 mg, 0.02 mmol), Ph ₃ P (5 mg, 0.02 mmol), K ₂ CO ₃ (110 mg, 0.8 mmol, 2M) and DME (2 mL ). The mixture was heated to 90 ° C. for 2 d. Water was added to the reaction mixture and extracted with CH ₂ Cl ₂ . The organic layer was dried over Na ₂ SO ₄ . The residue was concentrated in vacuo and then triturated with Et ₂ O to afford 2-anilino-5- (4-methoxyphenyl) -7-methyl-1-phenyl-1,6-naphthyridin-4 (1H) -one (54 mg, 63%) was obtained: LCMS RT: 1.92 min, MH ⁺ : 434.5.
[815] Various compounds of formula (I) were prepared using the above described methods and examples for intermediates alone or in combination, using suitable starting materials and representative methods described. These results are summarized in Table 1A.
[816]
[817]
[818]
[819]
[820]
[821]
[822]
[823]
[824]
[825]
[826]
[827]
[828]
[829]
[830]
[831]
[832]
[833]
[834]
[835]
[836]
[837]
[838]
[839]
[840]
[841]
[842]
[843]
[844]
[845]
[846]
[847]
[848]
[849]
[850]
[851]
[852]
[853]
[854]
[855]
[856]
[857]
[858]
[859]
[860]
[861]
[862] Using the methods described above for the intermediates and examples alone or in combination, various compounds of formula (I) can be prepared using appropriate starting materials and representative methods described. The compounds are summarized in Table 1B.
[863]
[864]
[865]
[866]
[867]
[868]
[869]
[870]
[871]
[872]
[873]
[874]
[875]
[876]
[877]
[878]
[879]
[880]
[881]
[882]
[883]
[884]
[885]
[886]
[887]
[888]
[889]
[890]
[891]
[892]
[893]
[894]
[895]
[896]
[897]
[898]
[899]
[900]
[901]
[902]
[903]
[904]
[905]
[906]
[907] Intermediates and Examples and Flowcharts The methods described above for I-XIV, alone or in combination, may be used to prepare a variety of compounds of Formula I using appropriate starting materials. The compounds are summarized in Table 1C.
[908]
[909]
[910]
[911]
[912]
[913]
[914]
[915]
[916] Using the methods described above for the intermediates and examples alone or in combination, various compounds of Formula II were prepared using the appropriate starting materials and the representative methods described. The compounds are summarized in Table 2A.
[917]
[918]
[919]
[920]
[921]
[922]
[923]
[924]
[925]
[926] Using the methods described above for the intermediates and examples alone or in combination, various compounds of formula (II) can be prepared using appropriate starting materials and representative methods described. The compounds are summarized in Table 2B.
[927]
[928]
[929]
[930]
[931]
[932]
[933]
[934]
[935]
[936]
[937]
[938]
[939]
[940]
[941]
[942]
[943]
[944]
[945]
[946]
[947]
[948]
[949]
[950]
[951]
[952]
[953]
[954]
[955]
[956]
[957]
[958]
[959]
[960]
[961]
[962]
[963]
[964]
[965]
[966]
[967]
[968]
[969]
[970]
[971]
[972]
[973]
[974]
[975]
[976]
[977]
[978]
[979]
[980]
[981]
[982]
[983] Intermediates and Examples and Flowcharts The methods described above for I-XIV, alone or in combination, may be used to prepare a variety of compounds of Formula II using appropriate starting materials. The compounds are summarized in Table 2C.
[984]
[985]
[986]
[987]
[988]
[989]
[990]
[991]
[992]
[993]
[994]
[995]
[996] Biological assessment
[997] Demonstration of the activity of the compounds of the present invention is carried out through in vitro, ex vivo and in vivo assays known in the art.
[998] In vivo test method:
[999] Male Wistar rats (270-330 g) were fasted overnight and then fed compounds by vehicle or oral gavage. After 2-3 hours, rats were administered intraperitoneally with glucose (2 g / kg). Rat tails were bled using a Glucometer (Bayer Corporation, Mishawaka, Ind.) Immediately before and 15, 30, and 60 minutes after glucose administration. The area under the glucose curve was calculated by the isosceles method for both the vehicle and the treated animals, and the percentage reduction in glucose AUC by the compound was calculated. The typical positive effect of the compound results in a 12-20% reduction in AUC compared to AUC in the vehicle treated group. The compounds of the present invention were found to have a blood glucose lowering effect in the in vivo assay.
[1000] The invention can be embodied in other specific forms without departing from its concept or essential characteristics. The above-described embodiments are included for illustrative purposes only. Accordingly, the scope of the invention is limited only by the scope of the appended claims.

权利要求:
Claims (40)
[1" claim-type="Currently amended] A compound of formula (I) and pharmaceutically acceptable salts thereof.
<Formula I>

Where
R ¹ is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, and AR ⁹ , or
R ¹ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, wherein the heterocycloalkyl and the heterocycloalkenyl are further selected from phenyl, Or may be fused with 5 to 6 membered heteroaryl of 2 to 5 carbon atoms and 1 to 3 heteroatoms selected from N, S ( _═O ) _0-2 and O, and / or the heterocycloalkyl or heterocyclo One or more carbon atoms in alkenyl may be oxidized to C (═O), these parent It may be substituted with one to three R ^10;
R ¹⁰ is nitro, nitrile, hydroxy, halogen, acyl of 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, carbon of 1 to 6 carbon atoms 6 haloalkyl, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, aryl of 6 to 10 carbon atoms, 2 to 9 carbon atoms and N, S ( = O) 1 to 4 heteroaryls selected from _0-2 and O, NR ¹¹ R ¹² , C (= 0) OR ¹¹ , C (= 0) NHR ¹¹ , NHC (= 0) R ¹³ , NHS ( = O) ₂ R ¹³ , S (= O) _0-2 R ¹³ , S (= O) ₂ NHR ¹¹ , 3 to 6 cycloalkyl carbon atoms, 3 to 6 cycloalkenyl, 3 to carbon atoms 5 and 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from 6 and N, S (= 0) _0-2 and O, and 3 to 6 carbon atoms and N, S (= 0) _0-2 and Heteroatoms selected from O One to two five to seven membered heterocycloalkenyl; The heterocycloalkyl and the heterocycloalkenyl may further be selected from phenyl or 2 to 5 carbon atoms and 1 to 3 5 to 6 membered heteroaryl selected from N, S (= 0) _0-2 and O; May be fused and / or one or more carbon atoms in said heterocycloalkyl or heterocycloalkenyl may be oxidized to C (═O);
R ¹³ is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, and carbon atoms 4 to 6 cycloalkenyl;
R ¹¹ and R ¹² are hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms Independently selected from alkyl and cycloalkenyl of 4 to 6 carbon atoms;
A is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, and haloalkyl of 1 to 8 carbon atoms;
R ⁹ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, OAR ¹⁴ and NR ¹¹ R ¹² , or
R ⁹ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S ( _═O ) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Selected from cycloalkenyl of 5 to 8 carbon atoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ⁹ is 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl of 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N, S ( = O) from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and O, wherein said heterocycloalkyl and said heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon in the heterocycloalkyl or the heterocycloalkenyl The atom may be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ¹⁴ is cycloalkyl having 3 to 8 carbon atoms, cycloalkenyl having 5 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 5 heteroatoms selected from N, S (= 0) _0-2 and O; To 7 membered heterocycloalkyl and 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which are May be substituted with 1 to 3 R ¹⁰ ;
R ² is selected from NR ¹⁵ R ¹⁶ , S (O) _0-2 R ^17, and OR ¹⁷ ;
R ¹⁵ is hydrogen atom, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, cycloalkenyl of 4 to 8 carbon atoms , 5-6 membered heterocycloalkyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 3 to 6 carbon atoms and N, S (= 0) _From 5 to 7 membered heterocycloalkenyl having 1 to 2 heteroatoms selected from _0-2 and O, AR ⁹ , C (= 0) R ¹⁸ , C (= 0) NHR ¹⁸ and S (= 0) ₂ NHR ¹⁸ Selected;
R ¹⁸ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ¹⁸ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, and alkynyl of 2 to 6 carbon atoms, all of which are 1 to 3 halogens, or alkoxy of 1 to 6 carbon atoms May be substituted with
R ¹⁸ is AR ⁹ ;
R ¹⁶ is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, and AR ⁹ , or
R ¹⁶ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ¹⁵ and R ^16, in combination with the nitrogen atom to which they are attached, are 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S ( _═O ) _0-2 and O, or 3 to carbon atoms 6, and N, S (= O) _0-2, and 1 to 2 hetero atoms 5- to 7-membered heterocycloalkyl, 3-to 6 carbon atoms selected from N, O, and one N, S (= O) _0-2 and O 1 to 2 heteroatoms selected from 5 to 7 membered heterocycloalkenyl, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms and N, S (= 0) Or fused with 5 to 6 membered heteroaryls of 1 to 3 heteroatoms selected from _0-2 and O, wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) May all be substituted with 1 to 3 R ¹⁰ ;
R ¹⁷ is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, haloalkyl of 1 to 8 carbon atoms, or AR ⁹ , or
R ¹⁷ is 6-10 aryl carbon atoms, 2-9 carbon atoms and 1-4 heteroaryl heteroalkyls selected from N, S (= 0) _0-2 and O, 3-8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ ;
R ³ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S ( _═O ) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, 1 to 2 heterocycloalkyls selected from 3 to 6 carbon atoms and N, S (= 0) _0-2 and O, cycloalkenyl of 4 to 8 carbon atoms, and 3 to 6 carbon atoms and N , S (= 0) _0-2 and O is selected from 1 to 2 heterocycloalkenyl heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ³ is alkyl having 1 to 6 carbon atoms, alkenyl having 2 to 6 carbon atoms, alkynyl having 2 to 6 carbon atoms, haloalkyl having 1 to 6 carbon atoms, hydrogen, nitro, halogen, NR ¹⁹ R ²⁰ , A -OR ¹⁹ , A-NR ¹⁹ R ²⁰ and AR ²⁰ ;
R ¹⁹ and R ²⁰ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ⁹ ,
R ¹⁹ and R ²⁰ are 6 to 10 aryl carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryl, 3 to 8 carbon atoms, selected from N, S (= 0) _0-2 and O Cycloalkyl, cycloalkenyl of 5 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and carbon Independently selected from 5 to 7 membered heterocycloalkenyl having 3 to 6 atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, the heterocycloalkyl and the heterocycloalkenyl May further be fused with phenyl or 2 to 5 carbon atoms and 1 to 3 5 to 6 membered heteroaryl selected from N, S (= 0) _0-2 and O and / or the hetero In cycloalkyl or heterocycloalkenyl one or more carbon atoms may be oxidized to C (═O) And, all of which can be optionally substituted with one to three R ^10;
R ⁴ is selected from ═O, = S and OR ²¹ ;
R ²¹ is hydrogen,
R ²¹ is alkyl having 1 to 8 carbon atoms, alkenyl having 2 to 8 carbon atoms, alkynyl having 2 to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms, cycloalkenyl having 4 to 8 carbon atoms 3 to 6 and N, S (= 0) _0-2 and 1 to 2 5-7 membered heterocycloalkyl heteroatoms selected from O, and 3 to 6 carbon atoms and N, S (= 0) _0- One or two 5-7 membered heterocycloalkenyl heteroatoms selected from ₂ and O, all of which may be substituted with 1 to 3 R ¹⁰ ;
R ⁵ and R ⁶ are selected from cycloalkyls of 3 to 8 carbon atoms, cycloalkenyl of 4 to 8 carbon atoms, aryl of 6 to 10 carbon atoms, and heteroaryl of 1 to 4 carbon atoms and 2 to 9 carbon atoms. Independently selected, all of which may be substituted with one to three R ¹⁰ , or
R ⁵ and R ⁶ are 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N , S (= 0) _0-2 and O independently selected from 2 to 5 membered heterocycloalkenyls of 2 to 5 members, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or carbon May be fused with 5 to 6 membered heteroaryls of 2 to 5 atoms and 1 to 3 heteroatoms selected from N, S ( _═O ) _0-2 and O and / or the heterocycloalkyl or heterocycloalkenyl At least one carbon atom may be oxidized to C (═O), and the heterocycloalkyl or the heterocycloalkenyl is one to three R ¹⁰ , AR ²³ , ANR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , S (= O) ₂ R ²⁶ , AC (= O) R ²⁴ , AC (= O) OR ²⁴ or AC (= O) NR ²⁴ to R ²⁵ may be substituted Or
R ⁵ and R ⁶ are hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, halo of 1 to 8 carbon atoms Alkyl, alkoxy of 1 to 8 carbon atoms, haloalkoxy of 1 to 8 carbon atoms, cycloalkoxy of 3 to 8 carbon atoms, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , AC (= O) R ²⁴ , AC Independently selected from (═O) OR ²⁴ and AC (═O) NR ²⁴ R ²⁵ ;
Q is selected from O and S (= 0) _0-2 ;
R ²² is selected from hydrogen, alkyl of 1 to 8 carbon atoms, haloalkyl of 1 to 8 carbon atoms, and cycloalkyl of 3 to 8 carbon atoms;
R ²³ is selected from hydroxy, alkoxy of 1 to 8 carbon atoms, haloalkoxy of 1 to 8 carbon atoms, and cycloalkoxy of 3 to 8 carbon atoms, or
R ²³ is cycloalkyl of 3 to 8 carbon atoms, cycloalkenyl of 4 to 8 carbon atoms, aryl of 6 to 10 carbon atoms, and 2 to 9 carbon atoms and N, S (= 0) _0-2 and O Selected from 1 to 4 heteroaryl heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²³ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and S (= O) _0-2 is selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O), and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ,
With the proviso that when R ²³ for A (OR ²² ) -R ²³ is selected from hydroxy, alkoxy of 1 to 8 carbon atoms, haloalkoxy of 1 to 8 carbon atoms, and cycloalkoxy of 3 to 8 carbon atoms, Is not CH;
R ²⁴ and R ²⁵ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ²³ ,
R ²⁴ and R ²⁵ are 3 to 6 cycloalkyl carbon atoms, 3 to 6 cycloalkenyl carbon atoms, 6 to 10 aryl carbon atoms, and 2 to 9 carbon atoms and N, S (= 0) _0- Independently selected from 1 to 4 heteroaryl heteroatoms selected from ₂ and O, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ are 3 to 6 carbon atoms and 5 to 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from N, O and S ( _═O ) _0-2 , and 3 to 6 carbon atoms and N , O and S (= 0) independently selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 , wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or carbon May be fused with 5 to 6 membered heteroaryls of 2 to 5 atoms and 1 to 3 heteroatoms selected from N, S ( _═O ) _0-2 and O and / or the heterocycloalkyl or heterocycloalkenyl At least one carbon atom may be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ together with the nitrogen atom to which they are attached are 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 5 to 7 membered heterocycloalkenyl or 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and 0 hetero or 2 to 9 carbon atoms and 1 to 4 heteroatoms Aryl, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or from 5 to 5 carbon atoms and from 1 to 3 heteroatoms selected from N, S (= 0) _0-2 and O; May be fused with 6-membered heteroaryl and / or in said heterocycloalkyl or heterocycloalkenyl one or more carbon atoms may be oxidized to C (═O), all of which are substituted with 1 to 3 R ¹⁰ Can be;
R ²⁶ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ Selected,
R ²⁶ represents 3 to 6 cycloalkyl carbon atoms, 3 to 6 cycloalkenyl carbon atoms, 6 to 10 aryl carbon atoms, and 2 to 9 carbon atoms and N, S (= 0) _0-2 and O Selected from 1 to 4 heteroaryl heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁶ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and S (= O) _0-2 is selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁷ is selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ²³ , or
R ²⁷ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, 6 to 10 carbon atoms, and 2 to 9 carbon atoms and N, S (= 0) _0-2 and O Selected from 1 to 4 heteroaryl heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁷ is 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, O and S (= 0) _0-2 , and 3 to 6 carbon atoms and N, O and S (= O) _0-2 is selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁸ is hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , C (= 0) R ²⁴ , C (= O) OR ²⁶ , C (= O) NR ²⁵ R ³⁰ , S (= O) ₂ R ²⁶ , AC (= O) R ²⁴ , AC (= O) OR ²⁴ and AC (= O) NR ^Or selected from ²⁴ R ²⁵ ;
R ²⁸ is from 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, 6 to 10 aryl and 2 to 9 carbon atoms and N, S (= 0) _0-2 and O Selected from 1 to 4 heteroaryls, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁸ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl heteroatoms selected from N, O and S ( _═O ) _0-2 , and 3 to 6 carbon atoms and N, O and S (= O) _0-2 is selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ³⁰ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ Selected,
R ³⁰ is 3 to 6 cycloalkyl carbon atoms, 3 to 6 cycloalkenyl carbon atoms, 6 to 10 aryl carbon atoms, and 2 to 9 carbon atoms and N, S (= 0) _0-2 and O Selected from 1 to 4 heteroaryl heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ³⁰ is 5-6 membered heterocycloalkyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, O and S (= 0) _0-2 , and 3 to 6 carbon atoms and N, O and S (= O) _0-2 is selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁵ and R ³⁰ in combination with the nitrogen atom to which they are attached are 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 5 to 7 membered heterocycloalkenyl or 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and 0 hetero or 2 to 9 carbon atoms and 1 to 4 heteroatoms Aryl is formed, all of which may be substituted with one to three R ¹⁰ ;
R ²⁹ is alkyl having 1 to 6 carbon atoms, alkenyl having 2 to 6 carbon atoms, alkynyl having 2 to 6 carbon atoms, haloalkyl having 1 to 6 carbon atoms, AR ²³ , AC (═O) R ²⁴ , AC (= O) OR ²⁴ , AC (= O) NR ²⁴ R ²⁵ , A-NR ²⁷ R ²⁸ , or
R ²⁹ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, 6 to 10 aryl, and 2 to 9 carbon atoms and N, S (= 0) _0-2 and O Selected from 1 to 4 heteroaryl heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁹ is 5-6 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, O and S (= 0) _0-2 , and 3 to 6 carbon atoms and N, O and S (= O) _0-2 is selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O) and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ⁷ is selected from cycloalkyl of 3 to 8 carbon atoms, cycloalkenyl of 4 to 8 carbon atoms, aryl of 6 to 10 carbon atoms, and heteroaryl of 1 to 4 carbon atoms and 2 to 9 carbon atoms, All of which may be substituted with 1 to 3 R ¹⁰ , or
R ⁷ is 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl of 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N, S ( = O) from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and O, wherein said heterocycloalkyl and said heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms And one or three 5-6 membered heteroaryls selected from N, S (= 0) _0-2 and O and / or at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O), wherein the heterocycloalkyl or the heterocycloalkenyl is one to three R ¹⁰ , A (OR ²² ) -R ²³ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , S (= O) ₂ R ²⁶ , AC (= O) R ²⁴ , AC (= O) OR ²⁴ or May be substituted with AC (= 0) NR ²⁴ R ²⁵ or ,
R ⁷ is hydrogen, nitrile, nitro, hydroxy, alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, haloalkyl of 1 to 8 carbon atoms, carbon atom 1 To 8 alkoxy, haloalkoxy of 1 to 8 carbon atoms, cycloalkoxy of 3 to 8 carbon atoms, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , AC (= O) R ²⁴ , AC (= O) OR ²⁴ and AC (= 0) NR ²⁴ R ²⁵ ,
Of the compounds of formula (I)
1,5-dimethyl-2- (methylamino) -7- (4-morpholinyl) -1,8-naphthyridin-4 (1H) -one,
1,5-dimethyl-2- (methylamino) -7- (4-methyl-1-piperazinyl) -1,8-naphthyridin-4 (1H) -one,
1,5-dimethyl-2- (methylamino) -7- (1-pyrrolidinyl) -1,8-naphthyridin-4 (1H) -one,
1,5-dimethyl-2- (methylamino) -7- (1-piperidinyl) -1,8-naphthyridin-4 (1H) -one,
1,5-dimethyl-2- (methylamino) -7- (4-methyl-1-piperazinyl) -3-nitro-1,8-naphthyridin-4 (1H) -one,
1,5-dimethyl-2- (methylamino) -3-nitro-7- (1-pyrrolidinyl) -1,8-naphthyridin-4 (1H) -one or
1- (3-chlorophenyl) -2- (4-morpholinyl) -1,8-naphthyridin-4 (1H) -one is excluded.
[2" claim-type="Currently amended] The compound of claim 1, wherein R ⁴ is ═O.
[3" claim-type="Currently amended] The compound of claim 1, wherein R ³ is selected from 3 to 6 cycloalkyl carbon atoms, 3 to 6 carbon atoms and 1 to 2 heterocycloalkyl heteroatoms selected from N, S ( _═O ) _0-2 and O. All of which may be substituted with 1 to 3 R ¹⁰ , or
R ³ is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, hydrogen, nitro, halogen, NR ¹⁹ R ²⁰ , A-OR ¹⁹ , A-NR ¹⁹ R ²⁰ and AR ²⁰ .
[4" claim-type="Currently amended] The compound of claim 3, wherein R ¹⁹ and R ²⁰ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ⁹ , or R ¹⁹ and R ²⁰ are phenyl, carbon atom 2 1 to 3 monocyclic heteroaryls selected from 5 to 5 and N, S (= 0) _0-2 and O, 3 to 6 cycloalkyl carbon atoms, 3 to 6 carbon atoms and N, S ( = O) independently selected from 1 to 2 5-7 membered heterocycloalkyl heteroatoms selected from _0-2 and 0, wherein at least one carbon atom in said heterocycloalkyl can be oxidized to C (= 0), All of which may be substituted with 1 to 3 R ¹⁰ .
[5" claim-type="Currently amended] The compound of claim 1, wherein R ³ is selected from 3 to 6 cycloalkyl carbon atoms, 3 to 6 carbon atoms and 1 to 2 heterocycloalkyl heteroatoms selected from N, S ( _═O ) _0-2 and O. All of which may be substituted with 1 to 3 R ¹⁰ , or
R ³ is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, hydrogen, nitro, halogen, NR ¹⁹ R ²⁰ , A-OR ¹⁹ , A-NR ¹⁹ R ²⁰ and AR ²⁰ ;
R ⁴ is = O.
[6" claim-type="Currently amended] The compound of claim 5, wherein R ¹⁹ and R ²⁰ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ⁹ , or R ¹⁹ and R ²⁰ are phenyl, carbon atom 2. 1 to 3 monocyclic heteroaryls selected from 5 to 5 and N, S (= 0) _0-2 and O, 3 to 6 cycloalkyl carbon atoms, 3 to 6 carbon atoms and N, S ( = O) independently selected from 1 to 2 5-7 membered heterocycloalkyl heteroatoms selected from _0-2 and 0, wherein at least one carbon atom in said heterocycloalkyl can be oxidized to C (= 0), All of which may be substituted with 1 to 3 R ¹⁰ .
[7" claim-type="Currently amended] The compound of claim 1, wherein R ² is NR ¹⁵ R ¹⁶ .
[8" claim-type="Currently amended] 8. A compound according to claim 7, wherein R ¹⁵ is selected from hydrogen atom, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, 3 to 6 carbon atoms and N, S (= 0) _0-2 and O 5-7 membered heterocycloalkyl of 1 to 2 heteroatoms, AR ⁹ , C (= 0) R ¹⁸ , C (= 0) NHR ¹⁸ and S (= 0) ₂ NHR ¹⁸ ;
R ¹⁸ is phenyl, 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 6 cycloalkyl and 3 carbon atoms _Or from 1 to 2 5-7 membered heterocycloalkyl heteroatoms selected from 6 to 6 and N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ¹⁸ is alkyl of 1 to 6 carbon atoms which may be substituted with 1 to 3 halogens or 1 to 6 alkoxy of carbon atoms, or
R ¹⁸ is AR ⁹ ;
R ¹⁶ is selected from alkyl of 1 to 6 carbon atoms, and AR ⁹ , or
R ¹⁶ is phenyl, 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, and carbon atoms 3 to 6 and 1 to 2 5-7 membered heterocycloalkyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ ,
R ¹⁵ and R ¹⁶ in combination with the nitrogen atom to which they are attached are monocyclic heteroaryl having 2 to 5 carbon atoms and 1 to 3 heteroatoms selected from N, S ( _═O ) _0-2 and O, or carbon And form 5 to 7 membered heterocycloalkyl of 3 to 6 atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, wherein one carbon atom in the heterocycloalkyl is C (= O), all of which may be substituted with 1 to 3 R ¹⁰ .
[9" claim-type="Currently amended] The compound of claim 1, wherein R ² is NR ¹⁵ R ¹⁶ ;
R ³ is selected from cycloalkyls of 3 to 6 carbon atoms, heterocarbons of 1 to 2 heterocycloalkyls selected from 3 to 6 carbon atoms and N, S (= 0) _0-2 and O, all of which are 1 Or may be substituted with 3 R ¹⁰ ;
R ³ is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, hydrogen, nitro, halogen, NR ¹⁹ R ²⁰ , A-OR ¹⁹ , A-NR ¹⁹ R ²⁰ and AR ²⁰ ;
R ⁴ is = O.
[10" claim-type="Currently amended] 10. The hetero according to claim 9, wherein R ¹⁵ is selected from hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, 3 to 6 carbon atoms and N, S (= 0) _0-2 and O 5-7 membered heterocycloalkyl of 1 to 2 atoms, AR ⁹ , C (= 0) R ¹⁸ , C (= 0) NHR ¹⁸ and S (= 0) ₂ NHR ¹⁸ ;
R ¹⁸ is phenyl, 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 6 cycloalkyl carbon atoms, and carbon atoms 3 to 6 and 1 to 2 5-7 membered heterocycloalkyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ or ,
R ¹⁸ is alkyl of 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms or 1 to 6 alkoxy of carbon atoms, or
R ¹⁸ is AR ⁹ ;
R ¹⁶ is selected from alkyl of 1 to 6 carbon atoms and AR ⁹ , or
R ¹⁶ is phenyl, 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, and carbon atoms 3 to 6 and 1 to 2 5-7 membered heterocycloalkyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ or ,
R ¹⁵ and R ¹⁶ in combination with the nitrogen atom to which they are attached are monocyclic heteroaryl having 2 to 5 carbon atoms and 1 to 3 heteroatoms selected from N, S ( _═O ) _0-2 and O, or carbon And form 5 to 7 membered heterocycloalkyl of 3 to 6 atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, wherein one carbon atom in the heterocycloalkyl is C (= O), all of which may be substituted with 1 to 3 R ¹⁰ .
[11" claim-type="Currently amended] The method of claim 10,


Compound selected from the group consisting of.
[12" claim-type="Currently amended] The compound of claim 9, wherein R ¹⁹ and R ²⁰ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ⁹ , or R ¹⁹ and R ²⁰ are phenyl, carbon atom 2. 1 to 3 monocyclic heteroaryls selected from 5 to 5 and N, S (= 0) _0-2 and O, 3 to 6 cycloalkyl carbon atoms, 3 to 6 carbon atoms and N, S ( = O) independently selected from 1 to 2 5-7 membered heterocycloalkyl heteroatoms selected from _0-2 and 0, wherein at least one carbon atom in said heterocycloalkyl can be oxidized to C (= 0), All of which may be substituted with 1 to 3 R ¹⁰ .
[13" claim-type="Currently amended] 10. The monocy of claim 1, wherein R ⁵ is 3 to 6 cycloalkyl of carbon atoms, cycloalkenyl of 4 to 6 carbon atoms, phenyl, and 2 to 5 carbon atoms and 1 to 3 heteroatoms. Selected from click heteroaryl, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ⁵ is 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl of 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N, S ( = O) from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and 0, wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) Wherein the heterocycloalkyl or the heterocycloalkenyl is one to three R ¹⁰ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= 0) OR ²⁴ , C ( ═O) NR ²⁴ R ²⁵ , S (═O) ₂ R ²⁶ , AC (═O) R ²⁴ , AC (═O) OR ²⁴ or AC (═O) NR ²⁴ R ²⁵ , or
R ⁵ is hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, carbon Alkoxy of 1 to 6 atoms, haloalkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , AC (= O) R ²⁴ , AC (= O ) OR ²⁴ and AC (= 0) NR ²⁴ R ²⁵ ;
R ²² is selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms;
R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, or
R ²³ is a cycloalkyl having 3 to 6 carbon atoms, cycloalkenyl having 4 to 6 carbon atoms, phenyl, and 2 to 5 carbon atoms and heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, or
R ²³ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) Wherein the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ,
With the proviso that when R ²³ for A (OR ²² ) -R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, Is not CH;
R ²⁴ and R ²⁵ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ²³ ,
R ²⁴ and R ²⁵ are heteroalkyls selected from 3 to 6 cycloalkyl carbon atoms, 3 to 6 cycloalkenyl carbon atoms, phenyl, and 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; Independently selected from monocyclic heteroaryl of 1 to 3 atoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ are carbon atoms and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N Is independently selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from O and S (= 0) _0-2 , wherein at least one carbon atom in the heterocycloalkyl or heterocycloalkenyl is selected from C ( = 0), and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ together with the nitrogen atom to which they are attached 5 to 7 membered heterocycloalkyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 5 to 7 membered heterocycloalkenyl or 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O or 2 to 5 carbon atoms and 1 to 3 monoatoms Forms a cyclic heteroaryl, wherein at least one carbon atom in the heterocycloalkyl or heterocycloalkenyl may be oxidized to C (═O), all of which may be substituted with 1 to 3 R ¹⁰ ;
R ²⁶ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ Selected,
R ²⁶ represents 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and heteroatoms selected from N, S (= 0) _0-2 and O; 3 monocyclic heteroaryl, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁶ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁷ is selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ²³ , or
R ²⁷ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²⁷ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O and S (= 0) _0-2 , and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁸ is hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , C (= 0) R ²⁴ , C (= O) OR ²⁶ , C (= O) NR ²⁵ R ³⁰ , S (= O) ₂ R ²⁶ , AC (= O) R ²⁴ , AC (= O) OR ²⁴ and AC (= O) NR ^Or selected from ²⁴ R ²⁵ ;
R ²⁸ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and heteroatoms 1 to 0, selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²⁸ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ³⁰ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ Selected,
R ³⁰ has 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ³⁰ is 1 to 2 5 to 7 membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O, and _0-2 hetero atoms selected from carbon atoms and 3 to 6 N, O or S (= O) One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁵ and R ^{30 taken} together with the nitrogen atom to which they are attached are 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 5 to 7 membered heterocycloalkenyl or 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O or 2 to 5 carbon atoms and 1 to 3 monoatoms Cyclic heteroaryl, all of which may be substituted with one to three R ¹⁰ ;
R ²⁹ is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , AC (= 0) R ²⁴ , AC (= O) OR ²⁴ , AC (= 0) NR ²⁴ R ²⁵ and A-NR ²⁷ R ²⁸ , or
R ²⁹ is a heteroatom selected from 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²⁹ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O and S (= 0) _0-2 , and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) Wherein the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ .
[14" claim-type="Currently amended] The compound of claim 13, wherein R ⁵ is selected from cycloalkyls of 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryls of 2 to 5 carbon atoms and 1 to 3 heteroatoms, all of which are 1 to 3 carbon atoms. May be substituted with R ¹⁰ , or
R ⁵ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, wherein one carbon atom in the heterocycloalkyl is C Can be oxidized to (= O), wherein said heterocycloalkyl is 1 to 3 R ¹⁰ , AR ²³ , ANR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= 0) OR ²⁴ , C (= 0) ) NR ²⁴ R ²⁵ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ or AC (= 0) NR ²⁴ R ²⁵ , or
R ⁵ is hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, carbon atom 3 to 6 cycloalkoxy, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , and AC (= 0) R ²⁴ ;
R ²² is selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms;
R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, or
R ²³ is selected from cycloalkyl with 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl with 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²³ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O and S (= 0) _0-2 , wherein one carbon atom in the heterocycloalkyl is C May be oxidized to (═O), and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ ,
With the proviso that when R ²³ for A (OR ²² ) -R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, Is not CH;
R ²⁴ and R ²⁵ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ²³ , or
R ²⁴ and R ²⁵ are 3 to 6 cycloalkyl, phenyl, and 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O Independently selected from, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ are independently selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O and S (= 0) _0-2 , said heterocycloalkyl In which one carbon atom may be oxidized to C (═O) and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ are taken together with the nitrogen atom to which they are attached 5 to 7 membered heterocycloalkyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O or Monocyclic heteroaryl having 2 to 5 carbon atoms and 1 to 3 heteroatoms, wherein at least one carbon atom in the heterocycloalkyl can be oxidized to C (= 0), all of which are 1 to 3 May be substituted with R ¹⁰ ;
R ²⁶ is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ , or
R ²⁶ is selected from cycloalkyl, phenyl having 3 to 6 carbon atoms, and monocyclic heteroaryl having 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁶ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O and S (= 0) _0-2 , wherein one carbon atom in the heterocycloalkyl is C May be oxidized to (═O), and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁷ is selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ²³ , or
R ²⁷ is selected from cycloalkyls of 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryls of 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁷ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O and S (= 0) _0-2 , wherein one carbon atom in the heterocycloalkyl is C May be oxidized to (═O), and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁸ is hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , C (= 0) R ²⁴ , C (= 0) OR ²⁶ , C (= 0) NR ²⁵ R ³⁰ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ and AC (= 0) NR ²⁴ R ²⁵ , or
R ²⁸ is selected from cycloalkyl of 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl having 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁸ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O and S (= 0) _0-2 , wherein one carbon atom in the heterocycloalkyl is C May be oxidized to (═O), and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ ;
R ³⁰ is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ , or
R ³⁰ is selected from cycloalkyl with 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl with 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ³⁰ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O and S ( _═O ) _0-2 , wherein one carbon atom in the heterocycloalkyl is C May be oxidized to (═O), and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁵ and R ^{30 taken} together with the nitrogen atom to which they are attached have 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O or Monocyclic heteroaryl having 2 to 5 carbon atoms and 1 to 3 carbon atoms, all of which may be substituted with 1 to 3 R ¹⁰ ;
R ²⁹ is alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ , AC (= 0) NR ²⁴ R ²⁵ and A -NR ²⁷ R ²⁸ or
R ²⁹ is selected from cycloalkyl with 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl with 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁹ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O and S (= 0) _0-2 , wherein one carbon atom in the heterocycloalkyl is C And ═O), wherein the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ .
[15" claim-type="Currently amended] The method of claim 14,

Compound selected from the group consisting of.
[16" claim-type="Currently amended] ^10. The monocy according to claim 1, wherein R ⁶ is 3 to 6 cycloalkyl having 4 to 6 carbon atoms, cycloalkenyl having 4 to 6 carbon atoms, phenyl, and 2 to 5 carbon atoms and 1 to 3 monoatoms. Selected from click heteroaryl, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ⁶ is 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N, S ( = O) from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and 0, wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) Wherein the heterocycloalkyl or the heterocycloalkenyl is one to three R ¹⁰ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= 0) OR ²⁴ , C ( = 0) NR ²⁴ R ²⁵ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ or AC (= 0) NR ²⁴ R ²⁵ , or
R ⁶ is hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, carbon Alkoxy of 1 to 6 atoms, haloalkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , AC (= O) R ²⁴ , AC (= O ) Is independently selected from OR ²⁴ and AC (= 0) NR ²⁴ R ²⁵ ;
R ²² is selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms;
R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, or
R ²³ is a cycloalkyl having 3 to 6 carbon atoms, cycloalkenyl having 4 to 6 carbon atoms, phenyl, and 2 to 5 carbon atoms and heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²³ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) Wherein the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ,
With the proviso that when R ²³ for A (OR ²² ) -R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, Is not CH;
R ²⁴ and R ²⁵ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ²³ ,
R ²⁴ and R ²⁵ are heteroalkyls selected from 3 to 6 cycloalkyl carbon atoms, 3 to 6 cycloalkenyl carbon atoms, phenyl, and 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; Independently selected from monocyclic heteroaryl of 1 to 3 atoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ are carbon atoms and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N , O and S (= 0) are independently selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 , wherein at least one carbon atom in the heterocycloalkyl or heterocycloalkenyl is selected from C ( = 0), and the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ together with the nitrogen atom to which they are attached 5 to 7 membered heterocycloalkyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 1 to 2 5 to 7 membered heterocycloalkenyl or 2 to 5 carbon atoms and 1 to 3 heteroatoms selected from 3 to 6 carbon atoms and N, S (= 0) _0-2 and O Forms a cyclic heteroaryl, wherein at least one carbon atom in the heterocycloalkyl or heterocycloalkenyl may be oxidized to C (═O), all of which may be substituted with 1 to 3 R ¹⁰ ;
R ²⁶ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ Selected,
R ²⁶ represents 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and heteroatoms selected from N, S (= 0) _0-2 and O; 3 monocyclic heteroaryl, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁶ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁷ is selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ²³ , or
R ²⁷ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²⁷ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl of N, O and S ( _═O ) _0-2 , and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁸ is hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , C (= 0) R ²⁴ , C (= O) OR ²⁶ , C (= O) NR ²⁵ R ³⁰ , S (= O) ₂ R ²⁶ , AC (= O) R ²⁴ , AC (= O) OR ²⁴ and AC (= O) NR ^Or selected from ²⁴ R ²⁵ ;
R ²⁸ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and heteroatoms 1 to 0, selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²⁸ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ³⁰ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ Selected,
R ³⁰ has 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ³⁰ is 1 to 2 5 to 7 membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O, and _0-2 hetero atoms selected from carbon atoms and 3 to 6 N, O or S (= O) One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁵ and R ^{30 taken} together with the nitrogen atom to which they are attached are 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 5 to 7 membered heterocycloalkenyl or 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O or 2 to 5 carbon atoms and 1 to 3 monoatoms Cyclic heteroaryl, all of which may be substituted with one to three R ¹⁰ ;
R ²⁹ is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , AC (= 0) R ²⁴ , AC (= O) OR ²⁴ , AC (= 0) NR ²⁴ R ²⁵ and A-NR ²⁷ R ²⁸ , or
R ²⁹ is a heteroatom selected from 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²⁹ is a carbon atom and 3 to 6 N, O or S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O and One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) Wherein the heterocycloalkyl or the heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ .
[17" claim-type="Currently amended] The compound of claim 16, wherein R ⁶ is selected from cycloalkyls of 3 to 6 carbon atoms, which may be substituted with 1 to 3 R ¹⁰ , or
R ⁶ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, S (= 0) _0-2 and O and / or one from said heterocycloalkyl May be oxidized to C (═O), wherein the heterocycloalkyl is 1 to 3 R ¹⁰ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= 0) OR ²⁴ , C (= 0) NR ²⁴ R ²⁵ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ or AC (= 0) NR ²⁴ R ²⁵ Can be, or
R ⁶ is hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A- NR ²⁷ R ²⁸ , AQR ²⁹ , S (= O) _0-2 -R ²⁹ , S (= O) _0-2 -A-NR ²⁴ R ²⁵ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ and AC (= 0) NR ²⁴ R ²⁵ ;
R ²² is selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms;
R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, or
R ²³ is selected from cycloalkyl with 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl with 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²³ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O and S (= 0) _0-2 and / or one from said heterocycloalkyl May be oxidized to C (═O) and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ ,
With the proviso that when R ²³ for A (OR ²² ) -R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, Is not CH;
R ²⁴ and R ²⁵ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ²³ , or
R ²⁴ and R ²⁵ are 3 to 6 cycloalkyl, phenyl, and 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O Independently selected from, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ are independently selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O and S (= 0) _0-2 , and In heterocycloalkyl one carbon atom may be oxidized to C (= 0), said heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ are taken together with the nitrogen atom to which they are attached 5 to 7 membered heterocycloalkyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O or Form a monocyclic heteroaryl, and in said heterocycloalkyl one carbon atom may be oxidized to C (= 0), all of which may be substituted with 1 to 3 R ¹⁰ ;
R ²⁶ is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ , or
R ²⁶ is selected from cycloalkyl, phenyl having 3 to 6 carbon atoms, and monocyclic heteroaryl having 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁶ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O and S (= 0) _0-2 and / or one from said heterocycloalkyl May be oxidized to C (═O) and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁷ is selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms and AR ²³ , or
R ²⁷ is selected from cycloalkyls of 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryls of 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁷ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O and S (= 0) _0-2 and / or one from said heterocycloalkyl May be oxidized to C (═O) and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁸ is hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , C (= 0) R ²⁴ , C (= 0) OR ²⁶ , C (= 0) NR ²⁵ R ³⁰ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ and AC (= 0) NR ²⁴ R ²⁵ , or
R ²⁸ is selected from cycloalkyl of 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl having 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁸ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O and S (= 0) _0-2 and / or one from said heterocycloalkyl May be oxidized to C (═O) and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ ;
R ³⁰ is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ , or
R ³⁰ is selected from cycloalkyl with 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl with 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ³⁰ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O and S (= 0) _0-2 and / or one from said heterocycloalkyl May be oxidized to C (═O), and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁵ and R ^{30 taken} together with the nitrogen atom to which they are attached have 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O or Monocyclic heteroaryl having 2 to 5 carbon atoms and 1 to 3 carbon atoms, all of which may be substituted with 1 to 3 R ¹⁰ ;
R ²⁹ is alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ , AC (= 0) NR ²⁴ R ²⁵ and A -NR ²⁷ R ²⁸ or
R ²⁹ is selected from cycloalkyl with 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl with 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁹ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O and S (= 0) _0-2 and / or one from said heterocycloalkyl Wherein the carbon atom of can be oxidized to C (═O) and the heterocycloalkyl can be substituted with 1 to 3 R ¹⁰ .
[18" claim-type="Currently amended] The method of claim 17,


Compound selected from the group consisting of.
[19" claim-type="Currently amended] ^10. Monocy according to claim 1, wherein R ⁷ is monocyclo having 3 to 6 cycloalkyl carbon atoms, cycloalkenyl having 4 to 6 carbon atoms, phenyl, and 2 to 5 carbon atoms and 1 to 3 heteroatoms. Selected from click heteroaryl, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ⁷ is 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N, S ( = O) from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and O, and at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is C (= 0) And heterocycloalkyl or heterocycloalkenyl is 1 to 3 R ¹⁰ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= 0) OR ²⁴ , May be substituted with C (= 0) NR ²⁴ R ²⁵ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ , or AC (= 0) NR ²⁴ R ²⁵ ,
R ⁷ is hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, carbon Alkoxy of 1 to 6 atoms, haloalkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , AC (= O) R ²⁴ , AC (= O ) OR ²⁴ , and AC (= 0) NR ²⁴ R ²⁵ ;
R ²² is selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms;
R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, or
R ²³ is a cycloalkyl having 3 to 6 carbon atoms, cycloalkenyl having 4 to 6 carbon atoms, phenyl, and 2 to 5 carbon atoms and heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²³ is 5-6 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, O, S (= O) _0-2 , and 3 to 6 carbon atoms and N, O, One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 and / or wherein said at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is C (= 0) May be oxidized), and the heterocycloalkyl or heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
Provided that for A (OR ²² ) -R ²³ , when R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, A is not CH;
R ²⁴ and R ²⁵ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ²³ Or
R ²⁴ and R ²⁵ are heteroalkyl selected from cycloalkyl of 3 to 6 carbon atoms, cycloalkenyl of 3 to 6 carbon atoms, phenyl, and 2 to 5 carbon atoms and N, S (= 0) _0-2 and O Independently selected from monocyclic heteroaryl of 1 to 3 atoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ are 3-6 carbon atoms and 5-7 membered heterocycloalkyl of 1 to 2 heteroatoms selected from N, O, S (= 0) _0-2 , and 3-6 carbon atoms and N , O, S (= 0) independently selected from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and / or one or more carbon atoms in the heterocycloalkyl or heterocycloalkenyl May be oxidized to C (═O), and the heterocycloalkyl or heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ together with the nitrogen atom to which they are attached are 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 5 to 7 membered heterocycloalkenyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, or 2 to 5 carbon atoms and 1 to 3 heteroatoms Form a monocyclic heteroaryl and / or in said heterocycloalkyl or heterocycloalkenyl one or more carbon atoms may be oxidized to C (= 0), all of which may be substituted with 1 to 3 R ¹⁰ Can;
R ²⁶ is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ , and AR ²³ Selected from
R ²⁶ is a cycloalkyl having 3 to 6 carbon atoms, a cycloalkenyl of 3 to 6 carbon atoms, phenyl, and 2 to 5 carbon atoms and heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²⁶ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl of N, O, S (= O) _0-2 , and 3 to 6 carbon atoms and N, O, One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 and / or one or more carbon atoms in the heterocycloalkyl or heterocycloalkenyl is C (= O) and said heterocycloalkyl or heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁷ is selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ²³ , or
R ²⁷ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²⁷ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl heteroatoms selected from N, O, S (= 0) _0-2 , and 3 to 6 carbon atoms and N, O, One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 and / or wherein said at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is C (= 0) Can be oxidized, and the heterocycloalkyl or heterocycloalkenyl can be substituted with 1 to 3 R ¹⁰ ;
R ²⁸ is hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , C (= 0) R ²⁴ , C (= 0) OR ²⁶ , C (= 0) NR ²⁵ R ³⁰ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ , and AC (= 0) NR ²⁴ R ²⁵ , or
R ²⁸ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and heteroatoms 1 to 0, selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²⁸ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl heteroatoms selected from N, O, S ( _═O ) _0-2 , and 3 to 6 carbon atoms and N, O, One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 and / or wherein said at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is C (= 0) Can be oxidized, and the heterocycloalkyl or heterocycloalkenyl can be substituted with 1 to 3 R ¹⁰ ;
R ³⁰ is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ , and AR ²³ Selected from
R ³⁰ has 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ³⁰ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl heteroatoms selected from N, O, S (= O) _0-2 , and 3 to 6 carbon atoms and N, O, One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , and wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is C (= 0); May be oxidized), and the heterocycloalkyl or heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁵ and R ^{30 taken} together with the nitrogen atom to which they are attached are 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 5 to 7 membered heterocycloalkenyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, or 2 to 5 carbon atoms and 1 to 3 heteroatoms Forms a monocyclic heteroaryl, all of which may be substituted with one to three R ¹⁰ ;
R ²⁹ is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , AC (= 0) R ²⁴ , AC (= O) OR ²⁴ , AC (= O) NR ²⁴ R ²⁵ , A-NR ²⁷ R ²⁸ , or
R ²⁹ is a hetero atom selected from 3 to 6 cycloalkyl of 3 to 6 carbon atoms, cycloalkenyl of 3 to 6 carbon atoms, phenyl, 2 to 5 carbon atoms and N, S (= 0) _0-2 and O Monocyclic heteroaryl, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁹ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl of N, O, S (= 0) _0-2 and 3 to 6 carbon atoms and N, O, One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 and / or wherein said at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is C (= 0) Wherein the heterocycloalkyl or heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ .
[20" claim-type="Currently amended] 20. The compound of claim 19, wherein R ⁷ is selected from cycloalkyls of 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryls of 2 to 5 carbon atoms and 1 to 3 carbon atoms, all of which are 1 to 3 May be substituted with R ¹⁰ , or
R ⁷ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, S (= 0) _0-2 and O and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O), wherein the heterocycloalkyl is one to three R ¹⁰ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= 0) OR ²⁴ , C (= 0) NR ²⁴ R ²⁵ , S (= 0) ₂ R ²⁶ _, AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ or AC (= 0) NR ²⁴ R ²⁵ Can be, or
R ⁷ is hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, carbon atom 3 to 8 cycloalkoxy, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= 0) OR ²⁴ , C (= 0) NR ²⁴ R ²⁵ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ and AC (= 0) NR ²⁴ R ²⁵ ;
R ²² is selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms;
R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, or
R ²³ is selected from cycloalkyl with 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl with 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²³ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O, S (= 0) _0-2 and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O) and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ ;
Provided that for A (OR ²² ) -R ²³ , when R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, A is not CH;
R ²⁴ and R ²⁵ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ²³ , or
R ²⁴ and R ²⁵ are 3 to 6 cycloalkyl, phenyl, and 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O Independently selected from, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ are independently selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O, S (= 0) _0-2 , and In heterocycloalkyl one of the carbon atoms may be oxidized to C (═O), said heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ together with the nitrogen atom to which they are attached are 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, Or monocyclic heteroaryl having 2 to 5 carbon atoms and 1 to 3 heteroatoms, and / or one of the carbon atoms in said heterocycloalkyl may be oxidized to C (= 0), all of which May be substituted with 1 to 3 R ¹⁰ ;
R ²⁶ is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ , or
R ²⁶ is selected from cycloalkyl with 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl with 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁶ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O, S (= 0) _0-2 and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O) and the heterocycloalkyl may be substituted with one to three R ¹⁰ ;
R ²⁷ is selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ²³ , or
R ²⁷ is selected from cycloalkyls of 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryls of 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁷ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O, S (= 0) _0-2 and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O) and the heterocycloalkyl may be substituted with one to three R ¹⁰ ;
R ²⁸ is hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ , and AC (= 0) NR ²⁴ R ^Or from ²⁵
R ²⁸ is selected from cycloalkyl of 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl having 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁸ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O, S (= 0) _0-2 and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O) and the heterocycloalkyl may be substituted with one to three R ¹⁰ ;
R ³⁰ is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ , or
R ³⁰ is selected from cycloalkyl with 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl with 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ³⁰ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O, S (= 0) _0-2 and / or carbon in the heterocycloalkyl One of the atoms may be oxidized to C (═O) and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁵ and R ^{30 taken} together with the nitrogen atom to which they are attached are 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, Or monocyclic heteroaryl of 2 to 5 carbon atoms and 1 to 3 heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ ;
R ²⁹ is alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ , AC (= 0) NR ²⁴ R ²⁵ , A -NR ²⁷ R ²⁸ or
R ²⁹ is selected from cycloalkyls of 3 to 6 carbon atoms, phenyl, 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O, All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁹ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O, S (= 0) _0-2 and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O) and the heterocycloalkyl may be substituted with one to three R ¹⁰ .
[21" claim-type="Currently amended] The method of claim 20,



Compound selected from the group consisting of.
[22" claim-type="Currently amended] Compounds of formula (I) and pharmaceutically acceptable salts thereof
<Formula I>

Where
R ¹ is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, and AR ⁹ , or
R ¹ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, wherein the heterocycloalkyl and the heterocycloalkenyl are further selected from phenyl, Or may be fused with 5 to 6 membered heteroaryls of 2 to 5 carbon atoms and 1 to 3 heteroatoms selected from N, S (= 0) _0-2 and O and / or the heterocycloalkyl or heterocyclo One or more carbon atoms in alkenyl may be oxidized to C (═O), all of which It may be substituted with one to three R ^10, and;
R ¹⁰ is nitro, nitrile, hydroxy, halogen, acyl of 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, carbon of 1 to 6 carbon atoms 6 haloalkyl, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, aryl of 6 to 10 carbon atoms, 2 to 9 carbon atoms and N, S ( = O) 1 to 4 heteroaryls selected from _0-2 and O, NR ¹¹ R ¹² , C (= 0) OR ¹¹ , C (= 0) NHR ¹¹ , NHC (= 0) R ¹³ , NHS ( = O) ₂ R ¹³ , S (= O) _0-2 R ¹³ , S (= O) ₂ NHR ¹¹ , 3 to 6 cycloalkyl carbon atoms, 3 to 6 cycloalkenyl, 3 to carbon atoms 5 and 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from 6 and N, S (= 0) _0-2 and O, and 3 to 6 carbon atoms and N, S (= 0) _0-2 and Heteroatoms selected from O Selected from 1 to 2 5-7 membered heterocycloalkenyl, said heterocycloalkyl and heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms and N, S (= 0) _0-2 and O May be fused with 1 to 3 5-6 membered heteroaryls selected from and / or in said heterocycloalkyl or heterocycloalkenyl one or more carbon atoms may be oxidized to C (= 0);
R ¹³ is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, and carbon atoms 4 to 6 cycloalkenyl;
R ¹¹ and R ¹² are hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms Independently selected from alkyl and cycloalkenyl of 4 to 6 carbon atoms;
A is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, and haloalkyl of 1 to 8 carbon atoms;
R ⁹ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, OAR ¹⁴ , NR ¹¹ R ¹² ;
R ⁹ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S ( _═O ) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Selected from cycloalkenyl of 5 to 8 carbon atoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ⁹ is 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl of 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N, S ( = O) from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and O, wherein said heterocycloalkyl and heterocycloalkenyl are further selected from phenyl, or from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O can be fused with 1 to 3 5-6 membered heteroaryl selected from, and / or wherein at least one carbon atom in the heterocycloalkyl or heterocycloalkenyl Oxidized to C (═O), wherein the heterocycloalkyl or heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ¹⁴ is cycloalkyl having 3 to 8 carbon atoms, cycloalkenyl having 5 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 5 heteroatoms selected from N, S (= 0) _0-2 and O; To 7 membered heterocycloalkyl and 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which are May be substituted with 1 to 3 R ¹⁰ ;
R ² is NR ¹⁵ R ¹⁶ ;
R ¹⁵ is hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, cycloalkenyl of 4 to 8 carbon atoms, 5 to 7 membered heterocycloalkyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, and 3 to 6 carbon atoms and N, S (= 0) _From 5 to 7 membered heterocycloalkenyl having 1 to 2 heteroatoms selected from _0-2 and O, AR ⁹ , C (= 0) R ¹⁸ , C (= 0) NHR ¹⁸ , S (= 0) ₂ NHR ¹⁸ Selected;
R ¹⁸ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ¹⁸ is selected from alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, and alkynyl of 2 to 6 carbon atoms, all of which are selected from 1 to 3 halogen or alkoxy of 1 to 6 carbon atoms May be substituted, or
R ¹⁸ is AR ⁹ ;
R ¹⁶ is selected from alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, and AR ⁹ , or
R ¹⁶ is aryl having 6 to 10 carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, Cycloalkenyl of 4 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and 3 to carbon atoms 6 and 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ¹⁵ and R ^16, in combination with the nitrogen atom to which they are attached, are from 2 to 9 carbon atoms and from 1 to 4 heteroaryls selected from N, S (= 0) _0-2 and O, or from 3 to carbon atoms 5 and 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from 6 and N, S (= 0) _0-2 and O, and 3 to 6 carbon atoms and N, S (= 0) _0-2 and 1 to 2 heteroatoms selected from O form 5 to 7 membered heterocycloalkenyl, wherein the heterocycloalkyl and the heterocycloalkenyl are further phenyl, or 2 to 5 carbon atoms and N, S (= 0) ) May be fused with one to three 5-6 membered heteroaryls selected from _0-2 and O, and at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is C (= 0) Oxidized, all of which may be substituted with one to three R ¹⁰ ;
R ³ is selected from cycloalkyl of 3 to 6 carbon atoms, heterocyclic alkyl of 1 to 2 heteroatoms selected from 3 to 6 carbon atoms and N, S ( _═O ) _0-2 and O, all of which are 1 Or may be substituted with 3 R ¹⁰ ;
R ³ is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, hydrogen, nitro, halogen, NR ¹⁹ R ²⁰ , A-OR ¹⁹ , A-NR ¹⁹ R ²⁰ and AR ²⁰ ;
R ¹⁹ and R ²⁰ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ⁹ Or
R ¹⁹ and R ²⁰ are 6 to 10 aryl carbon atoms, 2 to 9 carbon atoms and 1 to 4 heteroaryl, 3 to 8 carbon atoms, selected from N, S (= 0) _0-2 and O Cycloalkyl, cycloalkenyl of 5 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, S (= 0) _0-2 and O, and carbon Independently selected from 3 to 6 atoms and 1 to 2 5 to 7 membered heterocycloalkenyl heteroatoms selected from N, S (= 0) _0-2 and O, the heterocycloalkyl and the heterocycloalkenyl May further be fused with phenyl, or 5 to 6 membered heteroaryl of 2 to 5 carbon atoms and 1 to 3 heteroatoms selected from N, S (= 0) _0-2 and O, and / or the hetero In cycloalkyl or heterocycloalkenyl one or more carbon atoms may be oxidized to C (═O) And, all of which can be optionally substituted with one to three R ^10;
R ⁴ is selected from ═O, = S, and OR ²¹ ;
R ²¹ is hydrogen,
R ²¹ is alkyl having 1 to 8 carbon atoms, alkenyl having 2 to 8 carbon atoms, alkynyl having 2 to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms, cycloalkenyl having 4 to 8 carbon atoms 3 to 6 and N, S (= 0) _0-2 and 1 to 2 5-7 membered heterocycloalkyl heteroatoms selected from O, and 3 to 6 carbon atoms and N, S (= 0) _0- One or two 5-7 membered heterocycloalkenyl heteroatoms selected from ₂ and O, all of which may be substituted with 1 to 3 R ¹⁰ ;
R ⁵ and R ⁶ are independently selected from cycloalkyls of 3 to 6 carbon atoms, cycloalkenyl of 4 to 6 carbon atoms, phenyl, and monocyclic heteroaryls of 2 to 5 carbon atoms and 1 to 3 carbon atoms All of which may be substituted with 1 to 3 R ¹⁰ , or
R ⁵ and R ⁶ are 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N , S ( _═O ) _0-2 and O to 1 to 2 5-7 membered heterocycloalkenyl selected from O, wherein at least one carbon atom in the heterocycloalkyl or heterocycloalkenyl is C (= O), wherein the heterocycloalkyl or the heterocycloalkenyl is 1 to 3 R ¹⁰ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= 0) OR ²⁴ , C (= 0) NR ²⁴ R ²⁵ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ , or AC (= 0) NR ²⁴ R ²⁵ Can be, or
R ⁵ and R ⁶ are hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, halo of 1 to 6 carbon atoms Alkyl, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , AC (= O) R ²⁴ , AC (= 0) OR ²⁴ , and AC (= 0) NR ²⁴ R ²⁵ ;
Q is selected from O and S (= 0) _0-2 ;
R ²² is selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms;
R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, or
R ²³ is cycloalkyl having 3 to 6 carbon atoms, cycloalkenyl having 4 to 6 carbon atoms, phenyl, and 2 to 5 carbon atoms and heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²³ is 5-6 membered heterocycloalkyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, and 3 to 6 carbon atoms and N, S ( = O) from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and O, wherein at least one carbon atom in said heterocycloalkyl or said heterocycloalkenyl is C (= 0) May be oxidized and the heterocycloalkyl or heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
Provided that for A (OR ²² ) -R ²³ , when R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, A is not CH;
R ²⁴ and R ²⁵ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ²³ Or
R ²⁴ and R ²⁵ are heteroalkyl selected from 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and N, S (= 0) _0-2 and O Independently selected from monocyclic heteroaryl of 1 to 3 atoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ are 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N , S ( _═O ) _0-2 and O is independently selected from 2 to 5 5-membered heterocycloalkenyl hetero heteroalkenyl, wherein at least one carbon atom in the heterocycloalkyl or heterocycloalkenyl is C ( = 0), and the heterocycloalkyl or heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ are combined with the nitrogen atom to which they are attached 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 5 to 7 membered heterocycloalkenyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, or 2 to 5 carbon atoms and 1 to 3 heteroatoms Forms a monocyclic heteroaryl, wherein at least one carbon atom in the heterocycloalkyl or heterocycloalkenyl may be oxidized to C (= 0), all of which may be substituted with 1 to 3 R ¹⁰ ;
R ²⁶ is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ , and AR ²³ Selected from
R ²⁶ represents 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²⁶ is 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl having 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N, S ( = O) from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and 0, wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁷ is selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ²³ , or
R ²⁷ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²⁷ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl heteroatoms selected from N, O, S ( _═O ) _0-2 , and 3 to 6 carbon atoms and N, O, One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ²⁸ is hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , C (= 0) R ²⁴ , C (= 0) OR ²⁶ , C (= 0) NR ²⁵ R ³⁰ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ , and AC (= 0) Or selected from NR ²⁴ R ²⁵ ;
R ²⁸ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²⁸ is 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl heteroatoms selected from N, O, S (= 0) _0-2 , and 3 to 6 carbon atoms and N, O, One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ³⁰ is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ , and AR ²³ Selected from
R ³⁰ is cycloalkyl having 3 to 6 carbon atoms, cycloalkenyl having 3 to 6 carbon atoms, phenyl, and 2 to 5 carbon atoms and heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ³⁰ is a carbon atom and 3 to 6 N, O, S (= O) _0-2 heteroatoms selected from 1 to 2 or 5 to 7-membered heterocycloalkyl, and 3 to 6 carbon atoms and N, O, One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁵ and R ³⁰ are in combination with the nitrogen atom to which they are attached 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, 5 to 7 membered heterocycloalkenyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, or 2 to 5 carbon atoms and 1 to 3 heteroatoms Forms a monocyclic heteroaryl, all of which may be substituted with one to three R ¹⁰ ;
R ²⁹ is alkyl having 1 to 6 carbon atoms, alkenyl having 2 to 6 carbon atoms, alkynyl having 2 to 6 carbon atoms, haloalkyl having 1 to 6 carbon atoms, AR ²³ , AC (═O) R ²⁴ , AC (= O) OR ²⁴ , AC (= O) NR ²⁴ R ²⁵ , A-NR ²⁷ R ²⁸ , or
R ²⁹ is 3 to 6 cycloalkyl, 3 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O; Selected from three monocyclic heteroaryls, all of which may be substituted with one to three R ¹⁰ , or
R ²⁹ is 5-6 membered heterocycloalkyl having 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, O, S (= 0) _0-2 , and 3 to 6 carbon atoms and N, O, One or two 5-7 membered heterocycloalkenyl heteroatoms selected from S (= 0) _0-2 , wherein at least one carbon atom in said heterocycloalkyl or heterocycloalkenyl is oxidized to C (= 0) The heterocycloalkyl or heterocycloalkenyl may be substituted with 1 to 3 R ¹⁰ ;
R ⁷ is selected from 3 to 6 cycloalkyl, 4 to 6 cycloalkenyl, phenyl, and 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls, all of which are May be substituted with 1 to 3 R ¹⁰ , or
R ⁷ is 3 to 6 carbon atoms and N, S (= 0) 5 to 7 membered heterocycloalkyl of 1 to 2 heteroatoms selected from _0-2 and O, and 3 to 6 carbon atoms and N, S ( = O) from 1 to 2 5-7 membered heterocycloalkenyl heteroatoms selected from _0-2 and O and / or in said heterocycloalkyl or heterocycloalkenyl one or more carbon atoms is C (= 0) Wherein the heterocycloalkyl or heterocycloalkenyl is 1 to 3 R ¹⁰ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= 0) OR ²⁴ , C Or may be substituted with (= O) NR ²⁴ R ²⁵ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ , or AC (= 0) NR ²⁴ R ²⁵ , or
R ⁷ is hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, carbon Alkoxy of 1 to 6 atoms, haloalkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , AC (= O) R ²⁴ , AC (= O ) OR ²⁴ , and AC (= 0) NR ²⁴ R ²⁵ are independently selected from
Of the compounds of formula (I)
1,5-dimethyl-2- (methylamino) -7- (4-morpholinyl) -1,8-naphthyridin-4 (1H) -one,
1,5-dimethyl-2- (methylamino) -7- (4-methyl-1-piperazinyl) -1,8-naphthyridin-4 (1H) -one,
1,5-dimethyl-2- (methylamino) -7- (1-pyrrolidinyl) -1,8-naphthyridin-4 (1H) -one,
1,5-dimethyl-2- (methylamino) -7- (1-piperidinyl) -1,8-naphthyridin-4 (1H) -one,
1,5-dimethyl-2- (methylamino) -7- (4-methyl-1-piperazinyl) -3-nitro-1,8-naphthyridin-4 (1H) -one,
1,5-dimethyl-2- (methylamino) -3-nitro-7- (1-pyrrolidinyl) -1,8-naphthyridin-4 (1H) -one or
1- (3-chlorophenyl) -2- (4-morpholinyl) -1,8-naphthyridin-4 (1H) -one is excluded.
[23" claim-type="Currently amended] The method of claim 22,
R ⁴ is ═O;
R ¹⁵ is hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O To 7 membered heterocycloalkyl, AR ⁹ , C (= 0) R ¹⁸ , C (= 0) NHR ¹⁸ , and S (= 0) ₂ NHR ¹⁸ ;
R ¹⁸ is phenyl, 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 6 cycloalkyl carbon atoms, and carbon atoms 3 to 6 and 1 to 2 5-7 membered heterocycloalkyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ or ,
R ¹⁸ is alkyl of 1 to 6 carbon atoms, which may be substituted with 1 to 3 halogens or alkoxy of 1 to 6 carbon atoms, or
R ¹⁸ is AR ⁹ ;
R ¹⁶ is selected from alkyl of 1 to 6 carbon atoms and AR ⁹ , or
R ¹⁶ is phenyl, 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 8 cycloalkyl carbon atoms, and carbon atoms 3 to 6 and 1 to 2 5-7 membered heterocycloalkyl heteroatoms selected from N, S (= 0) _0-2 and O, all of which may be substituted with 1 to 3 R ¹⁰ or ,
R ¹⁵ and R ¹⁶ combined with the nitrogen atom to which they are attached are monocyclic heteroaryl having 2 to 5 carbon atoms and 1 to 3 heteroatoms selected from N, S ( _═O ) _0-2 and O, or carbon And form 5 to 7 membered heterocycloalkyl of 3 to 6 atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, wherein one of the carbon atoms in the heterocycloalkyl is C (= Oxidized to O), all of which may be substituted with 1-3 R ¹⁰ ;
R ¹⁹ and R ²⁰ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ⁹ , or R ¹⁹ and R ²⁰ are phenyl, 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S ( _═O ) _0-2 and O, 3 to 6 cycloalkyl carbon atoms, 3 to 6 carbon atoms and N, S (═O) ₀ Independently selected from 2 to 5 membered heterocycloalkyl heteroatoms selected from _-2 and O, wherein at least one carbon atom in said heterocycloalkyl can be oxidized to C (= 0), all of which are 1 To 3 R ¹⁰ ;
R ⁵ is selected from cycloalkyls of 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryls of 2 to 5 carbon atoms and 1 to 3 heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ Or
R ⁵ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, S (= 0) _0-2 and O and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O), wherein the heterocycloalkyl is one to three R ¹⁰ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= 0) OR ²⁴ , C (= 0) NR ²⁴ R ²⁵ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ , or AC (= 0) NR ²⁴ R ²⁵ Or
R ⁵ is hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, carbon atom 3 to 6 cycloalkoxy, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , and AC (= 0) R ²⁴ ;
R ²² is selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and cycloalkyl of 3 to 6 carbon atoms;
R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, or
R ²³ is selected from cycloalkyl with 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl with 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²³ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O, S (= 0) _0-2 and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O) and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ ;
Provided that for A (OR ²² ) -R ²³ , when R ²³ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, and cycloalkoxy of 3 to 6 carbon atoms, A is not CH;
R ²⁴ and R ²⁵ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ²³ , or
R ²⁴ and R ²⁵ are 3 to 6 cycloalkyl, phenyl, and 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O Independently selected from, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ are independently selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O, S (= 0) _0-2 , and In heterocycloalkyl one of the carbon atoms may be oxidized to C (═O), said heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁴ and R ²⁵ together with the nitrogen atom to which they are attached are 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, Or monocyclic heteroaryl having 2 to 5 carbon atoms and 1 to 3 heteroatoms, and / or one of the carbon atoms in said heterocycloalkyl may be oxidized to C (= 0), all of which May be substituted with 1 to 3 R ¹⁰ ;
R ²⁶ is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ , or
R ²⁶ is selected from cycloalkyl with 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl with 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁶ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O, S (= 0) _0-2 and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O) and the heterocycloalkyl may be substituted with one to three R ¹⁰ ;
R ²⁷ is selected from hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, and AR ²³ , or
R ²⁷ is selected from cycloalkyls of 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryls of 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁷ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O, S (= 0) _0-2 and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O) and the heterocycloalkyl may be substituted with one to three R ¹⁰ ;
R ²⁸ is hydrogen, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , C (= 0) R ²⁴ , C (= 0) OR ²⁶ , C (= 0) NR ²⁵ R ³⁰ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ and AC (= 0) NR ²⁴ R ²⁵ , or
R ²⁸ is selected from cycloalkyl of 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl having 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁸ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O, S (= 0) _0-2 and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O) and the heterocycloalkyl may be substituted with one to three R ¹⁰ ;
R ³⁰ is selected from alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, A (OR ²² ) -R ²³ and AR ²³ , or
R ³⁰ is selected from cycloalkyl with 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryl with 1 to 3 heteroatoms selected from 2 to 5 carbon atoms and N, S (= 0) _0-2 and O; All of which may be substituted with 1 to 3 R ¹⁰ , or
R ³⁰ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyl selected from N, O, S (= 0) _0-2 and / or carbon in the heterocycloalkyl One of the atoms may be oxidized to C (═O) and the heterocycloalkyl may be substituted with 1 to 3 R ¹⁰ , or
R ²⁵ and R ^{30 taken} together with the nitrogen atom to which they are attached are 5 to 7 membered heterocycloalkyl of 3 to 6 carbon atoms and 1 to 2 heteroatoms selected from N, S (= 0) _0-2 and O, Or monocyclic heteroaryl of 2 to 5 carbon atoms and 1 to 3 heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ ;
R ²⁹ is alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ , AC (= 0) NR ²⁴ R ²⁵ , A -NR ²⁷ R ²⁸ or
R ²⁹ is selected from cycloalkyls of 3 to 6 carbon atoms, phenyl, 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O, All of which may be substituted with 1 to 3 R ¹⁰ , or
R ²⁹ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, O, S (= 0) _0-2 and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O) and the heterocycloalkyl may be substituted with one to three R ¹⁰ ;
R ⁶ is selected from cycloalkyl of 3 to 6 carbon atoms, all of which may be substituted with 1 to 3 R ¹⁰ , or
R ⁶ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, S (= 0) _0-2 and O and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O), wherein the heterocycloalkyl is one to three R ¹⁰ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= 0) OR ²⁴ , C (= 0) NR ²⁴ R ²⁵ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ or AC (= 0) NR ²⁴ R ²⁵ Can be, or
R ⁶ is hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A- NR ²⁷ R ²⁸ , AQR ²⁹ , S (= O) _0-2 -R ²⁹ , S (= O) _0-2 -A-NR ²⁴ R ²⁵ , C (= O) OR ²⁴ , C (= O) NR ²⁴ R ²⁵ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ and AC (= 0) NR ²⁴ R ²⁵ ;
R ⁷ is selected from cycloalkyls of 3 to 6 carbon atoms, phenyl, and monocyclic heteroaryls of 2 to 5 carbon atoms and 1 to 3 heteroatoms, all of which may be substituted with 1 to 3 R ¹⁰ Or
R ⁷ is selected from 3 to 6 carbon atoms and 1 to 2 5 to 7 membered heterocycloalkyls selected from N, S (= 0) _0-2 and O and / or carbon in said heterocycloalkyl One of the atoms may be oxidized to C (═O), wherein the heterocycloalkyl is one to three R ¹⁰ , AR ²³ , A-NR ²⁴ R ²⁵ , C (= 0) R ²⁴ , C (= 0) OR ²⁴ , C (= 0) NR ²⁴ R ²⁵ , S (= 0) ₂ R ²⁶ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ or AC (= 0) NR ²⁴ R ²⁵ Can be, or
R ⁷ is hydrogen, halogen, nitrile, nitro, hydroxy, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, carbon atom 3 to 6 cycloalkoxy, AR ²³ , A (OR ²² ) -R ²³ , NR ²⁷ R ²⁸ , A-NR ²⁷ R ²⁸ , AQR ²⁹ , QR ²⁹ , QA-NR ²⁴ R ²⁵ , C (= O) R ²⁴ , C (= 0) OR ²⁴ , C (= 0) NR ²⁴ R ²⁵ , AC (= 0) R ²⁴ , AC (= 0) OR ²⁴ and AC (= 0) NR ²⁴ R ²⁵ compound.
[24" claim-type="Currently amended] The compound of claim 23, wherein R ¹ is selected from alkyl of 1 to 8 carbon atoms, and AR ⁹ , or
R ¹ is selected from phenyl, 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 6 cycloalkyl carbon atoms, All of which may be substituted with one to three R ¹⁰ ;
A is selected from alkyl of 1 to 6 carbon atoms, and haloalkyl of 1 to 8 carbon atoms;
R ⁹ is selected from hydroxy, alkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, OAR ¹⁴ , NR ¹¹ R ¹² ;
R ⁹ is selected from phenyl, 2 to 5 carbon atoms and 1 to 3 monocyclic heteroaryls selected from N, S (= 0) _0-2 and O, 3 to 6 cycloalkyl carbon atoms, All of which may be substituted with 1 to 3 R ¹⁰ .
[25" claim-type="Currently amended] The compound of claim 24, wherein R ¹ is phenyl which may be substituted with 1 to 3 R ¹⁰ .
[26" claim-type="Currently amended] Diabetes mellitus (type 1 or 2), adolescent adult diabetes mellitus (MODY), latent autoimmune diabetes (LADA) in adults, comprising administering to a mammal an effective amount of a compound of claim 1 or 22, A method of treating or preventing a disease or condition selected from the group consisting of impaired glucose tolerance (IGT), fasting glucose disorders, gestational diabetes, and metabolic syndrome X.
[27" claim-type="Currently amended] The method of claim 26, wherein the disease or condition is diabetes (type 1 or type 2).
[28" claim-type="Currently amended] The method of claim 27, wherein said disease or condition is type 2 diabetes.
[29" claim-type="Currently amended] 27. The method of claim 26, wherein the PPAR-agonist, insulin agonist, sulfonylurea, insulin secretagog, a compound that lowers hepatic glucose production, an α-glucosidase inhibitor or insulin with the compound of claim 1 or Further comprising administering in combination.
[30" claim-type="Currently amended] The method of claim 29, wherein said PPAR-agent is selected from rosiglitazone and pioglitazone.
[31" claim-type="Currently amended] 30. The method of claim 29, wherein the sulfonylurea is selected from glybenclamide, glymepyride, chlorpropamide, and glyphideide.
[32" claim-type="Currently amended] 30. The method of claim 29, wherein said insulin secretagog is a GLP-1, GIP, PAC / VPAC receptor agonist, secretin, nateglinide, meglitinide, lepaglinide, glybenclamide, glimepiride, chlorpropamide, And glipizide.
[33" claim-type="Currently amended] 30. The method of claim 29, wherein said α-glucosidase inhibitor is selected from acarbose, miglitol and bogliboss.
[34" claim-type="Currently amended] The method of claim 29, wherein the compound that lowers hepatic glucose production is metformin.
[35" claim-type="Currently amended] 27. The method of claim 26, further comprising administering an HMG-CoA reductase inhibitor, nicotinic acid, a bile acid sequestrant, and a fibric acid derivative, an antihypertensive drug, or an anti-obesity agent in combination with the compound of any one of the preceding claims. Way.
[36" claim-type="Currently amended] 36. The method of claim 35, wherein said anti-obesity agent is selected from β-3 agonists, CB-1 antagonists, and lipase inhibitors.
[37" claim-type="Currently amended] A method of treating or preventing a secondary cause of diabetes selected from glucocorticoid hyperplasia, growth hormone hyperplasia, pheochromocytoma, and drug-induced diabetes, comprising administering to a mammal an effective amount of the compound of claim 1.
[38" claim-type="Currently amended] A method of increasing the sensitivity of the beta cells of the pancreas to insulin secretagogues comprising administering to a mammal an effective amount of a compound of claim 1 or 22.
[39" claim-type="Currently amended] The method of claim 38, wherein said insulin secretagog is a GLP-1, GIP, PAC / VPAC receptor agonist, secretin, nateglinide, meglitinide, repaglinide, glybenclamide, glimepiride, chlorpropamide, And glipizide.
[40" claim-type="Currently amended] A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable carrier.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US10047086B2|2018-08-14|Imidazopyridines and imidazopyrazines as LSD1 inhibitors

---

US9187497B2|2015-11-17|Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly|polymerase |

---

US9403819B2|2016-08-02|Apoptosis signal-regulating kinase 1 inhibitors

---

RU2660429C2|2018-07-06|Novel compounds that are erk inhibitors

---

US9108963B2|2015-08-18|Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

---

EP2635577B1|2014-10-01|Substituted 6-fluoro-1h-pyrazolo[4,3-b]pyridines and use thereof

---

US8163918B2|2012-04-24|Azaindazole compounds as CCR1 receptor antagonists

---

US8796305B2|2014-08-05|Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use

---

US9498480B2|2016-11-22|Substituted azabicycles and use thereof

---

JP6316888B2|2018-04-25|Heterocyclic amines and uses thereof

---

US10736896B2|2020-08-11|Substituted 5-fluoro-1H-pyrazolopyridines and their use

---

RU2684644C1|2019-04-11|Purine derivatives as tnf activity modulators

---

AU2013279597B2|2017-04-20|Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof

---

AU2011217489B2|2015-09-03|Pyrazole derivatives as JAK inhibitors

---

JP5469666B2|2014-04-16|cMET inhibitor

---

ES2626908T3|2017-07-26|5-phenyl- [1,2,4] triazolo [1,5-a] pyridin-2-yl-carboxamides as jak inhibitors

---

DE60315796T2|2008-06-05|Hydroxynaphthyridinoncarboxyl acid amides sufficient as inhibitors of the hiv integrase

---

US9334269B2|2016-05-10|Carboxamides as inhibitors of voltage-gated sodium channels

---

US8697739B2|2014-04-15|Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof

---

US6818646B2|2004-11-16|Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors

---

TWI447118B|2014-08-01|Novel compounds useful for the treatment of degenerative and inflammatory diseases

---

KR101616133B1|2016-04-27|Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors

---

EP1846035B1|2011-09-21|Combination therapy

---

US20190248783A9|2019-08-15|Amino-substituted imidazo[1,2-a] pyridinecarboxamides and their use

---

ES2274111T3|2007-05-16|Quinolinas as ligandos of the prostaglandinas receiver.

同族专利:

---

公开号 | 公开日

---

US20040209866A1|2004-10-21|

---

WO2003027113A1|2003-04-03|

---

CO5560542A2|2005-09-30|

---

ECSP045084A|2004-06-28|

---

US20040157875A1|2004-08-12|

---

HU0402310A2|2005-02-28|

---

JP2005504807A|2005-02-17|

---

US20040014751A1|2004-01-22|

---

IL160708D0|2004-08-31|

---

GT200200194A|2003-07-03|

---

US6677352B1|2004-01-13|

---

US20060189609A1|2006-08-24|

---

PE20030549A1|2003-08-18|

---

RU2004112787A|2005-10-10|

---

AR037503A1|2004-11-17|

---

CN1578780A|2005-02-09|

---

EP1432710A1|2004-06-30|

---

NO20041560L|2004-05-11|

---

PE20030601A1|2003-09-07|

---

CN1578781A|2005-02-09|

---

BR0212864A|2004-08-17|

---

MA27079A1|2004-12-20|

---

MXPA04002035A|2004-06-07|

---

US6964971B2|2005-11-15|

---

EP1432711A1|2004-06-30|

---

US7109196B2|2006-09-19|

---

KR20040041177A|2004-05-14|

---

HN2002000275A|2005-02-22|

---

UY27456A1|2003-04-30|

---

MA26344A1|2004-10-01|

---

AR037504A1|2004-11-17|

---

ZA200403064B|2005-06-29|

---

RU2004112771A|2005-10-10|

---

ZA200403063B|2005-04-22|

---

PL369567A1|2005-05-02|

---

WO2003027112A1|2003-04-03|

---

JP2005504808A|2005-02-17|

---

MXPA04002136A|2005-03-07|

---

UY27457A1|2003-04-30|

---

IL160707D0|2004-08-31|

---

CA2463039A1|2003-04-03|

---

HRP20040309A2|2006-05-31|

---

CO5560611A2|2005-09-30|

---

CA2461132A1|2003-04-03|

---

HU0401889A2|2005-01-28|

---

GT200200191A|2003-05-23|

---

US6900205B2|2005-05-31|

---

BR0212829A|2004-08-03|

---

HRP20040317A2|2006-06-30|

---

ECSP045081A|2004-06-28|

---

PL369531A1|2005-05-02|

---

NO20041567L|2004-05-11|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
2001-09-26|Priority to US32451101P

---

2001-09-26|Priority to US60/324,511

---

2002-09-23|Application filed by 바이엘 파마슈티칼스 코포레이션

---

2002-09-23|Priority to PCT/US2002/030176

---

2004-05-14|Publication of KR20040041178A

优先权:

---

申请号 | 申请日 | 专利标题

---

US32451101P| true| 2001-09-26|2001-09-26|

---

US60/324,511|2001-09-26|

---

PCT/US2002/030176|WO2003027112A1|2001-09-26|2002-09-23|1, 8-naphthyridine derivatives as antidiabetics|